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 2 
Abstract 
 
Background: Overuse injuries of the tendon—encompassed by the term 
‘tendinopathy’—represent a largely underestimated group of musculoskeletal 
disorders associated with chronic inflammation and dysregulated tissue repair. 
Tendinopathies account for 30-50% of all sporting injuries and a high proportion 
of rheumatological and orthopaedic referrals from  primary care physicians. 
Despite historical disagreement between ‘inflammation’ vs ‘degeneration’ 
hypotheses it is now widely accepted that inflammatory mechanisms elicited by 
persistent mechanical injury at a microscopic level disturb the intricate 
homeostatic balance that exists between stromal and immune cell compartments 
within the tendon during the initial stages of disease. The molecular mechanisms 
that regulate inflammatory pathways in tendinopathy are largely unknown 
therefore this thesis sought to characterize mechanisms involved in activation of 
the innate immune system and subsequent development of persistent 
inflammation and aberrant matrix repair.   
 
Key results: Gene expression analysis of tendon tissue identified the presence of 
myeloid associated alarmins S100A8 and S100A9 in early tendinopathy. Treatment 
of primary human tenocytes with exogenous S100A8 & A9 enhanced cytokine and 
chemokine release; however, no alterations in genes associated with matrix 
remodelling were observed indicating these alarmins act to exaggerate the 
inflammatory response in the early stages of disease. Extensive phenotyping of 
tendon stromal cells by flow cytometry identified the presence of novel subsets 
of tenocytes that are expanded under chronic inflammatory conditions. 
Furthermore, enhanced expression of markers associated with stromal cell 
activation was observed ex vivo in late tendinopathic tissue and in vitro in 
response to inflammatory stimuli. I next identified a contact dependent 
mechanism through which stromal cells influence immune cell phenotype and 
differentiation in a direct tenocyte-monocyte co-culture model. Finally, 
expression of stromal activation markers podoplanin and VCAM1 in tenocytes was 
silenced by siRNA mediated knockdown; however, no discernible alterations in 
tenocyte behaviour or changes in monocyte phenotype (induced by monocyte-
tenocyte co-culture) were observed indicating alternate mechanisms are 
responsible for these interactions. 
 3 
Conclusions:  This study has identified novel stromal-immune cell crosstalk in 
tendinopathy and highlighted the significance of these interactions in the 
development of non-resolving chronic inflammation.  
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1.1 Tendon Biology 
1.1.1. Tendon structure and function 
Tendons are connective tissue structures interposed between muscles and bones. 
The primary function of a tendon is to enable transduction of mechanical load 
generated by a muscle to bone thus enable movement at a joint.1 Tendons are 
highly organised structures composed mainly of water, type 1 collagen 
(approximately 70% of its dry weight) and a combination of other matrix proteins. 
The basic cellular component of the tendon is the ‘tenocyte’; a fibroblast like cell 
that regulates turnover of the extracellular matrix.2 
 
The high tensile strength of the tendon is derived from the hierarchical 
organisation of collagen molecules interspersed with a highly hydrated matrix at 
each level of the hierarchy.3 Commonly referred to as ground substance, this is 
composed largely of water, proteoglycans and glycoproteins.4 The axial and 
lateral organisation of collagen molecules ensures strong intermolecular 
interactions and cross linkage. At the molecular level, insoluble collagen 
molecules are formed by the cross linking of soluble tropocollagen. Arrangement 
into microfibrils and subsequent assembly into fibrils make up the macroscopic 
units of the hierarchy.5 Tendon structure and composition can vary according to 
both anatomic location and specific sites within the tendon.6  
 
A ‘bunch’ of collagen fibrils makes up a collagen fibre which is the basic structural 
unit of a tendon. This is encapsulated by a fine sheath of connective tissue called 
the endotenon that binds fibres together. A bunch of fibres makes up the 
subfascicle or primary fibre bundle that in turn aggregates into a group of 
secondary fascicles. These tertiary bundles make up the whole tendon that is 
encased by the epitenon.7  In regions away from joints a loose connective tissue 
structure called the paratenon surrounds tendons to enable movement beneath 
the skin. Around joint structures the tendon is contained within a synovial sheath 
to protect it from bony surfaces that may cause friction.8  
 
The point of union between the tendon and adjoining muscle is the myotendinous 
junction (MTJ). This is the primary site of force transmission and is based on 
structural relationships between cytoskeletal proteins and the extracellular 
 18 
matrix.9 Proximally, the osteotendinous junction or enthesis comprises the tendon 
bone interface. The enthesis has a unique molecular and cellular composition a 
gradual transition from tendinous to bone tissue. The enthesis may be classified 
as fibrous or fibrocartilaginous with the former representing an area where the 
tendon attaches directly to the bone. The fibrocartilaginous enthesis describes an 
area where chondrogenesis has occurred through several zones that ultimately 
results in enthesial tissue indistinct from bone.10  It has been postulated that the 
enthesis is in fact a collection of related tissues termed the ‘enthesis organ’. This 
is composed of the fibrocartilages, bursae and fat pad that act synergistically to 
dissipate stress.11  
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(A) Anatomical location of extensor tendons in the arm
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C
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1.1.2. Extracellular tendon matrix 
Collagen  
Collagen protein is comprised of a triple helix, most commonly two identical alpha 
chains (a1) and one structurally similar a2 chain.12 Collagen I is the primary 
component of tendon tissue accounting for approximately 70% of its dry weight 
and 95% of total collagens. The next most abundant is type III collagen accounting 
for 3% of total tendon dry weight and is mainly found in the endotenon and 
epitenon.13 Types II, IV, XI are also present and, in cartilaginous areas, type IX, X 
and XI have been described.2  
 
Ground substance 
Ground substance is a highly hydrated gel like substance that confers the 
viscoelastic properties to a tendon.14 It is a complex mixture of glycoproteins and 
proteoglycans and binds tenocytes to collagen fibres. It is an extremely viscous 
substance that provides structural support to the collagen fibres and also acts as 
a medium for diffusion of gases and essential nutrients.15  
 
Proteoglycans 
Proteoglycans- a subclass of glycoproteins- are the most abundant non fibrous 
proteins in the tendon accounting for between 1 and 5% of its dry weight.15 Small 
leucine rich proteoglycans (SLRPs)  consist of a protein core covalently attached 
to one or more glycosaminoglycan side chains (GAGs) and are capable of holding 
up to fifty times their weight in water.16 They play an important regulatory role 
in matrix assembly, cytokine binding and hydration.17 The most abundant 
proteoglycan within the tendon matrix is decorin which accounts for 80% of total 
proteoglycans. Decorin shares a common collagen 1 binding site with another SLRP 
biglycan with decorin possessing higher affinity binding.18 Tendons also express 
type II SLRPs fibromodulin19 and lumican20 in smaller quantities. Aggrecan¾the 
major proteoglycan in articular cartilage¾is expressed throughout the tendon and 
is reported to be most abundant in fibrocartilaginous regions.21,22   
 
Glycoproteins 
Structurally, glycoproteins are macromolecules that consist of a protein to which 
a carbohydrate molecule is attached. They differ to proteoglycans in their protein-
carbohydrate ratio. A variety of these proteins are expressed within the tendon 
 21 
including fibronectin, COMP, tenascin, vitronectin, tenomodulin.23 Fibronectin 
possesses binding sites for cells, collagen and glycosaminoglycans and acts to 
facilitate cell adhesion and migration. Fibronectin binds fibroblasts to collagens 
and enables proliferation and phagocytosis thus facilitating wound healing 
responses.24 Tenascin C is a glycoprotein that regulates cell behaviour and matrix 
organization during remodelling processes. It is found in regions of compression 
such as the osteotendinous junction. Its anti-adhesive properties are thought to 
result from a cellular adaptation to compression that aids in maintaining the 
fibrocartilage.25,26  
 
Elastin 
Elastin is the core component of elastic fibres that comprise approximately 1-2% 
of tendon dry mass.15 Generally, elastin content is low and limited to sparse 
distribution within the fascicles. It has recently been postulated that elastin is 
most abundant in energy storing tendons such as the Achilles and lowly expressed 
in positional tendons.27 
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Molecule Structure/ type Properties
Proteoglycan
Decorin SLRP Binds collagen, affects 
collagen-fibril formation, binds 
growth factors
Biglycan SLRP Binds collagen, affects 
collagen-fibril formation, binds 
growth factors
Fibromodulin SLRP Binds collagen, affects 
collagen-fibril formation, binds 
growth factors
Lumican SLRP Binds collagen, affects 
collagen-fibril formation
Aggrecan Hyalectin Resists compression, 
expression prominent in 
fibrocartilage and low in 
tensional areas of tendon
Versican Hyalectin Lubricates boundaries between 
fibres
Glycoprotein
Tenascin-C Branched molecule Mediates cell-matrix 
interactions
Fibronectin Modular protein Mediates cell-matrix 
interactions, role in tendon 
healing
COMP Branched molecule Mediates cell-matrix 
interactions, role in fibril 
formation
Tenomodulin Type II
transmembrane
glycoprotein
Role in collagen fibril 
maturation
Elastin Branched network Forms elastic fibres, provides 
elastic properties of tissue
Table 1.1 Properties of tendon extracellular matrix components
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1.1.3. Tendon cells 
Tenocytes and tenoblasts make up 90-95% of the cellular component of tendon 
tissue. The remaining percentage is accounted for by  chondrocytes at insertion 
sites, synovial cells of the tendon sheath and vascular cells (smooth muscle cells 
and endothelial cells) of the arterioles in the endotenon and epitenon.28 Under 
homeostatic conditions there is also a small compartment of tissue resident 
immune cells that may be expanded under pathological conditions.29  
 
Tenoblasts are spindle shaped immature tendon cells (approximately 20-70µm in 
length). Young tendon has a high cell-matrix ratio and tenoblasts exhibit numerous 
cytoplasmic organelle that reflect the high metabolic activity of the developing 
tissue.30 As tenoblasts elongate they develop into tenocytes (approximately 80-
300µm in diameter). Tenocytes have extremely elongated nuclei that span almost 
the entire length of the cell. Consequently, the lower nucleus to cytoplasm ratio 
results in reduced metabolic activity.1 Mature tendon is relatively acellular with 
tenocytes interspersed between collagen fibrils accounting for 20% of total tissue 
volume.31 
 
Tenocytes are mechanosensitive cells capable of detecting changes in mechanical 
load. Deformation of their cell membrane and cytoskeleton due to ECM strain 
activates membrane bound integrin receptors that signal to the nucleus and alter 
gene expression.32 As such, this cellular response to mechanical load is a 
particularly practical adaptation in the context of tissues exposed to high levels 
of strain.  
 
1.1.4. Tendon development and tenocyte lineage commitment 
Mesenchymal stem cells (MSCs) are the common progenitors for skeletal muscle 
and tenocyte progenitors and lineage commitment is regulated by a number of 
environmental variables. During embryogenesis genes expressed in the developing 
tendon include homeobox genes six1, six2 and their transcriptional co-activators 
eyes absent homologue 1 (Eya1) and Eya2, tenascin, follistatin, mohawk and 
scleraxis.33,34,35 Scleraxis¾a basic helix loop helix (bHLH) transcription factor¾is 
the most well characterised regulator of tendon development.36 It is expressed in 
tendon progenitors and differentiated cells during embryogenesis and at later 
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stages of development. At embryonic day (E) 10.5 scleraxis is detected in the 
developing limb bud in the somitic compartment called the syndetome.37,38 
Conditional knockout of the scleraxis gene in a mouse model of tendon 
development resulted in significant deficits in tendon differentiation and 
consequent loss of tendons that transmit force to the limbs, tail and trunk.37 
Tenomodulin (TNMD) is a type II transmembrane protein predominantly expressed 
in dense connective tissue including tendon and ligament. Tenomodulin is 
considered a marker of tenocyte differentiation and its expression is positively 
regulated by scleraxis.39 In mice deletion of the tenomodulin gene was shown to 
significantly reduce tenocyte proliferation and alter collagen fibril structure.40 
 
1.1.5. Innervation and vasculature 
 
Tendon is a bradytrophic tissue that generally displays a low degree of innervation 
and is poorly vascularized.41 This may contribute to its propensity for injury and 
explain periods of protracted, inferior healing.  
 
Nerve supply 
Innervation of the tendon originates in neighbouring muscular, cutaneous and 
peritendinous nerve trunks. From the myotendinous junction nerve fibres enter 
the tendon septa and form plexuses in the paratenon.42 Under normal conditions 
nerve fibres do not enter the tendon but terminate on the tendon surfaces 
(paratenon, epitenon and endotenon).43 Innervating nerves consist of lowly 
abundant myelinated fast transmitting fibres (Aa and Ab) with three types on 
nerves endings responsible for mechanoception. Ruffin corpuscles (Type 1) are 
pressure and stretching sensors. Similarly, Vater-Pacini corpuscles (Type II) are 
pressure sensors that react to accelerating and decelerating forces. Golgi tendon 
organs (Type III) are tension receptors predominantly found at the myotendinous 
junction and around insertion sites. 44 
 
Within the tendon sheath there is a greater number of unmyelinated slow 
transmitting fibres (Ag, Ad, B and C fibres). These fibres predominantly function 
in nociception and mediate deep tissue pain. Autonomic function is conferred by 
B fibres that exert vasomotor actions on the small arterial and venous structures.45 
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The peripheral nervous system (PNS) is also involved in tendon homeostasis and 
efferent physiological functions such as cell proliferation, hormone release and 
immune responses, particularly during periods of stress. This is mediated by 
classical neurotransmitters including monoamines and acetylcholine as well as 
neuropeptides such as substance P.46  
 
Blood supply 
Blood vessels generally enter the tendon through the myotendinous junction, 
osteotendinous junction and surrounding connective tissue structures including 
the paratenon. Within the endotenon vessels pass around collagen fibre bundles 
in a longitudinal manner.47   The number of vessels and the manner in which they 
are arranged is highly specific to each tendon. For example, there is a great 
difference in bloody supply of sheathed and unsheathed tendons. In unsheathed 
tendons vessels pass through the paratenon at any given point. Conversely, in 
sheathed tendons around joint capsules blood supply is significantly more 
organised and well defined.41  
1.1.6. Mechanobiology of tendon 
Tendons possess unique biomechanical properties that facilitate transmission of 
dynamic mechanical forces. This is predominantly derived from their hierarchical 
collagen structure and viscoelastic properties.48 Tissue mechanical adaptation 
occurs in response to altered load conditions and allows for changes in tendon 
structure and function. Under physiological conditions loading may be beneficial; 
however, excessive loading may have detrimental effects and ultimately lead to 
tendon rupture.49  
 
A typical stress strain curve for a tendon consists of four regions. The initial toe 
region consists of tendon strained up to 2% and represents ‘stretching out’ of 
crimped tendon fibrils as a result of mechanical loading on the tendon. The ‘crimp 
pattern’ influences the tendons biomechanical properties and differs according to 
tendon type.50 The linear region accounts for strain of up to 4%; this is the point 
at which collagen fibres lose their crimp pattern. The slope of the line at this 
point is referred to as Young’s module of tendon which describes the relationship 
between tensile stress and tensile strain. At strain above 4% (the physiological 
limit of strain) microscopic tearing occurs resulting in microtear failure. At 8-10% 
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strain macroscopic tearing occurs that may ultimately result in tendon 
rupture.51,48  
 
Both age and anatomical location of tendons affect their mechanical properties. 
For example, the Young’s modulus of the patellar tendon is 600±266MPa while the 
elastic modulus of the tibialis anterior is 1200MPa. Similarly, young patellar 
tendons (29-50 years) have a Young’s modulus of 660±266MPa compared with 
504±222 in old patellar tendons (64-93 years).52  
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1.1.7. Tendon injury and healing 
Tendon injuries can be acute or chronic and arise as result of a combination of 
both intrinsic and extrinsic factors. Tendon repair occurs over several days in 
three overlapping stages: inflammation, proliferation and remodelling.53  
 
The Inflammatory Phase  
In the initial inflammatory phase, rupture of blood vessels results in the immediate 
formation of a blood clot and release of cytokines, chemokines, growth factors 
and vasoactive substances that result in local acute inflammation. Inflammatory 
cells, red blood cells and platelets infiltrate the area using the clot as a 
preliminary scaffold.54 Initial cell influx (within hours) is predominately 
neutrophils. In the following 24 hours monocytes and macrophages predominate 
and phagocytosis of necrotic debris occurs.55 Vasoactive substances increase 
vascular permeability and initiate angiogenesis and the inflammatory milieu 
generated by the accumulated cells stimulates recruitment and proliferation.56 
This gives rise to the proliferation or repair stage where collagen III synthesis is 
initiated.57 
 
The Proliferative Phase 
At approximately two days into the injury response the proliferative or healing 
phase commences. This phase is characterized by high synthetic activity and 
recruitment and expansion of the tenocyte population.58 Tenocytes are recruited 
to the wound from the paratenon and synovial sheath and proliferate. Similarly, 
intrinsic tenocytes from the endotenon and epitenon migrate to the site of injury 
and proliferate. This new pool of tenocytes together with macrophages present in 
the wound direct synthesis of ECM components, release of growth factors, cell 
recruitment and neoangiogenesis. The role of macrophages shifts from phagocytic 
to reparative.59 Collagen III production peaks as tenocytes lay down a temporary, 
mechanically inferior, matrix composed of type III collagen and 
glycosaminoglycans.53 
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The Remodelling Phase 
The remodelling phase begins approximately 6 weeks after the initial wound 
formation. It is characterised by decreased cellularity, reduction of ECM synthesis 
and organization of the collagen matrix.58 Between 6-10 weeks tenocyte 
metabolism remains high and alignment of tenocytes and fibril collagen occurs. 
Type I collagen synthesis predominates at the stage. Cellularity and synthetic 
activity gradually decline as the healing tissue changes from cellular to fibrous. 
After 10 weeks the tissue starts to become scar like and the healing process can 
take up to one year to resolve.60 However; the repaired tissue remains inferior 
and the tendon never fully recuperates the biomechanical properties it possessed 
prior to injury.61 
 
 
  Table 1.2 Phases of tendon injury and healing 
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1.2 Tendinopathy  
 
Tendinopathies account for approximately 30% of musculoskeletal consultations 
in general practice and 30-50% of all sporting injuries.62,63 It is commonly 
associated with overuse injury of the tendon and characterised by pain, decline 
in function and reduced exercise tolerance.28 Tendon injury affects people of all 
ages and the prevalence of tendinopathy amongst the general population poses a 
significant economic burden to public health services. Chronic or acute injuries 
can occur in any tendon but are particularly prevalent in major tendons with high 
loading demands including the rotator cuff, Achilles, patellar and forearm 
extensor tendons.64,65 
1.2.1 Aetiology and pathophysiology 
The aetiology of tendinopathy remains unclear; however, it is becoming 
increasingly recognised that a multitude of factors are implicated in disease 
initiation and progression. Chronic disorders are attributed to a combination of 
extrinsic and intrinsic factors while acute injury is generally associated with one 
isolated overloading event. Intrinsic factors include sex, age and chronic 
conditions including type 2 diabetes and obesity.65 The following section will 
address theories pertaining to the pathophysiology of tendinopathy. The role of 
inflammation in tendinopathy will be discussed in greater detail in the subsequent 
section.   
 
Mechanical stress 
Excessive loading is considered the main causative factor in tendon 
degeneration.66 Tendons subject to mechanical strain above the physiological 
limit exhibit inflammation of their sheath and degeneration of the tendon body.67 
Weakening of tendons occurs when fatigue damage is not sufficiently repaired and 
may ultimately lead to complete rupture. In addition, damage may occur under 
physiological conditions as a result of repetitive microtrauma and incomplete 
healing.66 Mechanical strain is thought to disrupt the hierarchical organisation of 
collagen structure within the tendon causing vessel disruption and impaired tissue 
perfusion.  
Under physiological conditions mechanical loading of the tendon results in 
increased collagen synthesis likely regulated by the mechanoresponsive properties 
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of tenocytes.68,69 Degradation of collagen proteins occurs simultaneously (due to 
increases in matrix degrading enzymes such as MMPs) and a net increase in 
collagen requires a restoration period.70 It has been postulated that insufficient 
rest leads to progressive collagen loss and tendinopathy occurs as a result of an 
imbalance between synthesis and breakdown of matrix proteins.71,65 
 
Mechanical stretching of human tenocytes was shown to stimulate production of 
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) and an inverse relationship 
between static load and MMP-1 expression has been observed in rodent 
tenocytes.72,73 This indicates that mechanical stress can act directly on the 
cellular component of the tendon as well as influencing the structure of the 
extracellular matrix. The precise role of mechanical load in the pathogenesis of 
tendinopathy remains unclear; however, evidence suggests that a combination of 
biological factors and structural alterations may weaken the overall architecture 
of the tendon.   
 
Matrix turnover  
Proteolytic activity is required to orchestrate maintenance and repair of tissue. 
Following injury, proteolysis is required to clear debris from damaged ECM and 
remodel the injured tissue. MMPs have been implicated in ECM turnover under 
both physiological and pathological conditions.6 MMP production in tendon 
explants in stimulated by cytokines which indicates that inflammation influences 
proteolytic activity. Tenocytes have been shown to respond to stress by increasing 
production of MMPs; as alluded to previously, this provides indication that 
mechanical strain is an important stimulus for ECM remodelling.74 In a rodent 
model of acute tendon injury MMPs were identified at different locations and time 
points following injury. Levels of MMP-9 and MMP-13 peaked between days 7-14, 
whereas MMP-2, MMP-3 and MMP-14 levels increased following injury and 
maintained high levels until day 28. The authors propose that MMP-3 and MMP-13 
participate in collagen degradation in the inflammatory phase of tendon healing 
while MMP-2, MMP-3 and MMP-14 predominantly function in the remodelling 
phase.75 Increased activity of MMP-1, MMP-2 and MMP-3 has been observed in 
ruptured supraspinatus tendons that corresponds with collagen turnover and 
deterioration of the collagen network. This activity is thought to represent a 
repair function that is associated with degenerative processes caused by repeated 
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injury or mechanical strain.76 Furthermore, expression of MMP-13, MMP-3, TIMP-
2, TIMP-3 and TIMP-4 mRNA was shown to be altered in both torn and intact 
tendinopathic rotator cuff tendons.77,78 
 
Apoptosis 
Several studies have highlighted the presence of increased apoptosis in 
tendinopathy. Excessive apoptosis of tendon cells has been described in 
supraspinatus, patellar and tibialis anterior tendons.79 Further studies have shown 
that apoptosis is induced by oxidative stress in human tenocytes and is mediated 
by release of cytochrome C from mitochondria to the cytosol and subsequent 
activation of caspase-3.80 A rodent running overuse model demonstrated increased 
levels of heat shock proteins and apoptotic genes. This was confirmed in human 
supraspinatus and subscapularis tendons and suggests that heat shock proteins 
play  a role in stress-activated cell death.81 In addition, IL-18, IL-15 and IL-6 
expression has been associated with expression of caspases 3 and 8 and Fas ligand; 
all of which are genes associated with oxidative stress induced apoptosis.82  
 
Oxygen free radicals 
Reactive oxygen species (ROS) have traditionally been viewed as inducers of 
cellular or tissue damage; however, it is now accepted that ROS (alone or in 
concert with reactive nitrogen species) at lower levels may be physiological and 
induce processes such as proliferation, differentiation and cellular adaptation.83 
Several studies have demonstrated a role for nitric oxide (NO) signalling in the 
pathophysiology of tendinopathy.84,85 Following tendon injury, NO is produced by 
all three isoforms of nitric oxide synthase (inducible NOS, endothelial NOS and 
brain NOS).86 In a rodent model of Achilles tendon injury iNOS, eNOS and bNOS 
have been detected sequentially and all three isoforms were detected in 
tenocytes.87 Expression of all isoforms has been observed in human rotator cuff 
biopsy samples.85 Furthermore, human tenocytes respond to NO by increasing 
collagen synthesis in vitro88 and microarray analysis has demonstrated increases 
of type I, III and IV collagen as well as biglycan, decorin, laminin and MMP10.89  
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Vascular changes and hypoxia 
Historically, it has been proposed that vascular damage and impaired blood flow 
due to trauma or aging results in tissue degeneration that precedes acute 
rupture.90 Decreased microcirculation and vessel number has been reported in 
areas of degeneration or rupture in rotator cuff tendons.91 Furthermore, hypoxic 
damage and associated apoptosis has been observed in rotator cuff tendons 
through the progression of pathology and in both partial and full thickness tears.92 
Hypoxic alterations have also been observed in tenocytes forty eight hours after 
tendon rupture.93 Conversely, neovascularization and increased blood flow have 
also been observed in tendinopathic lesions.94,95 This presents an interesting 
paradox regarding the implications of vascular changes in tendinopathy as hypoxia 
is capable of inducing angiogenesis while impaired vascularity may ultimately lead 
to hypoxia.  
 
Neurological factors 
The primary symptom of tendinopathy is pain thus it has been postulated that 
neurological factors may play a role in the pathogenesis of tendinopathy. Healthy 
tendon bodies are virtually devoid of nerve fibres and innervation is confined to 
the paratenon.96 However, several studies have reported abberations in the 
distribution and types of nerve fibres present in tendinopathy in addition to 
increased vascular innervation.97,98 The neuropeptide substance P (associated with 
the sensation of pain) has been reported to be increased in patients with rotator 
cuff tendinopathy.99 Substance P has also been reported to stimulate neurogenic 
inflammation in and around the tendon.100 Substance P has also been shown to 
induce mast cell degranulation resulting in release of growth factors that 
modulate fibroblast proliferation, angiogenesis and tissue oedema.6 In addition, 
glutamate signalling has been shown to induce a pro-apoptotic response in rat 
tenocytes in vitro which suggests a role for excitotoxic neurotransmitter responses 
in tendinopathy.101 
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Drug induced tendinopathy 
Fluoroquinolones including ciprofloxacin and levofloxacin have been associated 
with the development of tendinopathy, generally presenting as rupture of the 
Achilles tendon (accounting for 90% of cases, half of which are bilateral). 
Tendinopathy occurs in 0.5% to 2% of patients treated with fluroquinolones. 
Fluoroquinolones inhibit tenocyte metabolism thus reducing cell proliferation and 
synthesis of ECM components including collagen.102,103 Furthermore, ciprofloxacin 
has been shown to induce IL-1b mediated MMP-3 release which may contribute to 
inflammation and degeneration of tendon tissue.104  
 
1.2.2 Histopathology of tendinopathy 
Painful tendons show alterations in cellularity (both increased and decreased), 
decreased matrix organization and increased infiltration of blood vessels.94 
Ruptured tendons display similar degenerative features; however, reduced 
cellularity is observed and there is little evidence of neovascularization.105 
Healthy tendon appears white in colour and has a firm fibroelastic texture, 
whereas tendinopathic tendon is grey or brown and thin and fragile.106 
Microscopically, collagen bundles appear disorganised and at the electron 
microscope level fibres are angulated and vary in diameter and orientation.107,108 
There is also increased ground substance and an increased number of nuclei.109 
Infiltrations of small blood vessels and ingrowths of small nerves are observed in 
tendinopathic tendon.110,107 Furthermore, the presence of lipid vacuoles, 
degranulated endoplasmic reticulum and enlarged lysosomes are consistent with 
tissue hypoxia.105  
 
Many early histological studies failed to demonstrate the presence of 
inflammatory cells in human tendon tissue.107,105,106 However, more recently the 
presence of several immune cell subsets has be documented in tendinopathy.111 
This will be reviewed in the forthcoming section.  
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Figure 1.3 Pathophysiology and histopathology of tendinopathy
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1.3 Inflammation in tendinopathy 
 
Historically, there has been considerable disagreement with regard to 
classification and terminology related to tendon disorders. The term ‘tendonitis’ 
was traditionally used to describe painful symptoms attributed to inflammation of 
the tendon while ‘tendinosis’ refers to damage at a cellular level and is associated 
with chronic degenerative changes.112,113 Divergence from the original, widely 
accepted ‘tendonitis’ paradigm came from histological observations that showed 
load bearing regions of tendons were devoid of an inflammatory cell component 
while studies documenting long term administration of NSAIDs and periodic local 
corticosteroid injections showed little alleviation of symptoms.66 Henceforth, 
theories relating to the ‘degenerative’ hypothesis became prominent and widely 
advocated by many research groups and clinicians.114,115,116,117,118 
 
However, due to recent advancements in immunohistochemistry and gene 
expression analysis it is becoming increasingly apparent that a lack of observation 
of acute inflammatory infiltrate does not exclude a pivotal role for inflammation 
in the pathogenesis of acute and chronic tendon injury.119,120 Chronological 
restraints including late presentation of symptoms in human patients, cases of 
recurrent injury and the availability of tissue samples for study (the majority of 
biopsy samples are usually acquired during surgery following acute rupture) may 
have a bearing on observations of inflammation during different stages of disease. 
With regard to the resurgence of interest in inflammation in tendinopathy a 
comparison can be made with the classification of joint conditions where 
‘arthritis’ now takes precedence over ‘arthrosis’ as infiltration of inflammatory 
cells and cytokines have been identified as a key contributing factor to pathology, 
in addition to long term degenerative processes.121,122,123  
 
It is now well established that inflammatory mediators are essential in the 
initiation and maintenance of tendinopathy. Increased inflammatory cell infiltrate 
(particularly of macrophages, mast cells and T cells) and expression of 
inflammatory markers has been observed in the early stages of tendinopathy.111 
Several studies have outlined a role for a diverse range of inflammatory mediators 
including various cytokines and alarmins.82,124 
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1.3.1 Alarmins in tendinopathy  
As discussed in the previous section, the main external precipitating factor in the 
development of tendinopathy is mechanical strain. This can occur beneath the 
physiological threshold which results in repetitive microtrauma and cumulative 
injury due to incomplete healing.125 Alternatively, forces that exceed the elastic 
modulus of the tendon result in acute traumatic injury. In either case, damage to 
the tendon matrix occurs resulting in cellular damage or necrosis.48  
 
Historically,  the nature of host-innate immune response to pathogen invasion has 
been well documented.126 Over the last decade, damage associated molecular 
patters (DAMPs) or alarmins have been identified as an analogue to pathogen 
associated molecular patterns (PAMPs) and are considered signalling mediators of 
sterile inflammatory responses. ‘Alarmins’ are so called as they provide the initial 
molecular signal that alerts surrounding cells to damage or danger.127 The ‘danger 
hypothesis’ was first described in 1994 and suggested that cells are activated by 
alarm signals from injured cells such as those exposed to toxins and mechanical 
damage.128 It was suggested that alarmins were intracellular factors that become 
exposed and available for recognition by the immune system when cells lose their 
compartmentalization during necrosis. Being entirely theoretical the hypothesis 
attracted a great deal of debate; however, the existence of several ‘alarmins’ 
have since been revealed.129 Upon binding of pattern recognition such as toll like 
receptors (TLRs) on the cell surface, alarmins induce the expression of cytokines 
and chemokines to mobilize and recruit immune cells to the site of injury.130 
 
S100 proteins 
S100 proteins are low molecular weight calcium binding proteins (approximately 
10-12kDA) that regulate a variety of intracellular and extracellular processes 
including cell growth and motility, cell cycle regulation, transcription, 
differentiation, energy metabolism and inflammation.131 S100 proteins may 
function in an intracellular or extracellular manner while some display both 
properties.132,133,134 The extracellular S100 proteins are considered ‘alarmins’ and 
play a role in immune homeostasis, post-traumatic injury and inflammation. In 
addition, some have been adopted as surrogate biomarkers in a number of 
diseases.135 S100 proteins with extracellular functions include S100B, S100A4, 
S100A8, S100A9 S100A12, S100A13. S100B exhibits neurotrophic activity, S100A4 
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is pro-angiogenic, S100A12 participates in the host-parasite response and S100A13 
is a component of a secreted complex containing fibroblast growth factor FGF-1. 
136  Of the S100 proteins, S100A8 and S100A9 are the most well studied in the 
context of tissue damage and inflammation.137  
 
S100A8 and S100A9¾also known as myeloid-related proteins 8 and 9 (MRP8 and 
MRP9)¾are constitutively expressed in monocytes and neutrophils. Human S100A8 
and S100A9 are composed of 93 and 113 amino acid residues, respectively and are 
able to form a stable heterodimer.138 Under inflammatory conditions they are 
actively secreted to modulate the inflammatory response through induction of 
leukocyte recruitment and cytokine secretion.137 S100A8/S100A9 heterodimer or 
calprotectin is the most abundant naturally occurring S100 heterodimer and is 
thought to play a cytokine-like role in inflammation. S100A8 and S100A9 bind to 
pattern recognition receptors including toll-like receptor 4 (TLR4) and receptor 
for advanced glycation end products (RAGE).139,140  
 
S100A8 and S100A9 in inflammation 
S100A8 protein is abundant in some immune cells (accounting for 20% of neutrophil 
cytoplasm) and genetic deletion of S100A8 in mice is lethal.141 Its expression is 
induced in macrophages, dendritic cells, epithelial cells and fibroblasts in 
response to inflammatory stimuli.142 S100A8 has been implicated in a variety of 
immunomodulatory roles including myeloid cell differentiation, scavenging of ROS 
generated by activated neutrophils, and inhibition of transendothelial migration 
of neutrophils. Studies in the context of inflammation have shown S100A9 inhibits 
differentiation of macrophages, DCs and accumulation myeloid-derived suppressor 
cells (MDSCs) in cancer through generation of ROS.87 Furthermore, S100A9 gene 
deletion compromises neutrophil responses to chemoattractants and cytoskeletal 
dynamics thus inhibiting transendothelial cell migration.143  
 
S100A8 and S100A9 have also been associated with myeloid cell differentiation 
toward macrophages and dendritic cells.144 They are co-expressed in fetal myeloid 
progenitors where their expression level correlates with commitment to the 
myeloid lineage.145 S100A8/A9 heterodimer is thought to amplify pro-
inflammatory cytokine production by macrophages via NFkB and p38 MAPK in 
rheumatoid arthritis.146 In addition, S100A8/A9 has been implicated in monocyte 
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and neutrophil transmigration and has been shown to enhance expression of CD11b 
and adhesion of phagocytes.107,144  
 
S100A8 and S100A9 in inflammatory diseases  
Expression of S100A8 and S100A9 has been documented in various models of 
osteoarthritis and rheumatoid arthritis.147 In mice, S100A8/A9 is upregulated in 
early but not late phase OA while S100A9 knockout mice display significantly 
reduced osteophyte size.148 In antigen induced arthritis articular cartilage 
destruction is absent in S100A9-/- mice and synovial gene expression of MMP-3, -9 
and -13 is low. Furthermore, expression of these genes was elevated in murine 
macrophages stimulated with S100A8 or S100A8/A9.149 In human OA patients 
S100A8/A9 plasma levels are elevated at baseline.148 S100A8, S100A9 and the 
heterodimer have all been identified in joint fluid in patients with RA and levels 
of S100A8/A9 correlate with disease activity. Histologically, S100A8 and S100A9 
expression has been identified in synovial lining and sublining macrophages. 
Furthermore, expression of S100A8/A9 heterodimer is strongly correlated with 
severity of radiological bone erosion in RA.150 Taken together, these data suggest 
that S100A8 and S100A9 play a role in the pathogenesis of musculoskeletal disease.  
 
S100A8 and S100A9 proteins have been proposed as biomarkers of disease activity 
in several chronic inflammatory pathologies including RA151, psoriatic arthritis 
(PsA)152, inflammatory bowel disease (IBD)153 and cystic fibrosis (CF).154 In RA 
S100A8/A9 was proposed as a biomarker for predicting clinical outcome of 
treatment. Others have proposed S100A8/A9 levels may be a more accurate 
predictor of synovial inflammation in RA patients compared to traditional markers 
such as C-reactive protein (CRP).155  
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Figure 1.4 Summary of S100A8 & A9 signaling
Figure adapted from Xia et al 2018
 40 
High Mobility Group Box 1 
High mobility group box 1 (HMGB1) is a highly abundant nuclear protein that 
modulates intracellular and extracellular biological activities. Within the nucleus 
HMGB1 is involved in determining chromosomal architecture and regulating 
transcription.156 In the extracellular space it functions as an alarmin to stimulate 
the innate immune system, alone or in concert with various cytokines, endogenous 
or exogenous molecules.157 HMGB1 is released from cells passively under necrotic 
conditions or secreted actively during late apoptosis (secondary necrosis).158  It is 
also secreted actively by immune cells including monocytes, macrophages and 
DCs.159 HMGB1 acts through PRRs including TLR2, TLR4, TLR9 AND RAGE to 
modulate immune activities including cytokine production, cell proliferation, 
chemotaxis and differentiation.160 
 
Extracellular HMGB1 is thought to contribute to the pathogenesis of numerous 
chronic inflammatory and auto-immune diseases including RA, systemic lupus 
erythematosus (SLE), atherosclerosis and pulmonary fibrosis.161 Several studies 
have identified the expression of HMGB1 in tendon pathology.162,163,164 In a human 
model of tendinopathy HMGB1 was shown to regulate expression of inflammatory 
mediators and matrix proteins. Furthermore, blocking HMGB1 signalling via TLR4 
silencing reversed these inflammatory and matrix changes.162 Recently, several in 
vitro and in vivo studies targeting HMGB1 signalling have provided promising 
results in the context of inflammation and matrix remodelling.165 
 
IL-33 
IL-33 is a nuclear cytokine of the IL-1 family and is most well studied in the context 
of type-II innate immunity and asthma.166 Biologically active full length IL-33 can 
be released into the extracellular space following cell damage or mechanical 
injury thus it is considered a classical cytokine alarmin.167,166 It is constitutively 
expressed in normal tissue and can be induced in haematopoietic cells during 
allergic inflammation and infection.168 Increased expression of IL-33 has been 
observed in pathologies with large numbers of necrotic cells including RA and SLE; 
it is thought to act in a similar manner to HMGB1 as both are released from dying 
cells and both are nuclear factors.169,170  
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Heat shock proteins 
Heat shock proteins are the most abundant soluble intracellular proteins found in 
all prokaryotes and eukaryotic cells. Although some HSPs are constitutively 
expressed, expression is generally induced in response to stress including heat 
shock, inflammation and infections.171  Functioning as alarmins, they are released 
into the extracellular space upon necrotic cell death and signal through PRRs such 
as TLRs to activate innate immunity. HSPs induce secretion of pro-inflammatory 
cytokines including TNF-a, IL-1b and GM-CSF by macrophages172, induce iNOS and 
subsequent NO production by macrophages and DCs173 and promote secretion of 
chemokines including monocyte chemoattractant protein (MCP-1) and 
macrophage inflammatory protein (MIP-2) from T cells.174 The reported cytokine-
like effects of HSPs have been postulated to contribute to the pathogenesis of 
many autoimmune and chronic inflammatory diseases.175 
 
HSP27 and HSP70 expression has been identified in rat and human models of 
tendinopathy and was found to correlate with expression of apoptotic regulators 
including caspases 3 and 8 and cFLIP. The authors propose that extracellular heat 
shock proteins released under conditions of cellular stress are implicated in 
degenerative processes in tendinopathy.81  
1.3.2 Cytokines in tendinopathy and chronic inflammation 
Cytokines are small secreted proteins (of approximately 30-50KDa) released by 
cells to facilitate cellular communication. Cytokines are crucial mediators of both 
acute and chronic inflammation.176 Dysregulated cytokine production and 
accumulation is thought to contribute to persistence of inflammation and 
pathological chronic inflammation.177 Cytokines can be classified according to 
their cell of origin or purpose. For example, interleukins are cytokines made by 
leukocytes that predominantly act on other leukocytes and chemokines are 
cytokines with chemotactic properties. Cytokines are extremely versatile and may 
act in an autocrine, paracrine or endocrine manner thereby facilitating a diverse 
range of cellular functions.178 Historically, cytokines have been classified 
according to their ‘pro-inflammatory’ or ‘anti-inflammatory’ properties; however, 
it is now widely accepted that cytokines and their signalling pathways are 
extremely sophisticated and non-binary in their mode of action.  
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IL-6 
IL-6 was first cloned and studied in 1986 and has since been described as a 
pleiotropic cytokine that influences antigen specific immune responses and 
inflammatory responses.179 It is produced by several types of cell including T cells, 
B cells, monocytes, fibroblasts and endothelial cells and modulates numerous 
biological activities.180 IL-6 is a key mediator of the acute phase response which 
is characterised by changes of concentration of plasma proteins known as ‘acute 
phase reactants’ and several other biochemical and physiological responses.181 As 
well as mediating acute inflammatory processes IL-6 is crucial in the switch from 
acute to chronic inflammation. In acute inflammation the leukocyte infiltrate is 
primarily neutrophilic; after 24 to 48 hours monocytic cells predominate. 
Histologically, chronic inflammation is associated with the presence of 
mononuclear cells including macrophages and lymphocytes.182,183 The transition 
from neutrophil to monocyte recruitment is dependent on the specificity of 
chemokines produced at the inflammatory site. IL-8 and CCL2 (MCP-1) are the 
predominant cytokines involved in recruitment of neutrophils and monocytes, 
respectively. IL-8 production by neutrophils occurs in the 24 hours following 
initiation of the inflammatory cascade resulting in further recruitment and local 
activation of neutrophils. CCL2 production is delayed but often persists for several 
days resulting in monocyte recruitment and accumulation at the site 
inflammation.184,185 The shift in from neutrophil to monocyte recruitment may also 
mediated by chemokines secreted by stromal cells or macrophages.186 
 
The IL-6-IL-6Ra complex has been shown to activate endothelial cells to secrete 
IL-8 and CCL2 in addition to the expression of adhesion molecules. IL-6-IL-6Ra 
complex associates with signal transducing membrane protein gp130 to initiate 
intracellular signalling cascades in a mechanism termed trans signalling.187 Gp130 
is ubiquitously expressed; however, in humans IL-6Ra expression is limited to 
leukocytes and hepatocytes.  Soluble IL-6Ra has been identified in neutrophil rich 
inflammatory fluids such as synovial fluid.188 Several studies have identified a 
mechanism through which the IL-6-IL-6Ra complex favours leukocyte 
accumulation and a transition from acute to persistent inflammation through 
regulation of IL-8 and CCL2 production.189,190  
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The expression of IL-6 and its interactions with transcription activator STAT3 in 
tendinopathy has been well characterised. IL-6 expression was first identified in 
tendon and found to be upregulated in tendon pathology.191  Tendons of surgically 
injured IL-6 knockout mice show inferior mechanical and structural properties 
compared with controls indicating IL-6 is implicated in tendon healing.192 
Furthermore, cyclical loading of tendons resulted in increased expression of IL-6 
and collagen 1 suggesting a role for IL-6 in tendon adaptation to exercise.193 
Additional mechanical studies showed that tenocytes release IL-6 in response to 
mechanical loading; however, IL-6 did not exhibit any autocrine function in an in 
vitro model of tenocyte stimulation.194,195 Cytokines and alarmins including IL-1b, 
IL-33, HMBG1 and S100A8 & A9 induce IL-6 gene expression and protein release in 
human tenocytes.196,197,162,198 Furthermore, damaged tendons show dysregulated 
IL-6 signalling as a result of decreased expression of IL-6R and upregulation of 
intracellular signal transducer STAT3.199 In line with its pleiotropic properties, the 
data suggest that IL-6 is capable of modulating a number of cellular processes in 
tendinopathy which may involve pro- or anti-inflammatory actions.  
 
TNF-a 
TNF-a is a prototypic pro-inflammatory cytokine that is a product of activated 
monocytes/macrophages, fibroblasts, mast cells, T cells and NK cells. It is a 
potent paracrine inducer of other inflammatory cytokines including IL-1, IL-6, IL-
8 and GMCSF as well as acting as an autocrine stimulator.200 It is also known to 
induce expression of adhesion molecules on fibroblasts.201 The physiological role 
of TNF-a has been widely studied in RA where TNF plays a crucial role in disease 
pathogenesis. Individuals with RA have high levels of TNF-a in the synovial fluid 
and Inhibiting TNF signalling in RA fibroblast-like synoviocytes (FLS) reduces the 
production of IL-6, IL-8, IL-1 and GMCSF.202,203  
 
Expression of TNF-a and TNFR1 has been identified in inflamed equine tendon and 
TNFR1 and TNFR2 expression is co-localized on the surface of equine tenocytes. 
This expression can be upregulated in response to TNF-a stimulation suggesting 
the existence of an autocrine feedback mechanism.204,205 In human tendon tissue 
TNF-a mRNA is increased 11-fold in torn supraspinatus tendon (representative of 
late pathology) compared with control and increased expression of TNF receptors 
has been observed in Achilles tendon.82,206,207 Cultured human tenocytes 
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stimulated with TNF-a showed reduced type I collagen deposition and increased 
elastin gene expression. In addition expression of MMP-1, TNF-a, IL-1b, IL-6 and 
IL-10 was highly upregulated in response to TNF-a stimulation.195 Culture of 
tendon explants with exogenous TNF-a resulted in increased expression of TLR2 
but not TLR4.208 Evidence suggests that TNF signalling through both TNFR1 and 
TNFR2 has an autoregulatory effect on amplifying the inflammatory response in 
tendinopathy. 
 
IL-1 family cytokines 
IL-1 family cytokines are important regulators of innate and adaptive immunity 
regulating early non-specific defence to pathogen invasion and other insults such 
as injury or stress. They are unique in their properties as IL-1 cytokines and TLRs 
share a common cytoplasmic domain called the Toll-IL-1-Receptor (TIR).209 Signal 
transduction mechanisms and biological consequences of TLR and IL-1 family 
ligands are virtually indistinguishable. IL-1 family members include IL-1a, IL-1b, 
IL-18 and IL-33. IL-1 cytokines are potent inducers of inflammation and amplify 
the immune response thus their expression must be tightly regulated to avoid 
tissue damage.210 Dysregulated activity of these cytokines is associated with 
autoimmunity and chronic inflammatory diseases including RA, SLE and IBD.211  
 
IL-1b is a potent inducer of several inflammatory mediators in human tenocytes 
including IL-6, IL-8, CCL2, COX-2 and PGE2.196,212,197 In addition, it has been shown 
to induce the expression of MMP-1, -3 and -13.196 Stimulation of tenocytes with IL-
1b downregulates expression of type I collagen with a resultant increase in type 
III collagen indicating this inflammatory stimulus may have a detrimental effect 
on the integrity of the tendon matrix.213 IL-8 mRNA expression has also been 
identified in human tissue samples from patients with rotator cuff tears.82 More 
recently, the effect of IL-33 has been investigated in tendinopathy. As discussed 
previously, IL-33 is released into the extracellular space following tissue damage 
and acts as an ‘alarmin’ molecule to activate the innate immune system. Millar et 
al demonstrated significantly increased expression of IL-33 in early human 
tendinopathy that is lost in end stage disease.197 Increased expression of type I 
and type III collagen mRNA and protein levels in tenocytes was also reported in 
response to stimulation with  recombinant human IL-33. This was accompanied by 
increases in inflammatory mediators IL-6, IL-8 and CCL2. The stimulatory effect 
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of IL-33 was abrogated by inhibition of NF-kB signalling suggesting canonical IL-1R 
signalling may be responsible for this effect. Further in vivo work demonstrated 
rhIL-33 increased synthesis of type III collagen and resulted in diminished tendon 
tensile strength in a murine tendon injury model. In mice that lack IL-33 decoy 
receptor (ST2), rhIL-33 had no effect on ECM synthesis indicating the action of IL-
33 is dependent on ST2 signalling. Furthermore, pharmacological neutralization of 
endogenous IL-33 mitigated the switch from type I to type III collagen and resulted 
in improved tendon biomechanical properties.197 
 
IL-21 is a proinflammatory cytokine of the IL-1 family and is produced mainly by 
CD4+ lymphocytes and natural killer T cells (NK). It is known to modulate T cell 
proliferation, B cell differentiation, and cytotoxic properties of NK cells, as well 
as the antigen presenting and T-cell activating abilities of dendritic cells.214 
Overexpression is associated with chronic inflammatory diseases including 
rheumatoid arthritis and inflammatory bowel disease.215 IL-21R expression has 
been identified in early tendinopathy and TNF-a and IL-1b induce expression of 
IL-21R transcript and protein in human tenocytes.216 
 
IL-8 
IL-8 is a member of the CXC chemokine family and an important modulator of 
neutrophil accumulation and activation of acute inflammation. IL-8 is produced 
by a number of cell types including monocytes, endothelial cells and fibroblasts.217 
As described previously IL-8, acting in concert with CCL2 and IL-6, is an important 
mediator in the transition from acute to chronic inflammation.218 Several studies 
have documented the expression of IL-8 in human tenocytes whereby expression 
is induced by IL-1b, IL-33, IL-17A, HMGB1, S100A8 and S100A9.197,219,162,198 In 
addition, IL-8 expression is upregulated in ruptured Achilles tendons.220 
 
CCL2 
CCL2, otherwise referred to as monocyte chemoattractant protein (MCP-1), is a 
member of the CC chemokine family and a potent chemotactic factor for 
monocytes.221 It is produced by fibroblasts, endothelial cells, smooth muscle cells, 
epithelial cells and myeloid cells although monocytes/macrophages are thought 
the main source of CCL2.222 CCL2 exerts its effects through binding of G protein 
coupled receptors on the surface of leukocytes targeted for activation and 
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migration.223 The CCL2/CCR2 axis plays a critical role in monocyte recruitment in 
response to infection or insult acting to promote resolution of inflammation by 
phagocytosis of cellular debris and apoptotic cells.  Under homeostatic conditions, 
CCL2 also promotes emigration monocytes from the bone marrow in to 
circulation.224 As discussed with IL-6 and IL-8, CCL2 is involved in the transition 
from acute to chronic inflammation and its expression is upregulated in human 
tenocytes in response to various cytokines and alarmin molecules. 197,219,162,198  
 
CXCL10 
CXCL10 (interferon g inducible protein) is a member of the CXC chemokine family 
which binds to the CXCR3 receptor to exert its biological effects.225 It is secreted 
by a variety of cells including activated neutrophils, leukocytes, monocytes, 
eosinophils, monocytes, epithelial cells, endothelial cells and stromal cells.226 It 
is chemoattractant for monocytes, T cells and NK cells. CXCL10 plays a key role 
in leukocyte homing to inflamed tissues thus has potential to exacerbate 
inflammation and cause tissue damage.227 CXCL10 overexpression has been 
observed in several inflammatory pathologies and cancer.228,229,2302 
 
CCL20 
CCL20 (also referred to as macrophage inflammatory protein-3alpha (MIP-3a)) is 
the only known chemokine to interact with its receptor CCR6. It is widely 
expressed by immune cells and stromal cells under both homeostatic and 
inflammatory conditions.231  The CCL20-CCR6 axis regulates chemotaxis of DCs, T 
cells and B cells. Diseases associated with CCL20 include RA and certain cancers.232 
CCL20 levels are significantly elevated in the synovial fluid of patients with RA 
and its expression is upregulated in RA-FLS in response to TNF-a, IL-1 and IL-17.233  
 
IL-4/IL-13 
IL-4 and IL-13 are related cytokines that play an important role in regulating 
responses of lymphocytes, myeloid cells and non-hematopoietic cells.234 IL-4 and 
IL-13 induce the differentiation of naïve T cells into Th2 cells and is implicated in 
‘alternative activation’ of macrophages.235 In a murine tendon injury model          
IL-4-/- mice show disorganised collagen structure and impaired mechanical 
properties.192 In addition expression of IL-4Ra, IL-13Ra1 and IL-13Ra2 but not the 
common gamma receptor chain are expressed in tendon tissue and cultured 
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tenocytes. Furthermore, tenocytes stimulated with rhIL-4 and IL-13 display 
increased proliferation rates.236 
 
IL-17 family cytokines 
The IL-17 family consists of IL-17A-F plays a crucial role is host defence to 
microbial organisms and the development of inflammatory disease.237 IL-17A is 
primarily produced by the Th17 subset of T helper cells and excessive production 
leads to excessive inflammation and consequent tissue damage.238 Increased 
expression of IL-17A and IL-17F has been identified in tendinopathy.219,199  In early 
tendinopathy, IL-17A expression was localised to mast cells, macrophages and T 
cells. Furthermore, tenocytes stimulated with IL-17A exhibit increased production 
of pro-inflammatory cytokines, altered expression of ECM components including 
type III collagen and increased expression of several genes associated with 
regulation of apoptosis.219  
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Figure adapted from Millar et al 2017
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1.4 Immune cells in tendinopathy 
  
The concept of cells existing in specific subsets or ‘compartments’ within the 
tendon is a theory that has emerged over the past decade following the departure 
of the ‘degenerative hypothesis’. In 2001 Marsolais et al published a study 
documenting the sequential accumulation of neutrophils and monocytes in tendon 
post injury.239 Due to the emergence of the ‘tendinosis’ model it was almost ten 
years until the concept of immune cells in tendinopathy was revisited. In 2010 a 
study in human rotator cuff tendon biopsies demonstrated the presence of 
macrophages in the subintimal layer, mast cells around the vasculature and 
diffuse distribution of T cells. In particular, mast cells and ‘M2’ macrophages were 
observed in  biopsies with increased fibroblast cellularity.111 Subsequent studies 
of macrophage populations in equine tendons demonstrated the presence of ‘M1’ 
and ‘M2’ macrophages in sub-acute and chronic tendinopathy, respectively.240 
Furthermore, increased numbers and inflammatory activity of mast cells was 
observed in rodent and human tendinopathy.241,242 A systematic review detailing 
evidence of immune cell subsets in human tendinopathy identified four studies 
highlighting increased numbers of macrophages and three of increased mast 
cells.243  
 
A recent review has proposed the presence of three cellular ‘compartments’ 
within the tendon, comprising of the stromal compartment, the immune sensing 
compartment and the infiltrating compartment. The authors propose the 
‘immune-sensing’ compartment consists of tissue resident macrophages and mast 
cells while the ‘infiltrating compartment’ is comprised of neutrophils and 
circulating monocytes/macrophages recruited to the site of injury.29 A study 
detailing infiltration of inflammatory cells in surgically induced tendon injury 
showed rapid and transient accumulation of neutrophils immediately following 
injury. This was succeeded by gradual infiltration of macrophages 1-28 days post 
injury.239 NK cells and T cells may also be present in this infiltrating 
compartment.244 This evidence, together with activation of inflammatory 
signalling pathways, suggests there is a dynamic immune environment within the 
tendon both under homeostatic conditions and following injury.  
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1.4.1 Monocytes and macrophages 
Monocytes and macrophages are critical regulators of inflammation and the innate 
immune response. The ‘mononuclear phagocyte system’ (MPS) is a population of 
cells derived from erythromyeloid progenitors in the bone marrow that 
differentiate to form blood monocytes and circulate in the blood before entering 
tissues in response to environmental cues.245  The MPS is divided into three subsets 
including (monocytes, dendritic cells and macrophages) on the basis of their 
functional and phenotypical characteristics.246 Monocytes and monocyte-derived 
macrophages from the peripheral blood are actively recruited to sites of 
inflammation to perform phagocytosis and participate in the immune response by 
secreting cytokines and chemokines. 247 They are also recruited in the steady state 
to aid in tissue homeostasis.248 
 
The original MPS classification was based on the premise that the majority of cell 
division occurs in the monoblast and pro-monocyte stage and replication of tissue 
macrophages was a minor mechanism that aided in the maintenance of tissue 
macrophage populations.246 More recent studies have refuted this hypothesis 
based on evidence of a separate lineage of ‘tissue resident’ macrophages that are 
embryonic in origin.249 Tissue macrophages are widely distributed throughout the 
body and are able to undergo self-renewal in situ by proliferation. They are highly 
specialized to their environment and fulfil tissue-specific and niche-specific 
functions.250   
 
The majority of ontogenetic and phenotyping studies in monocytes/macrophages 
have been conducted in mice. Monocytes have been divided into subsets based on 
their expression of the membrane monocytic marker Ly6C and CCR2.251 ‘Classical’ 
or inflammatory monocytes are Ly6C+ CCR2+ and ‘alternative’ monocytes are 
Ly6ClowCCR2-. In humans, monocytes are characterized based on their expression 
of CD14 (TLR4 co-receptor) and CD16 (FcgRIII) where ‘classical’ monocytes are 
CD14+CD16-, intermediate monocytes are CD14+CD16+ and ‘alternative’ monocytes 
are CD14lowCD16+.252 The classification of macrophages is somewhat more 
complex; however, F4/80 (murine) and CD68 (human) are generally considered 
pan macrophage markers.253  
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Under normal homeostatic conditions macrophages perform housekeeping 
functions independently of activating stimuli generated by immune cells. 
Macrophages recognize both exogenous (PAMPs) and endogenous danger signals  
generated by necrotic cells (DAMPs) and signal through PRRs such as TLRs.254 Upon 
activation macrophages express a wide variety of receptors including scavenger 
receptors that enhance their activity and capacity for phagocytosis, endocytosis 
and adhesion.255,256 Furthermore, integrin receptors play an important role in 
tissue homeostasis by facilitating the attachment of macrophages to the 
extracellular matrix and signal transduction from the ECM to the cell.257  
 
Macrophages are essential mediators of innate and adaptive immunity and display 
a remarkable degree of plasticity. Initial observations of phenotypical and 
functional adaptability were likened to polarization of T helper cell responses that 
represent two distinct and opposing states of activation. Henceforth, 
macrophages were described as ‘classically activated’ (M1) or ‘alternatively 
activated’ (M2) mirroring Th1 and Th2 nomenclature.258 Interactions with T 
lymphocyte subsets were crucial to defining their phenotype as M1 macrophages 
are activated as a result of stimulation with IFN-γ or initiation of TLR signalling by 
LPS while M2 macrophages are activated by IL-4 and IL-13 predominantly released 
by Th2 cells.259 ‘M1’ macrophages have a largely pro-inflammatory cytokine profile 
acting through the release of IL-1, IL-6 and IL-23 thus promoting a Th1 response. 
Moreover, classically activated macrophages have strong antimicrobial and 
tumoricidal properties conferred by release of reactive oxygen and nitrogen 
species. 260 
 
As the classification of macrophages as ‘M1’ and ‘M2’ represented two distinctly 
polarized states, nomenclature was expanded to include three subsets of M2 
macrophages: ‘M2a’ activated by IL-4/IL-13 signalling, ‘M2b’ induced by 
immunocomplexes and TLR agonists and ‘M2c’ activated by IL-10 and 
glucocorticoids.261 It has since been postulated that the process of macrophage 
polarization is not confined to distinct subsets but rather it represents a variable 
and fluid spectrum of activation states dependent upon the tissue 
microenvironment.262  
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1.4.2 Monocytes and macrophages in wound healing and tendinopathy 
Previous studies have identified the presence of macrophages in normal and 
diseased human tendons.111,212 Thus far, the question of the origin of these 
macrophages has not been addressed. Monocyte-derived macrophages are actively 
recruited to the tissue as part of the acute inflammatory infiltrate in response to 
injury. Tissue resident macrophages are unique to their microenvironment and 
critical for maintaining homeostasis within the cell; they also retain the capacity 
to respond to local cues within the tissue milieu.250 Taking evidence from 
literature that documents the contribution of macrophages to inflammation and 
fibrosis in other chronic inflammatory pathologies, it may be postulated that both 
foetal tissue macrophages and monocyte-derived macrophages co-exist within the 
tendon under inflammatory conditions.263,264,265   
 
There is evidence to suggest that the ‘activation’ state of macrophages is fully 
and rapidly reversible.266 This potential activation plasticity is relevant to 
tendinopathy where, in the early stages, inflammation is the major factor 
contributing to matrix dysregulation. At this stage, it is conceivable that a ‘pro-
inflammatory’ macrophage phenotype dominates and contributes to matrix 
destruction and alterations in tissue architecture by release of MMPs.267 In 
cutaneous wound healing, various studies have proposed a role for ‘pro-
inflammatory’ macrophages during the onset of injury (inflammatory phase) while 
an ‘alternatively activated’ or pro-resolving phenotype dominates in the 
resolution phase.268,269 These interpretations led to the creation of further ‘M2 
like’ subgroups such as ‘wound healing macrophages’. 
 
It has been postulated that the phenotype of macrophages evolves with the stages 
of wound healing based on spatiotemporal cues within the wound.262 Pro-wound 
healing macrophages secrete a variety of factors including platelet-derived 
growth factor (PDGF), insulin-like growth factor (IGF-1),TGF-β1,VEGF and IL-10. 
Secretion of these factors by macrophages is thought to stimulate fibroblast 
proliferation and synthetic activity.268 Furthermore, wound-healing macrophages 
secrete TIMPs to counteract the activity of MMPs and facilitate formation of the 
extracellular matrix.267 
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Literature from various pathologies attributed to inflammation induced matrix 
deposition has suggested alternative activation of macrophages is responsible for 
a failed healing response.265,270,271 It is evident that dysregulated macrophage 
function can lead to aberrant tissue repair, perpetuated inflammation and 
impaired communication between macrophages and stromal cells. If left 
unchecked this may lead to chronic inflammation and development of pathological 
fibrosis. 
1.4.2 Surface markers associated with a pro-resolving phenotype  
Nomenclature surrounding the various activation states of macrophages is 
complex and widely disputed. As such, the term ‘pro-resolving’ macrophage will 
be used hereafter in reference to macrophages displaying characteristics of 
‘alternative activation’. The following section will briefly describe surface 
markers associated with a ‘pro-resolving’ phenotype relevant to this thesis.  
 
CD163 
CD163 (haemoglobin scavenger receptor) expression is specific to monocyte-
macrophage lineage. It is highly expressed in certain types of macrophages 
(including bone marrow macrophages, alveolar macrophages and Kupffer cells) 
and it exhibits modest expression in monocytes.272 High CD163 expression is 
characteristic of tissues responding to inflammation and its expression has been 
documented in chronic inflammatory pathologies including inflammatory arthritis 
and atherosclerosis.273,274 
 
CD206 
CD206 (also referred to as mannose receptor or MRC-1) is a transmembrane 
glycoprotein that belongs to the C-type lectin family. It is predominantly 
expressed by macrophages but may be expressed by immature DCs and specialized 
lymphatic and endothelial cells.275 Functionally, CD206 is active in antigen 
processing, endocytosis and phagocytosis, playing an important role in the 
innate immune response.276 In addition, increased expression of CD206 has 
been observed in human tendinopathy.212     
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MerTK 
The TAM receptors (Tyro3, Axl and Mer) are receptor tyrosine kinases that play an 
important role in anti-inflammatory feedback mechanisms. The receptors share 
ligands Gas6 and Protein S (Pros1).277 MerTK is expressed on macrophages and DCs 
where ligand binding enhances phagocytic capacity of the cell. It is also thought 
TAM receptors negatively regulate inflammation by inducing SOCS (suppressor of 
cytokine signalling) proteins 1 and 3 that inhibit TLR and cytokine signalling.278 
TAM deficient mice develop auto-immunity associated with impaired inhibition of 
inflammation and dysregulated phagocytosis.279 MerTK expression is associated 
chronic inflammatory pathologies including RA, SLE and MS.280,281,282 
 
HLA-DR 
HLA-DR is an MHC class II cell surface receptor expressed on antigen-presenting 
cells (macrophages, B cells, DCs). MHC-II expression is upregulated in alveolar 
macrophages and tumour associated macrophages (associated with an 
‘alternatively activated’ phenotype).283,284  
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1.5 Stromal Biology 
 
Stromal cells are tissue resident cells that support tissue function and   
homeostasis.285 Fibroblasts, endothelial cells, pericytes and epithelial cells are 
stromal cells that modulate a variety of niche specific functions. Fibroblasts are 
highly specialized to their microenvironment and are essential in the maintenance 
of tissue architecture.286 ‘Fibroblast’ is an umbrella term that encompasses cells 
within tissues that synthesize components of the extracellular matrix. As discussed 
in section 1.1.3, tenocytes are fibroblast-like differentiated cells that perform 
this function within the mature tendon.31 The composition of ECM products 
secreted by fibroblasts is highly influenced by the local microenvironment thus 
cellular heterogeneity is observed between tissues.287 It has also been postulated 
that more discreet differences exist between fibroblasts from various anatomical 
locations within the same tissue.288  
 
Historically, immunologists have considered fibroblasts somewhat benign in the 
co-ordination of immune responses within tissues. Studies largely focused on 
lymphocyte-myeloid cell interactions and antigen-driven responses in the 
development of chronic inflammation and autoimmunity.289 However, more 
recently it has been acknowledged that molecular danger signals are not antigen 
specific and the immune environment has since been broadened to include a role 
for fibroblasts in inflammation.290 Key questions in the current fibroblast 
literature focus on identifying factors that trigger persistence of inflammation 
with the ultimate aim of developing strategies to prevent disease chronicity. 
1.5.1 Chronic inflammation 
Chronic inflammation is a feature of many diseases of differing aetiology and 
pathophysiology. Autoimmune diseases associated with chronic inflammation 
include RA, psoriasis, SLE and IBD.291 Cancers include gastric cancer (caused by 
chronic H.pylori infection), colorectal cancer (arising as a result of IBD), liver 
carcinoma due to hepatitis C infection and pancreatic ductal adenocarcinoma 
(PDAC).292 In addition, fibrotic disorders associated with excessive ECM production 
manifest as end organ pathology in the lung, heart, kidneys and liver and fibrotic 
disorders of connective tissue include scleroderma, adhesive capsulitis (frozen 
shoulder), Dupuytren’s contracture and Peyronie’s disease.293  
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Inflammation as a result of tissue insult or infection is generally beneficial as 
recruitment of inflammatory cells to the site of injury aids in the clearance of 
cellular debris and pathogens.294 Chronic inflammation occurs as a result of an 
imbalance between inflammatory cell recruitment, proliferation and apoptosis. 
Stromal cells, specifically vascular endothelial cells, play a key role in initiation 
of the innate immune response.295 Damage compromises the vessel wall triggering 
an acute vascular response characterized by increased blood flow, vascular 
permeability, activation of fibroblasts and endothelial cells and infiltration of 
polymorphonuclear cells. This is succeeded by the chronic cellular response that 
consists of increased trafficking of mononuclear cells. Here, the term chronic is 
used to represent a physiological phenomenon that occurs over weeks and is 
characterized by phagocytosis, tissue repair by fibroblasts, emigration and 
apoptosis of leukocytes and ultimately resolution of inflammation.296  
 
Identifying the point at which physiological self-limiting inflammation becomes 
truly chronic or pathological is crucial to understanding the pathogenesis of many 
inflammatory diseases. Mechanisms regulating chemotaxis of immune cells to sites 
of inflammation are well characterized; however, mechanisms that govern 
retention and accumulation of leukocytes are less well defined.178 Theories 
relating to selective accumulation of leukocyte subsets have been attributed to 
endothelial selection at the point of entry mediated by expression of a variety of 
adhesion molecules.297 It is now widely accepted that upon entry to the stromal 
microenvironment, cells are subject to a variety of stimulating factors that 
promote the expansion of leukocyte pools.298 Studies have shown that induction 
of apoptosis and cytokine deprivation are key to removal of lymphocytes during 
resolution of inflammation.299 However, other inflammatory cells including 
macrophages appear to be relatively resistant to deprivation of external cytokines 
and growth factors.300  
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1.5.2 Stromal activation  
The involvement of the stroma in chronic inflammatory pathologies has generated 
a great deal of interest over the last few years. The idea of fibroblast activation 
was first proposed in the late 1990s as fibroblasts were found to secrete 
chemokines (which had recently been identified as novel group of chemotactic 
cytokines).301,302 Initial studies focused on the ability of bacterial products such as 
LPS to induce secretion of chemokines and facilitate recruitment of inflammatory 
cells. 303 Expression of these mediators by fibroblasts was found to be transient 
but sufficient enough to induce recruitment of haematopoietic cells capable of 
perpetuating ‘fibroblast activation’ through expression of pro-inflammatory 
cytokines such as TNF-a.304 CD40 (a member of the TNF receptor superfamily) was 
deemed a major ‘activation antigen’ on fibroblasts and was proposed to act to 
activate fibroblasts through engagement of CD40L on the surface of immune cells. 
CD40 expression and engagement was found to correlate with expression of 
adhesion molecules, activation of NFkB pathways and secretion of cytokines and 
chemokines.305 These fibroblast-immune cell interactions were considered 
analogous to interactions between leukocytes and antigen presenting cells (APCs). 
As fibroblasts are relatively long lived cells, it was quickly acknowledged that this 
mechanism must be tightly regulated in the steady state to avoid overstimulation 
of the immune response.306 These findings were succeeded by a body of work in 
RA that established fibroblasts derived from the synovium of patients were 
phenotypically distinct from those in non-inflamed joints.307,308 Furthermore, a 
distinctive subset of ‘tumour-associated’ activated fibroblasts has been identified 
in several cancers.309 
 
As yet, the concept of stromal activation in tendinopathy is relatively unexplored. 
The RA synovium and tumour micro-environment are highly dynamic areas of 
exaggerated inflammation. To provide context for this thesis, the following 
sections will review the concept of ‘stromal activation’ and fibroblast 
heterogeneity in RA and cancer.  
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1.5.3 Synovial fibroblasts  
In RA, cells of the synovium were originally classified as type A synoviocytes 
(macrophage-like synovial cells of myeloid origin expressing CD11b, CD68, CD14, 
CD163 and MHC-II) and type B synoviocytes (fibroblast-like synoviocytes of 
mesenchymal origin that express cadherin 11, VCAM-1, ICAM-1 and CD55).310 Type 
B synovial cells or synovial fibroblasts are the most abundant cell type within the 
joint synovium responsible for synthesis of ECM in the synovial fluid. RA-FLS have 
been described as ‘aggressive’ and likened to tumour cells due to their expression 
of oncogenes such as c-Myc and Raf-1 that promote growth and invasion.311 
Furthermore, their aggressive phenotype is associated with tissue destruction 
through dysregulated activity of MMPs/TIMPs. Synovial fibroblasts express a 
number of PRRs including TLR1-9 that are involved in recognition of pathogens 
and products joint damage. Activation of TLRs in synovial fibroblasts has been 
shown to induce the production of cytokines, chemokines and MMPs.312   FLS 
interact with several cell types in the synovium including macrophages, T cells, B 
cells, endothelial cells and osteoclasts.  
 
Synovial fibroblasts isolated from different joints have different phenotypic 
characteristics and heterogenous populations of fibroblasts have been observed in 
the synovium.313  Differences in FLS phenotype were first noted in fibroblasts 
derived from the lining and sub-lining layer. Cells were acquired through 
enzymatic digestion, cultured and stimulated with cytokines (TNF-a, IL-1b and 
TGF-b). Fibroblasts from the lining layer in RA were shown to express high levels 
of podoplanin compared to normal synovium while CD248 expression was 
restricted to sub-lining layer cells. Stimulation with TNF-a or IL-1b resulted in 
increased expression of podoplanin while TGF-b stimulation induced expression of 
CD248. Furthermore, in a SCID human-mouse mode RA-FLS induced expression of 
PDPN and CD248. This study was the first to identify distinct populations of 
fibroblasts based on their surface marker expression.313  
 
This was succeeded by characterization studies in two cohorts of patients with 
early RA to identify any possible relation of expression of stromal markers and 
relationship to diagnosis and prognostic outcome. Immunofluorescence was used 
to detect stromal markers CD55, CD248, FAP and podoplanin in synovial tissue. 
Expression of CD55, CD248, FAP and podoplanin was observed in synovial tissue of 
 59 
all early arthritis patients regardless of prognostic outcome and baseline 
expression of FAP was higher in patients who fulfil criteria for diagnosis of 
established RA. The authors conclude that significant fibroblast activation occurs 
in the early stages of RA.314  
 
Further studies by the aforementioned authors and others have emerged 
describing distinct subsets of fibroblasts in RA using next generation sequencing 
technologies. The first study by Mizgouchi et al identified three fibroblast subsets 
using a combination of bulk transcriptomics on pre-sorted subpopulations and 
unbiased single cell analysis. Populations identified were defined according to 
their expression of CD34, CD90 and cadherin 11.  It was found that the anatomical 
localization of fibroblasts differed according to their surface phenotype with 
CD34-CD90+ localized to the perivascular zone in the sublining layer of the 
synovium and near accumulations of lymphocytes and CD34+CD90+ fibroblasts were 
observed in both superficial lining and deeper sublining layers of the synovium. 
CD34-CD90- fibroblasts were mostly observed in the lining layer. Cadherin 11 was 
expressed in the majority of fibroblasts with highest expression in the lining layer 
and the CD34-CD90+CAD11+ subpopulation was found to be expanded threefold in 
patients with RA compared to OA. The authors proceeded to explore the 
functional differences between fibroblast subsets and found CD34+ fibroblasts 
have a transcriptomic profile characterized by the expression of IL-6, CXCL12 and 
CCL2. This effect was replicated in vitro with CD34+ fibroblasts stimulated with 
TNF-a found to secrete large amounts of IL-6, CXCL12 and CCL2. Furthermore, 
this subset demonstrated enhanced recruitment of peripheral blood monocytes in 
a transwell leukocyte recruitment assay suggesting CD34+ fibroblasts may play a 
role in monocyte recruitment in inflamed synovial tissue.315 Another study using 
droplet-based techniques for single-cell transcriptome profiling of synovial tissue 
identified distinct subsets of CD55+ and CD90+ fibroblasts that are localized to the 
lining and sublining layer, respectively.316 
 
Deletion of FAP-a+ fibroblasts in mice has been shown to suppress inflammation 
and bone erosion in models of resolving and persistent inflammation.317 Single cell 
RNA sequencing identified two additional fibroblasts within the FAP-a+ fibroblasts 
based on their expression of CD90. FAPa+CD90+ fibroblasts were deemed ‘immune 
effector fibroblasts’ localised to the sublining and FAP+CD90- ‘destructive 
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fibroblasts’ were found in the lining layer. Adoptive transfer of FAPa+CD90- 
fibroblasts into the joint resulted in bone and cartilage damage while transfer of 
FAPa+CD90+ fibroblasts resulted in more severe arthritis characterised by 
persistent inflammation with limited bone or cartilage erosion.317  In addition, 
subsequent studies integrating single cell transcriptomics and mass cytometry 
identified four fibroblast subpopulations (based on expression of CD34, HLA-DRA 
and CD90) displaying differential expression in leukocyte rich RA, leukocyte poor 
RA and OA. In leukocyte rich RA (representative a highly inflammatory 
environment) sub-lining specific subsets showed enriched expression of genes 
associated with regulation of leukocyte migration, regulation of the inflammatory 
response, NFkB signalling and IL-6 production.318 Taken together, it is evident that 
fibroblast populations within that RA synovium are heterogeneous and display 
different phenotypical and functional characteristics according to their 
anatomical localization.  
 
1.5.4 Fibroblasts in cancer 
Cancer tissue is composed of cancer cells and associated stromal cells. Stromal 
cells are non-malignant; however, fibroblasts within the tumour 
microenvironment can acquire an ‘activated’ phenotype.292 The tumour 
microenvironment regulates the influx and retention of inflammatory cells such 
as macrophages and is also responsible for the development of ‘carcinoma 
associated fibroblasts’ (CAFs) characterized by expression of a-smooth muscle 
actin (a-SMA) and vimentin; features typical of activated myofibroblasts during 
wound healing responses.319 The concept of ‘fibroblast activation’ was first 
described in the context of solid cancers and expression of fibroblast activation 
protein (FAP) by fibroblasts is now considered a hallmark feature of activated 
stroma.320,321,322  In primary fibroblasts partial silencing of FAP using siRNA resulted 
in reduction of proliferation and production of collagen I, laminin and 
fibronectin.323 Furthermore, FAP-/-  mice show reduced vascularization in lung 
tumours.324 Conversely, overexpression of FAP in CAFs resulted in changes to the 
CAF secretome by inducing expression of inflammatory, proliferative and ECM 
remodelling factors.325  
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FAP has also been shown to promote immunosuppression by CAFs through 
activation of STAT3-CCL2 signalling that enhances recruitment of myeloid-derived 
suppressor cells (MDSCs) thereby promoting tumour growth.326 In addition, 
accumulation of ROS has been shown to induce activation of CAFs through 
induction of growth factors including PDGF and TGF-b.327 Several studies targeting 
FAP have been conducted including the use of CAR-T cells to recognize FAP-
positive cells and allow specific targeting of stromal cells.328 T cell mediated 
elimination of FAP+ CAFs resulted in reduced collagen density allowing for greater 
uptake of chemotherapeutic drugs.329 Studies using cancer vaccines specific for 
FAP have also resulted in tumour regression in the absence of cytotoxic drugs.330 
 
More recently, studies have highlighted the significance of fibroblast 
heterogeneity in PDAC where CAFs are associated with chemotherapy resistance. 
The authors identified two CAF subtypes designated as myofibroblastic 
(characterized by increased expression of a-SMA)  or inflammatory (associated 
with increased expression of IL-6 and leukaemia inhibitory factor (LIF)).331 
Subsequently, tumour secreted factors IL-1 and TGF-b were found to promote CAF 
heterogeneity as IL-1 induces expression of LIF and activation of the JAK/STAT 
pathway to generate inflammatory CAFs and TGF-b reversed this through 
downregulation of IL-1R expression and promotion of differentiation to a 
myofibroblastic phenotype.332 Furthermore, single cell RNA-seq of cells isolated 
from human lung tumours identified five subsets of fibroblasts in tumours 
compared with matched non-malignant lung samples and all subsets of fibroblast 
were found to have differing collagen and ECM molecule expression profiles.333 
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1.5.5 Candidate markers of stromal activation and fibroblast heterogeneity in 
tendinopathy 
The concepts of stromal activation and fibroblast heterogeneity are inextricably 
linked and perhaps only defined by the evolution of modern methodologies. Given 
the nature and diversity of proteins expressed by stromal cells, identifying 
markers relevant to specific disease pathologies is crucial. This section will 
summarise the properties of a panel of cell surface proteins deemed relevant to 
this study. 
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Name(s) Properties References 
CD146 
 
melanoma  
cell adhesion 
molecule 
(MCAM) 
ú Cell adhesion molecule involved in cell migration 
 
ú Regulates inflammatory response in chronic 
inflammatory diseases 
 
ú Involved in recruitment of activated T cells to sites 
of inflammation 
 
ú Regulates cancer cell adhesion 
 
ú Marker for synovial membrane angiogenesis in 
RA 
334,335,336,337,  
CD90  
 
Thy-1  
ú Promotes adhesion of leukocytes to endothelial 
cells and fibroblasts 
 
ú Promotes T cell activation 
 
ú Modulates fibroblast phenotype in wound healing 
and fibrosis  
338,339,340  
CD34 ú Ligand for L-selectin (CD62L); promotes adhesion 
of leukocytes to vascular endothelium  
 
ú Regulates cell proliferation and differentiation  
 
ú Enhances trafficking and migration of 
haematopoietic cells  
 
ú Expression prevalent in solid tumours 
341,342,343 
VCAM1 
(Vascular cell 
adhesion 
molecule-1) 
 
CD106 
ú Mediates contact between cell surface and stroma  
 
ú Mediates leukocyte extravasation to sites of tissue 
inflammation 
 
ú Influences behavior of inflammatory cytokines 
344,345,346  
CD10 
 
Neutral 
endopeptidase 
ú ECM degrading enzyme involved in matrix 
remodelling  
 
ú Influences activation and degradation of pro-
inflammatory peptides involved in immune system 
regulation and autoimmune diseases 
347,348,349 
  
Table 1.3.1 Candidate stromal cell surface markers in tendinopathy 
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Name(s) Properties                           References 
CD47 
 
Integrin 
associated 
protein (IAP) 
ú Regulates the function of monocytes and 
macrophages 
 
ú Interacts with the thrombospondin family of 
extracellular matrix proteins  
 
ú Interacts with SIRPa to regulate lymphocyte 
homeostasis, DC activation and cellular 
translocation 
 
ú Involved in the induction of apoptosis in 
fibroblasts  
350,351,352,353,354 
CD29 
 
Integrin b1 
(ITGB1) 
ú Associates with a integrins to form receptors for 
collagen, laminin, fibronectin, vitronectin and 
VCAM1 
 
ú Links the actin cytoskeleton with the ECM to 
transmit bidirectional signals  
 
ú Migration and development of T and B cells 
 
ú Migration of monocytes, macrophages and DCs 
355,356,357,358 
FAP 
 
Fibroblast 
activation protein 
 
Seprase 
ú Exhibits exopeptidase and endopeptidase 
activities  
 
ú Specifically expressed by cells under stress 
 
ú Marker of carcinoma associated fibroblasts 
(CAFs) 
 
ú Involved in pathological fibrosis 
359,360,328,325 
Podoplanin 
 
PDPN 
ú Associates with the ECM to facilitate migration, 
adhesion and proliferation 
 
ú Plays a key role in platelet aggregation 
 
ú Expression is upregulated in areas of wound 
healing 
 
ú Expressed on CAFs and involved in invasion 
and metastasis 
 
ú Differentially expressed in normal and diseased 
synovium 
  
361,362,363,364,365 
Table 1.3.2 Candidate stromal cell surface markers in t ndinopathy 
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Name(s) Properties                           References 
CD248 
 
Endosialin  
 
Tumour 
endothelial 
marker-1 
(TEM-1) 
ú  Contains C-type lectin domains (CTLD) which 
function in cell adhesion and regulation of 
inflammation 
 
ú Plays a role in tissue remodelling associated 
with increased stromal cell proliferation and 
migration 
 
ú Expressed on pericytes and fibroblasts during 
inflammation 
 
ú Highly expressed in most cancers and on 
activated fibroblasts in RA  
366,367,368,369 
Cadherin 11 ú Regulates collagen and elastin synthesis 
 
ú Regulates inflammation and cartilage damage 
in models of RA  
 
ú Promotes malignant transformation and tumour 
invasiveness  
 
ú Expression is increased in fibrotic tissue 
370,371,308,372,373 
CD81 
 
Target of anti-
proliferative 
antibody-1 
(TAPA-1) 
ú Associates with CD4 and CD8 on T cells  
 
ú Mediates adhesion of T and B cells to stroma 
 
ú Promotes tumour growth and metastasis by 
modulating activities of Tregs and MDSCs 
 
ú Expression is upregulated in RA FLS 
374,375,376  
CD91 
 
low-density 
lipoprotein 
receptor related 
protein-1 
(LRP1) 
ú Involved in receptor mediated endocytosis 
 
ú Regulates cell growth, migration, apoptosis and 
inflammation 
 
ú Regulates macrophage mediated inflammation 
and ECM synthesis in atherosclerosis 
 
ú Tumour suppressing properties through 
clearing of proteases such as MMPs 
377,378,379 
Table 1.3.3 Candidate stromal cell surface markers in tendinopathy 
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1.6 Strategies targeting inflammation in musculoskeletal disease 
 
1.6.1 Current treatments for tendinopathy  
The pathophysiology of tendinopathy has been a subject of considerable 
disagreement which has resulted in significant challenges in the management and 
treatment of tendon disorders. To date, treatments have been largely 
conservative and surgery is only offered as a last resort. Many proposed treatment 
options have been largely experimental with some lacking adequate scientific 
rationale. Current treatments are summarised in Table 1.4. 
 
1.6.2 Targeting cytokines in tendinopathy 
With the advent of modern molecular techniques the role of inflammation in 
tendinopathy is now well established. Over the last decade the use of cytokine 
targeted therapies has become widespread in other musculoskeletal pathologies, 
most notably RA.380 The presence of IL-1 family cytokines (IL-1b and IL-33), TNF, 
IL-6 and IL-17 has been documented in tendinopathy and all represent potential 
targets for pharmacological manipulation.  
 
TNF  
Anti-TNF therapy is one of the most studied treatments in RA to date due to the 
central role of TNF in disease pathogenesis.381 Therapeutic agents (anti-TNF 
monoclonal antibodies) include infliximab, etanercept, adalimumab, certizumab 
pegol and golimumab. Inhibition of TNF-a in RA results in reduced IL-6 production, 
reduced recruitment of immune cell to the synovium and lower chemokine 
production.382 TNF blockade also results in fewer macrophages and lymphocytes 
in the synovium.383 In a pilot study in tendinopathy, adalimumab was trialled in a 
group of 10 athletes with symptomatic unilateral tendinopathy for more than six 
months. Significant improvement in pain at rest was recorded after 7 days and 
there was trend towards improvement in walking pain at 7 days and 12 weeks post 
treatment.384 
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Treatment  Mode of action 
Rest or modification 
of activity  
Removal of precipitating factors and prevention of  
injury 
Orthotics Removal of precipitating factors and prevention of  
injury 
Cryotherapy Reduction of acute inflammation and reduction in  
cell metabolism 
Heat treatment Stimulation of cellular activity and increased blood  
flow 
Physiotherapy Stimulation of cellular activity and increased blood  
flow  
Electrical stimulation Stimulation of cellular activity and increased blood  
flow, reduction in pain perception 
Laser treatment Possible analgesic effects and unspecified effects 
on cell activity  
Pulsed 
electromagnetic fields  
Possible analgesic effects and unspecified effects 
on cell activity 
Electrocorporeal 
Shock-wave therapy 
Possible stimulatory effects on neovascularization  
and inhibition of nociception 
NSAIDs Reduction in inflammation through inhibition of  
prostaglandin synthesis 
Pertendinous  
corticosteroid 
injection 
Inhibition of inflammation 
 
Low dose heparin Effect on blood flow possibly resulting 
in improved healing  
Glycosaminoglycan 
polysulfate 
Inhibition of inflammation, possible inhibition of  
MMP activity 
Eccentric exercise 
therapy 
Thought to promote restoration of tissue  
architecture through effects on cell activity and 
matrix remodelling 
Sclerosant injection Blocks tendon blood flow to target  
neovascularization and nerve in-growth 
Platelet-rich 
plasma injection 
Contains growth factors (including TGF-b and PDGF)  
thought to promote matrix synthesis and repair 
Surgery Excision of degenerative tissue 
 
  Table 1.4 Summary of current treatments for tendinopathy 
Adapted from Riley et al 2005 
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IL-1  
Agents involved in blockade of IL-1b signalling include Anakinra, rilonacept and 
canakinumab. Anakinra is an IL-Ra antagonist that is used in the treatment of 
moderate-severe RA.385 A pilot study in patients with chronic Achilles 
tendinopathy administered anakinra by ultrasound guided peritendinous injection. 
The investigators observed a substantial increase in tendon thickness over time; 
however, no changes in pain walking or at rest was noted. In addition, no changes 
in intratendinous blood flow were observed.384 
 
IL-6 
IL-6 expression in tendinopathy is well documented and several agents targeting 
IL-6 signalling are currently used as treatment in inflammatory arthritis including 
tocilizumab, sarilumab, clazakizumab, sirukumab.386 Toclizumab is a humanised 
monoclonal antibody against IL-6R that has shown efficacy in treatment of RA, 
particularly in those patients who have previously not responded to anti-TNF-α 
therapy.387,388 As yet, no approved IL-6 targeting biologics have been trialled in 
human tendinopathy; however, an historic study assessing alterations in ECM as a 
result of peritendinous infusion of recombinant human IL-6 found stimulation of 
collagen synthesis in the Achilles tendon.389 
 
IL-17 
IL-17 has been shown to play a role in inflammation and matrix remodelling in 
tendinopathy.390 A recent study has examined the effect of secukinumab (an anti-
IL-17 monoclonal antibody) in human tenocytes and in an in vivo rat model of 
tendinopathy. Results showed IL-17A blockade reduces the pro-inflammatory 
signature in human tenocytes and significantly improved tendon structure and 
function in vivo indicating potential for use in human tendinopathy.391  
 
Pilot studies have highlighted the potential of targeting inflammatory signalling in 
tendinopathy using biologic agents. Thus far these studies have been non-blinded 
and non-randomized limiting their interpretation. It is evident that biologic agents 
represent an attractive step forward in the treatment of tendon disorders; 
however, further quality studies are required to validate these findings.  
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1.6.3 Targeting signalling pathways in tendinopathy 
Recently, studies have identified NFkB as a potential therapeutic target in human 
tendinopathy.392 It was first noted that 65% of NFkB-associated genes assayed were 
dysregulated in clinical samples of early tendinopathy. Most notably, increases in 
the regulatory serine kinase subunit IKKb were observed and cre-mediated 
overexpression of IKKb resulted in degeneration of mouse rotator cuff tendons 
with associated increases in pro-inflammatory cytokines and innate immune cells 
within the joint. In addition, conditional knockout of IKKb improved outcomes 
after surgical repair while overexpression resulted in impaired healing. The 
authors propose that NFkB directed therapy could specifically target the stromal 
cell compartment while allowing tissue resident and infiltrating immune cells to 
initiate the healing response.392 
  
Several in vivo studies have identified a role for MAPK signalling in tenocyte 
behaviour. Increased extracellular signal regulated kinase (ERK) 1/2 signalling was 
increased in a rodent model of tendinopathy while inhibition of p38 decreased IL-
6 expression in a rodent model of plantaris tendon growth. In addition, reduced 
expression of ECM and cell proliferation genes was observed.393,394 In vitro, ERK 
and p38 inhibitors were shown to reduce expression of inflammatory cytokines 
and chemokines but did not induce tenocyte apoptosis.82 Several phase II trials 
using small molecule inhibitors of MAPK signalling have been conducted although 
all have proved unsuccessful. However, JAK inhibitors including tofacitnib and 
baricitnib have recently been approved for clinical use in RA which provides 
rationale for further studies interrogating signalling pathways in tendinopathy.  
 
Recently, regulatory pathways involving microRNAs have been described in human 
and murine models of tendinopathy.197 In a study detailing IL-33 mediated 
alterations in collagen synthesis, reduced expression of miR-29a was observed in 
human rotator cuff biopsy samples. Functional reduction of miR-29a activity led 
to the development of tendinopathy and miR-29a was shown to induce expression 
of type I collagen but not type III in tenocytes. The authors propose that 
reintroduction of miR-29a to an injured tendon could reverse the switch from type 
I to type III collagen which is the hallmark feature of pathological matrix 
remodelling.  
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Evidence suggests there is clear justification for the translation of immune based 
therapies used in other chronic inflammatory pathologies to tendinopathy. 
Targeting pathways and signalling molecules that regulate immune-cell matrix 
interactions may assist in restoring tendon homeostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.6 Potential therapeutic agents targeting inflammation in tendinopathy 
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1.7 Aims  
 
It is now well established that inflammation is a key precipitating factor in the 
development of tendinopathy. Studies investigating immune regulation in 
tendinopathy have largely focused on cytokine biology and the role of specific 
immune cell subsets and their interactions with stromal cells remains uncovered. 
This work seeks to define mechanisms through which immune cell-stromal 
interactions regulate inflammation in both early and late stage disease.  
 
The aims of this project were: 
 
1. To identify mechanisms through which damage regulates initiation of the 
innate immune response in tendinopathy  
2. Profile stromal cells in healthy and tendinopathic tendon and identify 
disease relevant characteristics 
3. Explore mechanisms through which markers of activated stroma regulate 
tenocyte behaviour 
4.  Directly assess the effect of tenocyte-monocyte interactions on immune 
cell phenotype 
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Chapter 2: Materials and Methods 
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2.1 Buffers and Media 
 
Complete Roswell Park Memorial Institute (RPMI) – RPMI 1640 medium 
supplemented with 10% heat inactivated foetal bovine serum (FBS), 1% L-
Glutamine (2nM), 1% Penicillin-Streptomycin (100µg/ml) (all Thermo Fisher 
Scientific).  
MACS buffer-1x PBS supplemented with 2% (w/v) FBS and 2nM EDTA 
FACS buffer- 1x PBS supplemented with 1% FBS and 0.09% (w/v) sodium azide 
ELISA assay buffer- 1x PBS supplemented with 0.5% (w/v) BSA (Sigma Aldrich) 
ELISA wash buffer- 1 x PBS in distilled water with 0.5% Tween 20 (Sigma Aldrich)  
ELISA stop solution- 2N sulphuric acid  
TBS Tween (TBST): 10x TBS buffer was made using: 876.6 g NaCl, 121.1 g Tris, 
40 ml HCl and adjusted to pH pH 8.0. 10x solution was diluted 1:10 with dH2O 
and 0.05% Tween added.  
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2.2 Ethics and collection of human tendon tissue 
  
All procedures and protocols were approved by the Ethics Committee under 
approval numbers Central Network, South East Health (HREC/96/55, 
HREC/14/130) and West of Scotland REC (REC14/WS/1035) with informed consent 
obtained and carried out in accordance with standard operative procedures. 
Tissue for explant culture was obtained following patient informed consent to use 
any residual tendon tissue not utilised at the time of surgery under the NHS 
Greater Glasgow Residual Tissue consent procedures which is a Pan Glasgow Ethics 
facility. 
  
Supraspinatus tendon samples were collected from patients with rotator cuff tears 
undergoing shoulder surgery. Control groups obtained comprised of subscapularis 
tendon collected from patients undergoing arthroscopic surgery for shoulder 
stabilisation without rotator cuff tears, no previous shoulder surgery, no 
radiographic signs of shoulder fracture, or history of RA or OA. The absence of 
rotator cuff tears was confirmed by arthroscopic examination. A separate control 
group of hamstring tendons was obtained at the time of routine anterior cruciate 
ligament reconstruction (utilised as control due to lack of healthy subscapularis 
tissue). Standardised patient demographics were obtained preoperatively and 
included the duration of shoulder symptoms experienced by the patient and the 
number of subacromial steroid injections. 
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2.3 Cell culture 
 
All cell culture was undertaken in a laminar flow hood. Cultures were maintained 
in a humidified environment at 37°C, 5% C02 in a cell culture incubator.  
2.3.1 Culture of primary human tenocytes  
Normal human tenocytes were explanted from hamstring tendon of patients 
undergoing anterior cruciate ligament reconstruction surgery. Healthy tendon 
tissue was cut into small pieces with a sterile blade and placed in a T25 tissue 
culture flask containing 5ml of complete RPMI. Flasks were incubated without 
disturbance for two weeks to allow tenocytes to adhere. Following this 1ml of 
RPMI was added to each flask on a weekly basis to replenish medium. When flasks 
reached confluency (no more than 4 weeks after the date of arrival of the 
specimen) the tissue was removed and cells were washed with 5mls of 1x PBS. To 
lift the cells 1ml of Trypsin EDTA was added and flasks were incubated at 37°C for 
approximately 5 minutes or until the cells were completely detached. Fresh 
complete medium containing 10% FBS was then added to inactivate the trypsin 
and cells were transferred to a fresh, sterile 15ml centrifuge tube. Cells were 
then reseeded in fresh, sterile T25 flasks.  
 
‘Tendinopathic’ tenocytes were explanted from supraspinatus tendon obtained 
from patients undergoing arthroscopic shoulder surgery using the same method as 
above. 
 
If required for immediate use all cells were maintained in complete RPMI and 
passaged at 70% confluency up to four times using the above method. If intended 
for future use, cells were stored in cryovials at -80°C. Following trypsinization and 
resuspension in complete RPMI cells were centrifuged at 1500rpm for 5 minutes, 
supernatant was removed and tenocytes were resuspended in 1ml of BAMBANKER 
(Alpha Laboratories) per 106 cells.  
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2.3.2 Culture of primary human monocytes 
2.3.3.1 Separation of peripheral blood mononuclear cells 
 
Buffy coats were obtained from the Scottish National Blood Transfusion Service 
(SNBTS). To separate PBMCs from whole blood samples the blood was diluted 1:1 
with sterile PBS in a 50ml centrifuge tube. In a sterile 15 ml tube 10mls of blood 
was carefully overlaid on to 4mls of Histopaque-1077 (Sigma Aldrich) and 
centrifuged at 2100 rpm for 25 minutes with no brake. The PBMC containing 
interface was carefully collected using a Pasteur pipette and transferred to a 50ml 
centrifuge tube. PBMCs were washed twice using cold MACS buffer and counted 
using a 1 in 10 dilution of trypan blue (Sigma).  
 
2.3.3.2 Isolation of CD14+ monocytes from peripheral blood mononuclear 
cells 
 
Cells were separated using the Miltenyi autoMACS Pro Separator according to 
manufacturer’s instructions. To prepare the cells for separation, once counted, 
the desired number of PBMCs were resuspended in 80µl of cold MACS buffer per 
107 cells. Samples were then placed in the chilled autoMACS tube rack where they 
are automatically labelled with magnetic anti-CD14 conjugated beads (Miltenyi 
Biotec). Cells were subsequently magnetically separated using the ‘PosselD’ 
setting that allows for positive selection of the CD14+ population. Purity check of 
CD14+ populations will be discussed in section 2.4.3. Generally enrichment of the 
CD14+ population was > 95% purity. 
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2.3.4 Stimulation of tenocytes  
Tenocytes from the 2nd or 3rd passage were seeded in sterile 12 or 24 well tissue 
culture plates at a density of 1x105/ml and stimulated in a volume of 500µl 
complete RPMI containing the given concentration of each stimulating agent 
(Table 2.1) for 24 hours at 37°C. Following stimulation supernatants were 
transferred into sterile Eppendorfs (under sterile conditions if intended for further 
use in tissue culture) and stored at -20°C for short term storage or -80°C for longer 
term storage.  
 
 
 Concentration Manufacturer 
S100A8 0.1µg/ml 
1µg/ml 
Abcam 
S100A9 0.1µg/ml 
1µg/ml 
Abcam 
IL-6 100ng/ml Biolegend 
CCL2 100ng/ml Biolegend 
IL-1b 10ng/ml Biolegend 
LPS 1ng/ml Sigma-Aldrich 
M-CSF 25ng/ml Biolegend 
GM-CSF 100ng/ml Biolegend 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1 Concentrations of agents used for cell stimulations  
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2.3.5 Transfection of human tenocytes  
In order to knockdown a markers expressed on the tenocyte surface, tenocytes 
were transfected using Silencer Select predesigned siRNAs (PDPN, assay ID  
S20884, VCAM1 assay ID S14760, Thermo Fisher Scientific) or a scrambled negative 
control (miRIDIAN microRNA Mimic Negative Control #1, Horizon). The following 
transfection protocol using DharmaFECT 3 (Dharmacon) was adapted from the 
manufacturer’s recommended protocol. DharmaFECT 3 and OptiMEM (Thermo 
Fisher Scientific) were added to an eppendorf, Tube A. 10 µM stock concentration 
siRNA and OptiMEM were added to a separate eppendorf, Tube B. The contents 
were mixed well and incubated at room temperature for 5 minutes. The contents 
of Tube A were added to Tube B and mixed thoroughly. This mixture was then 
incubated at room temperature for 15 minutes. The medium in which the cells 
were cultured was replenished with 200µl of fresh medium and 50µl of the 
transfection mixture was added for a total volume of 250µl in a 24 well plate. The 
cells were incubated at 37°C in a CO2 incubator for 48 hours. Cells were then 
retransfected for a further 24 hours using the same protocol.  
 
Reagent Volume per 
reaction 
Reagent Volume per 
reaction 
Tube A Tube B 
OptiMEM 24.5µl OptiMEM 23.75 µl 
DharmaFECT 3 0.5 µl Mimic or siRNA 
(10 µM) 
1.25 µl 
Final Volume 25.0 µl Final Volume 25.0 µl 
 
 
 
 
 
 
 
  
Table 2.2 Components of transfection mixture  
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2.3.6 Scratch assay  
Normal tenocytes were seeded at 5 × 104/ml in 12 well culture plates and 
allowed to adhere for 48 hours. Medium was then replenished and cells were  
scratched 4 times across the diameter of the plate with a sterile pipette tip. 
Injured cells were incubated for 24 hours before harvesting of supernatants.  
 
For monocyte experiments using tenocyte scratch supernatants human CD14+ 
monocytes isolated from buffy coats were seeded in 24 well culture plates at a 
density of 2.5x105 per well with supernatants (diluted 1 in 2 with complete 
RPMI) obtained from the tenocyte scratch assay for 24 hours.  
2.3.7 Direct co-cultures 
Tenocytes were seeded at a density of 1x105/ml in 24 well plates and allowed to 
adhere for 48 hours. Monocytes were isolated from buffy coats according to the 
aforementioned procedure, resuspended at 1x106/ml in complete RPMI and the 
tenocyte medium was replaced by the monocyte cell suspension. Following 48 
hours incubation, supernatants were transferred to FACS tubes and centrifuged at 
400 x g for 5 mins to allow any remaining suspended monocytes to adhere to the 
tube. Adherent cells were washed with PBS, detached using 250µl accutase for 10 
minutes at 37°C and the mixed cell suspension was then stained for analysis by 
flow cytometry.  
2.3.8 Transwell co-cultures  
Tenocytes were seeded at a density of 1x105/ml in 24 well plates and allowed to 
adhere for 48 hours. Monocytes were isolated from buffy coats according to the 
aforementioned procedure, resuspended at 1x106/ml in complete RPMI. Tenocyte 
medium was replaced with 500µl of fresh RPMI and pre-soaked 0.4µM transwell 
inserts (Corning) were added to the appropriate wells. 250µl of the monocyte cell 
suspension was then added for a total volume of 750µl. Co-cultures were 
incubated for 48 hours and supernatants were harvested for ELISA.  
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2.4 Fluorescence activated cell sorting (FACS)  
2.4.1 Enzymatic digestion of tendon tissue 
The product of enzymatic digestion of tendon tissue contains a heterogenous cell 
population that includes tenocytes, immune cells and endothelial cells. To 
identify these populations cells were stained with antibodies directed against cell 
surface markers. Under sterile conditions, healthy hamstring or diseased 
supraspinatus tendon was cut into small pieces in a petri dish containing serum-
free, phenol-free RPMI using a sterile blade. Tissue was then transferred to a 
sterile 20ml universal tube with 10mls of serum-free, phenol-free RPMI containing 
0.125mg/ml Liberase (Sigma Aldrich). To allow for optimal enzymatic digestion, 
tubes were incubated at 37°C for 2 hours on a MACSMix tube rotator (Miltenyi 
Biotec). The tubes were shaken briefly and 10mls of phenol free RPMI 
supplemented with 10% heat inactivated FBS was added to inhibit any further 
digestion. The solution containing the cellular component was passed through a 
100µm cell strainer into a sterile 50ml centrifuge tube and any remaining fibrous 
tissue debris was discarded.  Cells were centrifuged at 1500rpm for 5 minutes, 
media was aspirated and 50mls of FACS buffer was added for a 5 minute wash at 
1500rpm. Following aspiration of FACS buffer cells were carried on to the cell 
surface staining protocol as detailed below.  
2.4.2 Staining of cell surface proteins 
Cells obtained from cultures or enzymatic digestion of tissue were transferred to 
a round bottomed polystyrene FACS tube (BD Biosciences), 2mls of PBS was added 
and tubes were centrifuged at 1500rpm. This step was repeated once more to 
remove any residual serum. Excess PBS was poured off leaving a residual volume 
of approximately 100µl with the cells in a pellet to the bottom of the tube. Tubes 
were then vortexed gently to create a dense cell suspension. Fixable viability dye 
(eBioscience eFluor506™ or eFluor780™ viability dye, Thermo Fisher Scientific) 
working solution was made using a 1 in 1000 dilution with PBS. 100µl was added 
to each tube and cells were stained for 15 minutes at room temperature in the 
dark.  
 
Following viability staining, 2mls of FACS buffer was added and cells were 
centrifuged at 1500rpm for 5 minutes at 4°C.  Excess buffer was poured off and 
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the appropriate concentration of antibody was added to each tube. Cells were 
stained for 15 minutes at room temperature in the dark and washed a further two 
times with FACS buffer. If analysis was to be performed immediately, 250µl of 
FACS buffer was added to each tube for acquisition. For next day analysis, cells 
were resuspended in 250µl of BD Cell Fix (BD Biosciences) and stored at 4°C away 
from light.  
 
Exclusion channel staining (Table 2.4) was performed when tendon digests were 
stained for macrophage markers.   
 
FACS analysis was carried out using a BD LSR Fortessa or BD LSRII flow cytometer 
(BD Biosciences) and data was analysed with FlowJo software. 
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Target 
protein 
Conjugate Clone Isotype Supplier 
Podoplanin PerCP/Cy5.5 NC-08  Rat IgG2a k Biolegend 
CD29 PE TS2/16 Mouse IgG1 k Biolegend 
CD10 BV605 H110a Mouse IgG1 k Biolegend 
CD44 FITC  BT18 Mouse IgG1 k Biolegend 
CD146 Pe/Cy7 PIH12 Mouse IgG1 k  Biolegend 
CD34 APC 561 Mouse IgG2a k Biolegend 
CD47  APC/Fire750 CC2C6 Mouse IgG1 k  Biolegend 
CD81 Pe/Cy7 5A6 Mouse IgG1 k Biolegend 
CD90 BV421 5E10 Mouse IgG1 k Biolegend 
CD163 PerCP/Cyanine5.5 GH1/61 Mouse IgG1 k  Biolegend 
CD206 BV421 15-2 Mouse IgG1 k  Biolegend 
HLA-DR BV785  L243 Mouse IgG2a k Biolegend 
MERTK PE 590H11G1E3 Mouse IgG1 k  Biolegend 
CD64 BV605 10.1 Mouse IgG1 k  Biolegend 
CD45 Pe/Cy7  2D1 Mouse IgG1 k  Biolegend 
CD90 AF700 5E10 Mouse IgG1 k Biolegend 
VCAM1 PE STA Mouse IgG1 k Biolegend 
CD91  FITC A2MR-a2 Mouse IgG1 k BD 
Bioscience 
 
 
Target protein Conjugate Clone Cell type 
to exclude 
Supplier 
CD117 FITC 104D2 mast cells Biolegend 
CD15 FITC H198 neutrophils Biolegend 
CD19 FITC H1B19 B cells Biolegend 
CD31 FITC  WM59 endothelial Biolegend 
CD56 FITC 5.1H11 NK cells Biolegend 
CD3 FITC HIT3a T cells Biolegend 
CD90 FITC 5E10 tenocytes Biolegend 
  
Table 2.3 Antibodies used for flow cytometry   
Table 2.4 Antibodies used for flow cytometry (exclusion channel)  
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2.4.3 CD14 purity check 
Flow cytometry was used to analyse the efficiency of AutoMACS automated 
separation of CD14+ cell populations from PBMCs. After the separation was 
completed, 1x106 cells each were taken from the CD14+ and CD14- fractions. 1x106 
cells from the original PBMC sample were also counted and prepared for FACS 
analysis. The cells were washed with 1ml FACS buffer followed by centrifugation 
at 300xg for 5 minutes. Samples were resuspended in 100µl FACS buffer and the 
appropriate concentration of antibodies. Next, the cells were incubated at 4 °C 
in the dark for 30 minutes. Samples were washed once more with 1ml FACS buffer 
followed by centrifugation at 300xg for 5 minutes. The cells were resuspended in 
250µl FACS buffer and analysed using the BD LSRII flow cytometer (BD 
Biosciences).  
Under this set of experimental conditions, CD14+ cells generally make up 15-25% 
of total PBMCs isolated from whole blood and AutoMACS automated sorting 
isolated CD14+ cell populations with an efficiency of ~95%. 
 
 
  
Figure 2.1 Analysis of purity of CD14+ population isolated from PBMCs  
(A) Gating strategy for analysis of proportion of CD14+ cells in a PBMC sample. Cells were 
selected based on size and granularity.  (B) Doublets were omitted by segregating height 
and area. (C) CD14+CD3- cells were identified. (D) Analysis of the same CD14+CD3- 
population from the CD14+ selected fraction. Images are representative of one donor.  
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2.5 Quantitative Polymerase Chain Reaction  
2.5.1 Total RNA extraction from cells 
Total RNA was isolated and purified from cells using the PureLink RNA Mini Kit 
(Thermo Fisher Scientific). All RNA extraction procedures were carried out using 
RNase free, filter pipette tips. Each centrifugation step was performed at 12000xg 
at room temperature. 
 
Adherent cells (tenocytes and macrophages) were lysed for RNA extraction using 
350µl of lysis buffer (provided with the PureLink kit) containing 1% (w/v) 2-
mercaptoethanol (Sigma Aldrich). This was added to each well immediately after 
harvesting of the supernatant and incubated at room temperature for 
approximately 5 minutes. Samples were transferred into fresh eppendorfs, 
vortexed thoroughly and used immediately or stored at -20°C.  
 
Nonadherent cells were transferred into fresh eppendorfs and centrifuged at 1500 
rpm for 5 minutes to form a pellet. Supernatants were then carefully removed and 
350µl of lysis buffer containing 1% (w/v) 2-mercaptoethanol was added and tubes 
were vortexed thoroughly.  
 
One volume of 70% ethanol was added for each volume of cell lysate and vortexed 
thoroughly to disperse any visible precipitate. Samples were then transferred to 
the PureLink spin column and centrifuged for 15 seconds. Flow through was 
discarded and 700µl of Wash Buffer 1 was added and spun for 15 seconds. This 
process was repeated twice using 500µl of Wash Buffer 2. The spin column was 
placed into a new collection tube and centrifuged for 2 minutes to dry the 
membrane. 30µl of RNase-free water was added directly onto the membrane of 
the spin column and incubated at room temperature for 1 minute. The column 
was centrifuged for a further 2 minutes to elute the bound RNA from the 
membrane into a fresh Eppendorf. The columns were subsequently discarded. 
Henceforth, all RNA samples were stored on ice or frozen at -20°C or -80°C for 
long term storage. 
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2.5.2 Total RNA extraction from human tissue 
Normal, diseased subscapularis or diseased supraspinatus tendon samples were 
immersed in RNA later solution (Thermo Fisher Scientific) and stored overnight at 
4°C to allow the solution to penetrate the tissue. Samples were then transferred 
to -80°C for storage.  
 
Samples were thawed at room temperature and cut into small pieces with a sterile 
blade in a petri dish containing 700µl of PureLink lysis buffer (supplemented with 
1% (w/v) 2-mercaptoethanol). Ball bearings (purchased from Qiagen) were 
cleaned with RNase Zap (Thermo Fisher Scientific) and placed into round 
bottomed eppendorfs (4 per sample) alongside the tissue samples and lysis buffer. 
The Tissue Lyser LT (Qiagen) was used to disrupt and homogenize tissue by high 
speed shaking. Samples were shaken for 2 minutes, a total of 3 times, with a one 
minute incubation on ice between each disruption. The supernatant was then 
carefully removed from the tube into a fresh RNase-free eppendorf and the tissue 
debris discarded. Samples were centrifuged at 1500rpm for 5 minutes to remove 
the remaining debris and transferred into new RNase-free eppendorfs. At this 
stage, the samples are ready undergo RNA extraction and purification using the 
PureLink kit as detailed previously. 
2.5.3 Measuring concentration of nucleic acids 
The concentration and purity of RNA isolated from cells or tissue was measured 
using a Nanodrop NC-100 spectrophotometer (Thermo Scientific). Nuclease-free 
water was used as a blank. The absorbance of the RNA sample was measured at 
260 and 280nM with a background correction of 230nM. The A260/280 ratio is used 
to assess RNA purity and A260/230 ratio determines the level of protein 
contamination. 
 
 
  
 86 
2.5.4 cDNA synthesis 
cDNA synthesis was performed using the High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific) according to manufacturer’s instructions.  
 
RNA samples were diluted to a concentration of 10ng/µl with nuclease-free water 
and 10µl (a total of 100ng per reaction) of RNA was added to 200µl thin walled 
PCR tubes (Starlabs) with 2x High Capacity cDNA mastermix (Thermo Fisher 
Scientific) for a final volume of 20µl (Table 2.5). Tubes were vortexed thoroughly 
and placed in a thermal cycler (Applied Biosystems) for the following reverse 
transcription cycle outlined in Table 2.6.  
 
Reagent Volume per reaction (µl) 
10x RT Buffer 2.0 
dNTP (100mM) 0.8 
10X RT Random Primers 2.0 
MultiScribe™ Reverse Transcriptase 
(50 U/µl) 
1.0 
Nuclease-free water 4.2 
Total 10.0 
 
 
Settings Step 1 Step 2 Step 3 Step 4 
Temperature 25 °C 37 °C 85 °C 4 °C 
Time 10 minutes 120 minutes 5 minutes ∞ 
 
 
 
 
 
 
 
 
 
 
  
Table 2.5 High Capacity 2x reaction mix 
Table 2.6 Cycling parameters for High Capacity cDNA synthesis 
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2.5.5 SYBR Green PCR mRNA quantitation 
All qPCR experiments were performed using PowerUp SYBR Green Master Mix 
(Thermo Fisher) according to manufacturer’s instructions. Following reverse 
transcription cDNA samples were diluted 1 in 5 for a final volume of 100µl. 1µl of 
cDNA template was added with 9µl of PowerUp SYBR Green Master Mix (including 
RNase-free water and forward and reverse primers) in duplicate to 96 well qPCR 
plates (Table 2.7). Plates were covered with optical adhesive film (both Starlabs) 
and centrifuged at 300xg for 1 minute.  The StepOnePlus Real Time PCR system 
(Applied Biosystems) was used to measure mRNA expression and a non-template 
control (using RNase-free water in place of template cDNA) was used for each 
primer. The cycling parameters used are shown in table and a melt curve was 
performed after each run to confirm the presence of a single amplified product. 
qPCR primers used are shown in Table 2.8.  
 
Reagent Volume per reaction (µl) 
PowerUp SYBR® Master Mix 5.0 
Forward and Reverse Primers 
(5nM each primer) 
1.0 
cDNA template 1.0 
Nuclease free water 3.0 
Total 10.0 
 
 
 
Step Temperature Duration Cycles 
Uracil-DNA 
Glycosylase (UDG) 
Activation  
50 °C 2 minutes 1X 
AmpliTaq Fast DNA 
polymerase, UP 
activation 
95 °C 2 minutes  
1X 
Denature 95 °C 1 seconds  
40X Anneal/Extend 60 °C 30 seconds 
 
  
Table 2.7 PowerUp SYBR® reaction mix per well  
Table 2.8 Cycling parameters for PowerUp SYBR®  
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Target Forward Reverse 
GAPDH 5′-TCGACAGTCAGCCGCATCTTCTTT-3′ 5′-ACCAAATCCGTTGACTCCGA CCTT-3’ 
18S 5’-GTAACCCGTTGAACCCCATT-3’ 5’-CCATCCAATCGGTAGTAGCG-3’ 
Col1a1 5’-CAATGCTGCCCTTTCTGCTCC-3’ 5’-CACTTGGGTGTTTGAGCATTG-3’ 
Col3a1 5’- TATCGAACACGCAAGGCTGTG-3’ 5’-CACTTGGGTGTTTGAGCATTG-3’ 
S100A8 5’-AGACCGAGACCGAGTGTCCTC-3’  5’-CAGCTGCTTGTCTGCATTTG-3’ 
S100A9 5’-TCAAAGAGCTGGTGCGAAA-3’ 5’-CAGCTGCTTGTCTGCATTTG-3’ 
Tenascin C 5’-CTTTGGCTGGGTTGCTTGAC-3’ 5’-GTGCCAGGAGACCGTACCAC-3’ 
Periostin 5′-TTGAGACGCTGGAAGGAAAT-3′ 5′-AGATCCGTGAAGGTGGTTTG-3′  
Decorin 5′-CGCCTCATCTGAGGGAGCTT-3′ 5′-TACTGGACCGGGTTGCTGAA-3′ 
PDPN 5’-CTTGACAACTCTGGTGGA-3’ 5’-GGGCTTGGACTTGTTCTTG-3’ 
VCAM1 5’-GCAAGTCTACATATCACCCAAGA-3’ 5’-TAGACCCTGGCTGGAACA-3’ 
CD44 5’-CCTGCAGGTATGGGTTCATAG-3’ 5’-GGTGTTGGATGTGAGCATGT-5’ 
CD90 5’-CTAACAGTCTTGCAGGTCTCC-3’ 5’ACTGCTGGTATTCTCATGCC-3’ 
CD34 5’-AGCAGGCTGATGCTGATG-3’ 5’-TGCTGGAAATTTCTGCTCCAGCCTTT-3’ 
FAP 5’-ACGCATATACCAGTTATTGCCTATT-3’ 5’-GGATTCTTAGCTCCAGCCTTT-3’ 
CD29 5’-GGCCTTGCATTACTGCTGATA-3’ 5’-GTGTCCCATTTGGCATTCATTT-3’ 
CD146 5’-CGGCACGGCAAGTGAAC-3’ 5’-GCATTCAACACCTGTCTCCAAC-3’ 
CD47 5’-TACAGAGACTCAGTCCAACCA-5’ 5’-TTAGTACAGCGATTGGATTAACCT-3’ 
CD10 5’-GGTCTCGGGAATCACATACGTT-3’ 5’-AAATCAGCTGCTCGACTGATCC-3’ 
CD248 5’-CTGTGCTCGGCAAGACC-3’ 5’-CCCAAATCCCAAGGGAAGAT-3’ 
MMP3 5’-ACCCGACCTTACATACAGGATT-3’ 5’-GTCACCTCTTCCCAGACTTTC-3’ 
MMP9 5’-GGGCTTAGATCATTCCTCAGTG-3’ 5’-TTCAGGGCGAGGACCATA-3’ 
TIMP1 5’-GAACTAACCAGACCACCTAT-3’ 5’-TTCAGGGCGAGGACCATA-3’ 
TIMP2 5’-GGCCTTCCTGCAATGAGATA-3’ 5’-AGGGCCTGAGAAGCATATAGAG-3’ 
 
 
 
 
 
 
 
 
  
Table 2.9 Primers used for qPCR 
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2.5.7 Analysis of qPCR results 
For each sample, the target gene was run alongside an endogenous control or 
‘housekeeping’ gene that is required for maintenance of cell function. GAPDH and 
18S were used as they are ubiquitously expressed in all cell types and their 
expression is known to remain constant over the course of the experiment.  
 
2^-∆CT quantification 
The expression of target genes was expressed as 2-ΔCT. This figure was obtained by 
subtracting the Ct value of the housekeeping gene from the Ct value of the target 
gene, to give the ΔCt value for each sample. The final value was expressed as 2-
ΔCT
. 
 
2^-∆∆CT Relative Fold Change quantification 
Relative Fold Change Quantification represents the expression values for a given 
gene as a fold change relative to control samples within a data set. First, the Ct 
value of the housekeeping gene was subtracted from the Ct value of the target 
gene, to give the ΔCt for each sample. Next, the ΔCt value of the control sample 
was subtracted from the experiment sample, to give the ΔΔCt value of the sample. 
The final value was expressed as 2^-∆∆CT which indicates the fold change between 
the control and any given experimental condition. 
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2.6 Illumina BeadChip Array 
 
RNA was extracted from tendon tissue biopsies using the procedure outlined in 
section 2.5.2 and processed for the BeadChip array using an Illumina TotalPrep 
RNA Amplification kit (Life Technologies) according to manufacturer’s protocol as 
follows: 
 
1. Reverse transcription to synthesise first strand cDNA 
2. Second strand cDNA synthesis 
3. cDNA purification 
4. In vitro transcription to synthesise cRNA 
5. cRNA purification 
 
The hybridization procedure (HumanHT-12_v4_BeadChip, Illumina) was performed 
according to manufacturer’s instructions. GenomeStudio software was used for 
quality control including background correction. Genome studio was also used to 
calculate differential gene expression between the two groups (p<0.05) and the 
Euclidian method was used to cluster the differential genes. 
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2.7 Enzyme-Linked-Immunosorbent Assay (ELISA) 
 
ELISA was used to measure the concentration of cytokines in cell culture 
supernatants. Commercially available ELISA kits (summarised in table 2.10) were 
performed according to manufacturer’s instructions. All ELISAs were carried out 
using 96 Well Half Area High Bind Microplates (Corning) therefore all volumes were 
scaled down accordingly. Cell culture supernatants were used neat, diluted 1 in 
2, 1 in 5,1 in 10 or 1 in 20 with ELISA assay buffer to ensure sample O.D did not 
exceed that of the highest standard. The ELISA is performed with sets of standards 
(range specific to each kit) prepared by a 1 in 2 serial dilution in ELISA assay buffer 
or complete RPMI (dependent upon which medium most closely reflects the 
sample diluent). Assay buffer or RPMI alone was used as a blank.  
 
Plates were coated with capture antibody diluted in PBS, covered and incubated 
overnight at 4°C. They were washed once with ELISA wash buffer, blotted dry and 
blocked with 150µl ELISA assay buffer for one hour at room temperature.  
For Thermo Fisher Scientific kits, 50µl of samples and standards were then added 
to the plate with 25µl of detection antibody (diluted in ELISA assay buffer) and 
incubated with continual shaking for 2 hours at room temperature. Plates were 
washed 5 times, 50µl of Streptavidin-HRP working solution was added and 
incubated at room temperature for a further 30 minutes.  
For all other kits 50µl of samples and standards were added to the plate and 
incubated at room temperature for 2 hours with continual shaking at room 
temperature. Plates were washed 5 times, 50µl of working detection antibody was 
added and plates were incubated for an hour at room temperature. After five 
more washes, 50µl of Streptavidin-HRP working solution was added and incubated 
at room temperature for a further 30 minutes.  
Finally, the wash steps were repeated and 50µl of TMB chromagen solution 
(Thermo Fisher Scientific) was added and incubated at room temperature until 
the desired blue colour change had been achieved. The reaction was stopped with 
50µl of 2N sulphuric acid and the plate was read at 450nm on an MTX TC II 
microplate reader (Dynex Technologies).   
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2.8 Proteome profiler array  
 
Cell supernatants were evaluated for the presence and relative amounts of 35 
proteases using the Proteome Profiler Human Protease Array Kit (R&D Systems) 
according to the manufacturer’s protocol. For tenocyte experiments  equal 
volumes of supernatants from tenocytes stimulated were pooled from three 
donors and applied to the respective array membrane. Samples were then mixed 
with a combination of biotinylated detection antibodies and incubated 
overnight at 4°C. The membranes were then subject to a series of washes before 
addition of diluted solution of horseradish peroxidase-conjugated streptavidin 
at room temperature for 30 minutes. Visualization of protease expression was 
carried out by chemiluminescence and signal intensity was quantified using an 
Azure c500 imaging system (Azure Biosystems). Relative optical densities of 
immunoreactive bands were determined using Image Studio Lite software (Li-
Cor Biosciences). 
 
 
 
  
Target protein Sensitivity Manufacturer 
IL-6 31.25-2000pg/ml Thermo Fisher Scientific 
IL-8 12.5-800pg/ml Thermo Fisher Scientific 
CCL2 31.25-2000pg/ml Thermo Fisher Scientific 
CCL20 2.5-160pg/ml Biolegend 
CXCL10 7.8-500pg/ml Biolegend 
S100A8 31.25-2000pg/ml R & D Systems 
S100A9 31.25-2000pg/ml R & D Systems 
MMP3 1-2000pg/ml Thermo Fisher Scientific 
Table 2.10 ELISA kits   
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2.9 Immunohistochemistry of paraffin embedded sections 
 
For paraffin embedded sections, tissue was stored in formalin for 24 hours and 
transferred to 70% ethanol to retard the fixation process. Tissues were paraffin 
embedded and subsequently cut to thickness of 5µm. A minimum of 2 sections 
were mounted on one slide to facilitate isotype staining on the same slide in IHC 
protocols. For back-to-back sections, single sections were mounted on a slide with 
the next section being used on a different slide having the same anatomical 
surface in common. Sections for isotypes were added subsequently. Haematoxylin 
and eosin (H&E) staining was performed on one of the serial sections to allow 
tissue morphology to be assessed.   
Slides containing paraffin embedded sections were heated to 65°C for 35 minutes 
followed by dewaxing in xylene and rehydration through ethanol to TBS Tween 
(TBST). Endogenous peroxidase activity was blocked using H2O2/methanol 
(5%/95%). To expose the relevant antigen, sections were then microwaved in 0.5M 
citrate buffer, pH 6 for 8 min. The sections were blocked for 1 hour at room 
temperature in 2.5% serum TBST of the species in which the secondary antibody 
was raised. The relevant primary antibody was applied overnight at 4°C 2.5% 
serum TBST (antibodies were purchased from Abcam, Abnova and LSBio). The 
following day the sections were washed with TBST, incubated with relevant 
secondary antibody for 30 minutes in 5% horse serum containing TBST, washed 
twice with TBST then incubated with substrate Vector ABC (Vector) for 30 
minutes. Sections were washed twice with TBST before developing with 0.6mg/ml 
3,3’- diaminobenzidine tetrahydrochloride (DAB) (Sigma) with 0.01% H2O2 for up 
to 5 minutes at room temperature until brown reaction product was apparent. 
Sections were then washed in water and counterstained using Harris’s 
haematoxylin (BDH Ltd). Finally sections were dehydrated in ethanol, cleared in 
xylene and finally mounted in DPX mountant (both from BDH Ltd.).  
Alternatively, the second day staining protocol was altered by using the ImmPRESS 
kit (Vector) in which sections were incubated with a species specific polymer for 
30 min replacing the secondary antibody. Sections were washed with TBST and 
then developed with ImmPACT DAB (Vector) for up to 2 minutes. Further staining 
of the sections was carried out as described above.  
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2.9.1 Bonar score 
The Bonar scoring system is used to classify the histopathological findings of 
tendinopathy. Sections were stained with H&E and toluidine blue for 
determination of the degree of tendinopathy as assessed by a modified version of 
the Bonar score395 (grade 4 = marked tendinopathy; grade 3 = advanced 
tendinopathy; grade 2 = moderate degeneration; grade 1 = mild degeneration; 
grade 0 = normal tendon). This included the presence or absence of oedema and 
degeneration together with the degree of fibroblast cellularity and chondroid 
metaplasia. 
 
We applied a scoring system based on previous methods to quantify 
immunohistochemical staining.396 Five random high power fields (x400) were 
evaluated. In each field the number of positive and negatively stained cells were 
counted and the percentage of positive cells calculated giving the following semi-
quantitative grading; Grade 0 = no staining, Grade 1 = <10% cells stained positive, 
2 = 10–20% cells stained positive, Grade 3 = >20% cells positive.  
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2.10 Statistics 
 
Results are reported as mean values ± SEM or median. Comparisons between 
groups were made with Kruskal-Wallis One Way Analysis of Variance on ranks, 
Ordinary One-Way ANOVA with Tukey’s correction for multiple comparisons, 
Friedman test with Dunn’s correction for multiple comparisons,  two-way paired 
Student's t tests or Mann-Whitney U test using Graph Pad Prism 5 software. In all 
analysis p<0.05 was considered statistically significant. Details of all statistical 
methods used and number of biological replicates for each experiment are stated 
in the figure legend.  
 
2.11 Bioinformatic analysis 
 
2.11.1 Spanning Tree Progression Analysis of Density-normalized events 
(SPADE) 
SPADE organizes cellular populations into hierarchies based on similar phenotypes. 
It provides a 2D depiction of multiple cell-types in a branched tree structure. A 
typical SPADE tree is comprised of nodes representing cell clusters that are 
connected through edges to represent relationships and provide information about 
the underlying similarity of cell-types.397 Normal and tendinopathic tissue was 
digested and stained for a panel of cell surface markers as described previously 
and data was acquired on a BD Fortessa or LSRII cytometer. 
 
The acquired data was loaded into Cytobank (https://www.cytobank.org), 
manually gated for singlet cells then subjected to SPADE analysis using the 
following settings:  
 
• Target number of nodes=200 
• Percentage downsampling =10% 
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The SPADE algorithm performs 4 steps398: 
 
i. Density dependent downsampling to equalie the density in the point cloud 
of cells 
ii. Agglomerative clustering to partition the point cloud of cells into cell 
clusters 
iii. Minimum spanning tree construction to link the cell clusters 
iv. Up-sampling to map all the cells onto the resulting tree structure 
 
The SPADE tree generated was then analysed for populations of cells expressing 
surface markers stained for prior to FACS analysis. The tree was manually gated 
for positive populations by drawing ‘bubbles’ around selected nodes.  
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2.11.2 viSNE analysis  
viSNE is a tool that uses the t-distributed stochastic neighbour embedding (tSNE) 
algorithm to analyse and display high-dimensional data on a two-dimensional 
map.399 As stated previously, normal and tendinopathic tissue was digested and 
stained for a panel of cell surface markers and data was acquired on a BD flow 
cytometer. Data files were then compiled using the FCS file concatenation tool on 
FlowJo software. Tenocytes were manually gated out and data was loaded into 
Cytobank. viSNE analysis was run with the following settings: 
 
• Equal sampling (equal number of events sampled per FCS file) 
• Iterations – 1000 
• Perplexity- 30 
• Theta- 0.5 
 
An overlay plot coloured for different cell surface proteins was then generated by 
performing manual gating of positive cell populations.  
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Chapter 3: Dissecting the role of alarmins S100A8 and 
S100A9 in tendinopathy 
 
 
Content of this chapter has been published in the following manuscripts:  
 
Crowe LAN, McLean M, Kitson SM, Melchor EG, Patommel K, Cao HM, Reilly 
JH, Leach WJ, Rooney BP, Spencer SJ, Mullen M, Chambers M, Murrell 
GAC, McInnes IB, Akbar M, Millar NL  
 
S100A8 & S100A9: Alarmin mediated inflammation in tendinopathy 
 
Scientific Reports. 2019 Feb 6;9(1):1463. 
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3.1 Introduction 
 
Tendinopathy is a damage associated pathology whereby repetitive microtrauma 
elicits an immune response. Mobilization of immune cells within the tendon 
matrix is triggered by microenvironmental changes that occur in response to 
injury.212 
 
Alarmins, also referred to as damage associated molecular patterns (DAMPS), 
are endogenous molecules rapidly released into the extracellular milieu 
following tissue damage.400 S100A8 and S100A9, also known as myeloid related 
protein 8 (MRP8) and MRP14, are low molecular weight calcium binding proteins 
constitutively expressed by cells of myeloid origin.401 Under pathological 
conditions they are induced in other cell types in response to environmental 
triggers. Acting as alarmins they are released passively by necrotic cells or by 
active secretion from activated immune cells.136 Extracellular S100A8 and 
S100A9 bind pattern recognition receptors (PRRs) including Toll-like receptors 
(TLRs) and receptor for advanced glycation end products (RAGE) to activate the 
innate immune system and mediate inflammation by influencing monocyte and 
macrophage behavior.402 
 
In a rat model of Achilles tendon injury increased infiltration and accumulation 
of immune cells including neutrophils and macrophages was observed between 
1 and 28 days post injury.239 Subsequent human studies have identified distinct 
populations of myeloid monocytes and macrophages in both early and late 
tendinopathy.29,212   
Monocytes recruited to areas of damage enter tissue in response to activation 
of chemokine pathways such as the CCL2/CCR2 axis.403 In addition to monocytes, 
the myeloid compartment within the tendon may also include mature tissue 
macrophages that are programmed to respond to chemotactic factors following 
injury and assist in the initial inflammatory response. Current evidence suggests 
that immune cell infiltration and inflammatory mediators play diverse roles in 
the initiation and maintenance of tissue repair.404 In the context of 
tendinopathy an initial inflammatory response promotes beneficial healing; 
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however, sustained inflammatory conditions may eventually lead to 
dysregulated matrix remodelling. 
Both S100A8 and S100A9 are chemotactic for monocytes and have been 
implicated in myeloid cell maturation where their expression directly correlates 
with state of differentiation.405 ,406 Moreover, they may exert both pro and anti-
inflammatory effects by manipulating the cytokine profile of cells through PRR 
binding.136 S100A8 and S100A9 are considered biomarkers of disease activity in 
chronic inflammatory pathologies associated with impaired matrix remodelling 
such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and cystic 
fibrosis.407  
3.2 Aims 
 
Recent investigations have established tendinopathy as an alarmin-mediated 
pathology197,162 thus we sought to:  
1. Characterise the expression of S100A8 and S100A9 in human 
tendinopathy 
2.  Assess their effect on inflammation and matrix production in tenocytes 
in vitro 
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3.3 Results 
3.3.1 Characterising expression of S100A8 and S100A9 in tendinopathy 
S100A8 mRNA expression is significantly upregulated in early tendinopathy 
compared with control (p<0.05) (Fig. 3.1A). S100A9 expression was more 
profoundly increased in both intact (p<0.001) and torn tendon biopsies (p<0.01) 
compared with control (Fig. 3.1A). We observed greatest significant upregulation 
of S100A8 and S100A9 in early tendinopathy and a relative absence of S100A8 
mRNA expression in late tendinopathy suggesting these alarmins are key regulators 
in the early stage of disease. We noted positive staining of the alarmin molecules 
S100A8 and S100A9 in the early tendinopathy biopsy sections (Fig. 3.1B). The 
modified Bonar Score showed significantly increased expression of S100A8 in early 
tendinopathy vs control (p<0.05). S100A9 expression was significantly increased in 
both early and late tendinopathy (p<0.01 and p<0.05, respectively). In addition, 
there was a significant difference in S100A9 expression between early and late 
tendinopathy sections (p<0.05) (Fig. 3.1C).  Semi-quantitative analysis suggested 
that S100A9 (9% early tendinopathy, 5% late tendinopathy, % of cells stained 
positive) was more frequently expressed than S100A8 (4% early tendinopathy, 1% 
late tendinopathy, % of cells stained positive) in tissue biopsies (Fig. 3.1C).  
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Figure 3.1 S100A8 and S100A9 expression is increased in tendinopathy.  
(A)Relative mRNA expression (2^-𝚫CT) of S100A8 & S100A9 in control (hamstring 
tendon, n=7), early tendinopathy (intact subscapularis biopsy, n=14) and late 
tendinopathy (torn supraspinatus tendon, n=12). Data represent mean ± SEM relative 
to housekeeping gene GAPDH (mean of duplicate analysis). * p<0.05, **p<0.01, 
***p<0.001 (Kruskal-Wallis test with Dunn’s multiple comparisons) versus control.  
(B) Immunostaining of S100A8 and S100A9 in early tendinopathy (subscapularis 
biopsy) at 10x and 40x magnification. 
(C) Graphs illustrate modified Bonar scoring and percentage of cells stained positive 
for samples of human tendon biopsies for expression of S100A8 and A9 with mean 
and SEM shown. n=10 for control tendon, n=10 for early and late tendinopathy. 
Modified Bonar scoring system depicts mean score per sample based on five high-
power fields. 0= no staining, 1=<10%, 2=10%–20%, 3=>20% positive staining of cells 
per high-power field. *p<0.05, **p<0.01 (ANOVA) versus control biopsies. 
+p<0.05 late versus early tendinopathy.   
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There were no significant correlations between S100A8 & A9 expression and the 
mean duration of symptoms, patient age or number of steroid injections (data not 
shown). Late tendinopathy samples exhibited marked degeneration, mucoid 
change and frank chondroid metaplasia (grade 4), whereas matched subscapularis 
tendon biopsies had grade 2–3 changes indicative of early tendinopathy. All control 
samples were classified as grade 1 consistent with normal fibrotendinous tissue 
with large distinct collagen fibrils.  
 
Histological analysis showed both S100 proteins appeared not to be localised 
around the stroma. As S100A8 & A9 are known to be of myeloid origin, sub analysis 
using back-to-back staining with the macrophage marker CD68 was performed. 
Back-to-back staining utilises sections of tissue that are almost anatomically 
identical thus allowing comparison of multiple sections stained for different 
markers.  Staining revealed that S100A9 was localised to macrophage cells in 
tendinopathic sections (Fig. 3.2A & B). To confirm the presence of S100A8 and 
S100A9 in macrophages, human monocyte-derived macrophages were grown on 
chamber slides and stained with antibodies directed against S100A8 & A9 (Fig. 
3.2E & F). We observed positive staining of both S100A8 & A9 which suggests that 
myeloid cells rather than stromal cells may be the source of these alarmin proteins 
in tendinopathy.  
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Figure 3.2 S100 expression is localized to immune cell infiltration in tendinopathy 
(A) shows positive staining for CD68 (pan macrophage marker) localised to positive staining of S100A9 (B). 
(C), (D) CD68 and S100A9 staining in normal tendon (E) Macrophages stained for S100A9 and S100A8 (F). 
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3.3.2  Damage induces release of chemokines and S100 proteins in vitro 
Previous studies have shown that S100 proteins are released from myeloid cells in 
response to inflammatory stimuli408 thus we measured the effect of recombinant 
LPS, CCL2 and IL-6 on S100 expression in human monocytes. We observed a 
significant  increase in S100A8 (Fig. 3.3A, p<0.05) and S100A9 (Fig. 3.3B) 
transcript in response to CCL2 and IL-6. 
   
Given that alarmins are released into the extracellular compartment by necrotic 
cells, we used an in vitro model of microtrauma to investigate potential 
mechanisms of alarmin release in tendinopathy. The scratch assay did not induce 
direct release S100 protein from tenocytes (data not shown); however, we did 
observe significantly increased release of CCL2 versus control indicating damage 
precipitates an inflammatory reaction and potential recruitment of immune cells 
to the site of injury (Fig. 3.4A, p<0.01). We did not detect release of other 
chemokines (including CCL20 or CXCL10) following injury further indicating CCL2 
release from tenocytes is the primary mechanism of immune cell mobilization 
following tendon damage.    
 
As CCL2 is a known chemokine for monocyte recruitment we hypothesised that 
these cells are recruited post-injury within the tendon. To simulate the stromal 
environment following injury CD14+ monocytes were incubated with conditioned 
medium obtained from scratched tenocytes. We measured a significant increase 
in S100A8 protein release from monocytes by ELISA compared with unscratched 
control (p<0.05) (Fig 3.4B). Although not statistically significant, S100A9 release 
following incubation with tenocyte conditioned medium was also greater than 
unscratched and comparable to values observed with LPS stimulation (Fig. 3.4B). 
Taken together, these data suggest that tendon damage primes the local 
microenvironment to induce alarmin release from monocytes.  
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Figure 3.3 Inflammatory stimuli induce expression of S100A8 & A9 in human CD14+ monocytes
(A) (B) Tenocytes stimulated with 1ng/ml LPS , 100ng/ml CCL2 or 100ng/ml IL-6. Data represent
mean ± SEM of duplicate samples expressed as relative fold change normalised to control
(unstimulated) samples, n= 3. *p<0.05 versus control (Kruskal Wallis test).
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Figure 3.4 Damage induces release of CCL2 from tenocytes.
(A) CCL2 release measured by ELISA in supernatants collected from tenocytes scratched and
incubated for 24 hours post injury compared to unscratched control. (B) S100A8 and S100A9
concentration in supernatants from CD14+ monocytes (isolated from buffy coats) cultured in
conditioned medium from tenocyte scratch assay for 24 hours. ‘nd’ indicates not detected. All
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3.3.3 Measuring the effect of S100A8 and S100A9 on matrix regulation in 
tendinopathy  
Previous investigations have shown that alarmins differentially regulate collagen 
synthesis and expression of matrix proteins in tendinopathy197,162  thus we sought 
to assess the effect of extracellular S100A8 and S100A9 on matrix regulation in 
primary human tenocytes. Neither S100A8 or S100A9 had any significant effect on 
Col1a1, Col3a1, Decorin or Tenascin C gene expression following 24 hours 
stimulation relative to controls (Fig. 3.5A-D). Furthermore, no effect was 
observed on collagen I protein release from tenocytes in response to S100 
stimulation (Fig. 3.5E). 
 
As we found no significant alterations in genes associated with matrix deposition 
we performed an array (that allows simultaneous detection of 35 proteases)  to 
further assess the potential effect of S100A8 & A9 on matrix turnover in tenocytes 
(Fig. 3.6A). We observed a marked increase in MMP3 (Fig 3.6B) and MMP9 (Fig. 
3.6E) expression between control vs S100A9 and a modest increase in MMP12 (Fig. 
3.6D), Cathepsin B (Fig. 3.6G) and ADAMTS12 (Fig. 3.6H). 
 
This was validated at transcript and protein level where we found upregulation of 
MMP3 and MMP9 transcript in response to both S100A8 and S100A9 (Fig. 3.7A & B) 
and a significant increase in MMP3 release from tenocytes upon stimulation with 
S100A9 (Fig. 3.7E). We observed no discernible effect of S100A8 or S100A9 on 
inhibitors of metalloproteinases TIMP1 or TIMP2 (Fig. 3.7C & D).  
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Figure 3.5 S100A8 and S100A9 do not directly alter matrix proteins in vitro
(A) Col1a1, (B) Col3a1, (C) Decorin, (D) Tenascin C expression in tenocytes stimulated 0.1 or 1µg/ml
recombinant S100A8, 0.1 or 1µg/ml recombinant S100A9 or 1ng/ml LPS for 24 hours was determined
by real time PCR. (E) Collagen protein release measured by ELISA from tenocytes stimulated with
1µg/ml recombinant S100A9, S100A8 or 1ng/ml LPS. Data represent mean ± SEM of duplicate
samples expressed as relative fold change normalised to control (unstimulated) samples, n= 3.
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Figure 3.6 Single sample protease array using pooled supernatants (n=3) from tenocytes
stimulated with 1µg/ml S100A8, 1µg/ml S100A9 or 10ng/ml IL-1! for 24 hours with unstimulated
control. (B-H) Signal pixel density of proteases plotted relative to control. Statistical analysis was
not performed.
B C D
E F G
H
H
F
G
C
D
E
co
ntr
ol
S1
00
A8
S1
00
A9
 
IL-
1β
0
2×105
4×105
6×105
8×105
1×106
m
ea
n 
pi
xe
l d
en
si
ty
MMP2
co
ntr
ol
S1
00
A8
 
S1
00
A9
 
IL-
1β
0
1×105
2×105
3×105
4×105
m
ea
n 
pi
xe
l d
en
si
ty
MMP3
co
ntr
ol
S1
00
A8
 
S1
00
A9
 
IL-
1β
0
2×104
4×104
6×104
8×104
1×105
m
ea
n 
pi
xe
l d
en
si
ty
MMP12
co
ntr
ol
S1
00
A8
 
S1
00
A9
 
IL-
1β
0
1×104
2×104
3×104
4×104
m
ea
n 
pi
xe
l d
en
si
ty
MMP9
co
ntr
ol
S1
00
A8
 
S1
00
A9
 
IL-
1β
0.0
5.0×104
1.0×105
1.5×105
m
ea
n 
pi
xe
l d
en
si
ty
Cathepsin A
co
ntr
ol
S1
00
A8
 
S1
00
A9
 
IL-
1β
0.0
5.0×104
1.0×105
1.5×105
2.0×105
m
ea
n 
pi
xe
l d
en
si
ty
Cathepsin B
co
ntr
ol
S1
00
A8
 
S1
00
A9
 
IL-
1β
0
1×104
2×104
3×104
4×104
m
ea
n 
pi
xe
l d
en
si
ty
ADAMTS1
 112 
 
 
 
 
 
 
co
ntr
ol
0.1
µg
/m
l
1µ
g/m
l
0.1
µg
/m
l
1µ
g/m
l
LP
S
0
50
100
150
200
250
300
Re
la
tiv
e 
Fo
ld
 C
ha
ng
e 
(2
^-
Δ
Δ
CT
)
MMP3
S100A8 S100A9
co
ntr
ol
0.1
µg
/m
l
1µ
g/m
l
0.1
µg
/m
l
1µ
g/m
l
LP
S
0
1
2
3
4
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e 
(2
-^Δ
Δ
C
T)
TIMP1
S100A8 S100A9
co
ntr
ol
0.1
µg
/m
l
1µ
g/m
l
0.1
µg
/m
l
1µ
g/m
l
LP
S
0
1
2
3
4
TIMP2
R
el
at
iv
e 
Fo
ld
 C
ha
ng
e 
(2
-^Δ
Δ
C
T)
S100A8 S100A9
co
ntr
ol
S1
00
A8
 
S1
00
A9
 
IL1
β
0
500
1000
1500
2000
M
M
P3
 (p
g/
m
l)
n.d n.d
MMP3
*
Figure 3.7 The effect of S100 proteins on MMPs and TIMPs in tenocytes
(A) MMP3, (B) MMP9, (C) TIMP1, (D) TIMP2 expression in tenocytes stimulated 0.1 or 1µg/ml
recombinant S100A8, 0.1 or 1µg/ml recombinant S100A9 or 1ng/ml LPS for 24 hours was determined
by real time PCR. Data represent mean ± SEM of duplicate samples expressed as relative fold change
normalised to control (unstimulated) samples, n= 3. (E) Concentration of MMP3 in cell culture
supernatants (expressed as pg/ml) from tenocytes stimulated with 1ug/ml S100A8, 1ug/ml S100A9 or
10ng/ml IL-1! for 24 hours with unstimulated control. Data represent mean ± SEM, n=3, * p<0.05,
(paired t-test).
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3.3.4 Assessing the effect of S100A8 and S100A9 on the inflammatory 
microenvironment in tendinopathy 
We next explored the extent to which S100 proteins may influence the 
inflammatory microenvironment within the tendon post-injury. Recombinant 
S100A9 at a concentration of 1ug/ml significantly increased release of IL-6 
(p<0.01), IL-8 (p<0.05) and CCL20 (p<0.01) from tenocytes (Fig 3.8A, B & D). 
Furthermore, S100A9 stimulation induced a 40 fold increase in CXCL10 (Fig 3.8C) 
expression compared to control (not detected). S100A8 stimulation displayed the 
same trend of significant IL-8 (p<0.05) and CCL2 (p<0.001) release from tenocytes; 
however, increases in IL-6 and CCL20 release were not significant following 24 
hours’ stimulation (Fig. 3.8A-E). Taken together, these data suggest S100A8 and 
S100A9 play a role in the activation of resident tenocytes and initiate a cascade 
of inflammatory processes. 
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Figure 3.8 S100A8 and S100A9 induce cytokine and chemokine release from human tenocytes
Tenocytes stimulated with 1ug/ml S100A8, 1ug/ml S100A9 or 10ng/ml IL-1! .Concentrations of IL-6 (A)
IL-8 (B) CCL2 (C) CCL20 (D) or CXCL10 (E) in cell culture supernatants measured following 24 hours
stimulation. Values expressed as pg/ml. All data represent mean ± SEM, n= 3, * p<0.05, **p<0.01,
***p<0.001 compared to control (unstimulated) samples (Paired t-test )
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3.4 Discussion and Conclusions 
 
This chapter has established the presence of S100A8 and S100A9 in a human model 
of tendinopathy, most notably in the early stages of disease. Coupled with 
confirmation of passive release of CCL2 in response to acute injury our data 
supports the concept of S100A8 & A9 acting as functional tissue alarmins in 
tendinopathy by promoting immune cell recruitment. We have identified that 
S100A8 & A9 play an important immunomodulatory role in tendinopathy through 
activation of the innate immune system and manipulation of the stromal 
microenvironment.  
 
Increasingly, alarmins are becoming recognized as key regulators in 
musculoskeletal pathologies.400,124 S100A8 and S100A9 are considered surrogate 
markers of disease activity in RA where serum concentrations directly reflect 
levels of active inflammation.409,150 In addition, S100A8 & A9 promote recruitment 
of inflammatory monocytes to the synovium in a murine model of osteoarthritis 
and blockade of S100 signalling ameliorates inflammatory processes.410 Previous 
investigations in human models of tendinopathy have consistently established the 
presence of alarmins in diseased tendon and revealed functional roles in vitro. 
197,162,163 Most recently we have demonstrated the alarmin HMGB1 regulates 
expression of inflammatory cytokines and matrix changes in tenocytes in a TLR4 
dependent manner.162 Observations taken from the present study indicate S100A8 
and S100A9 regulate expression of inflammatory mediators in vitro which 
corroborates previous findings and suggests S100A8 & A9 are likely acting through 
DAMP receptors to influence downstream transcription and release of CCL2, 
CCL20, CXCL10, IL-6 and IL-8. 
 
Hallmark features of tendinopathy include dysregulated collagen synthesis with a 
detrimental transition from type 1 to an inherently weaker type 3.125 In addition, 
ECM turnover is regulated by non-structural matricellular proteins such as decorin 
and tenascin C that are thought to be upregulated under inflammatory conditions 
and in response to mechanical strain.411 Interestingly, the present study did not 
find any changes in collagen, decorin or tenascin C in tenocytes in response to 
S100A8 & A9 stimulation. This may reflect differences in endogenous activity of 
various DAMPs. In addition to passive secretion from necrotic cells, under 
pathological conditions intracellular alarmins reserve the potential to be secreted 
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from activated immune cells. In contrast to the relatively slow translocation 
dependent secretion of nuclear HMGB1165, active secretion of S100A8 & A9 from 
monocytes is rapid and energy dependent412 suggesting they are inherently 
programmed to facilitate early inflammatory responses rather than directly alter 
extracellular matrix production.  
 
Protease screening confirmed induction of MMPs in response to S100 stimulation. 
MMPs are generally considered to be fibrinolytic modulators of extracellular 
matrix turnover and have been associated with ongoing tissue damage and 
development of chronic disease.413,414 Evidence suggests they are also involved in 
regulation of inflammatory processes including cytokine processing and 
activation415,416 and leukocyte migration.417 We did not observe any changes in 
other matrix proteins or tissue inhibitors of metalloproteinases (TIMP1 and TIMP2) 
therefore, in the context of tendinopathy, MMPs may  regulate inflammation in 
addition to influencing matrix remodelling.  
 
Recent evidence has revealed that stromal fibroblast activation markers are 
persistently upregulated in diseased tendon.418 In response to recurrent injurious 
or inflammatory stimuli stromal cells are subject to phenotypic transformations 
that alter their functional properties; such adaptations reflect the activation state 
of the cell population. Typically, stromal cell activation is characterised by rapid 
induction of cytokines, chemokines and extracellular matrix components.419 We 
observed an induction of CCL2, CCL20, CXCL10, IL-6 and IL-8 release from 
tenocytes in response to S100A8 & A9 stimulation suggesting their primary action 
may be activation of the resident tenocyte population. This, in turn, will promote 
immune cell recruitment and influence the nature of stromal microenvironmental 
cues.  
 
The CCL2/CCR2 axis is primarily associated with the initial recruitment of classical 
inflammatory monocytes to sites of inflammation or tissue damage.247,420  Within 
the tendon a portion of the recruited monocytes may continue development into 
macrophages following egress into the stromal microenvironment. It is thought 
classical monocytes recruited by CCL2 are programmed to differentiate more 
readily into inflammatory macrophages and may promote excessive 
inflammation.421 Conversely, synergistic activities of IL-6 and CCL2 have been 
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shown to induce alternative activation of myeloid monocytes.422 As such, the 
recruitment and development of monocytes and macrophages is highly niche 
specific and undifferentiated monocytes/macrophages retain the potential to 
differentiate according to their environment. Given the complex nature of the 
stromal microenvironment is it likely that both ‘classical’ inflammatory 
macrophages and ‘alternatively activated’ macrophages exist as a dichotomy that 
drives a state of chronic inflammation.  
 
Based on our observations using a previously explored in vitro injury model we 
propose that acute injury induces CCL2 mediated monocyte recruitment.423 Here, 
soluble factors or biologically active ECM fragments induce subsequent release of 
S100A8 and S100A9 from monocytes that will, in turn, bind receptors on the 
tenocyte  surface and stimulate release of further inflammatory factors (Fig.3.9).  
Within the tendon matrix monocytes continue development to mature 
macrophages and differentiate according to environmental cues. Histologically 
the presence of mononuclear cells is associated with a state of chronic 
inflammation.424 Excessive immune cell infiltration and the presence of 
macrophages may contribute to persistence of inflammation and promote immune 
cell-matrix crosstalk that drives inflammatory healing characterised by aberrant 
and inferior matrix repair.  It may be postulated in the context of this study that 
CCL2, CCL20 and CXCL10 mediate initial inflammatory monocyte recruitment 
while IL-6 and IL-8 participate as potent inflammatory factors in the acute phase 
response. This will subsequently act to promote a transitory state towards 
established chronic inflammation. In addition to monocyte recruitment these 
chemokines are capable of recruiting T cells, mast cells and natural killer cells 
that will likely contribute to the development of a complex and dynamic 
inflammatory milieu.  
 
A recent study detailing the expression of alarmins in the fibrotic disorder 
adhesive capsulitis demonstrated S100A8/S100A9 expression is localised to 
immune cells; specifically, CD68+ macrophages.425 Our data describing S100A8 & 
A9 release from monocytes highlights the importance of activated immune cells 
as a source of alarmins in diseased tendon. Under inflammatory conditions S100A8 
and S100A9 are known to regulate positive feedback mechanisms thus it is 
plausible tenocytes and activated monocytes/macrophages mutually amplify 
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levels of extracellular alarmins and promote phagocyte recruitment.426,427  
Furthermore, S100A8/S100A9 are involved in myeloid cell differentiation and 
induce secretion of pro-inflammatory cytokines including TNF- ɑ  and IL-1ß from 
monocytes139; it is likely these mediators will also act to exaggerate and sustain 
inflammatory conditions.  
 
Our data confirms the presence of S100A8 and S100A9 in tendinopathy and 
suggests they actively contribute to pathological proceedings in the early stages 
of disease. We propose that by modulating the stromal microenvironment S100A8 
and S100A9 promote recruitment of inflammatory cells to the site of injury and 
support a detrimental transition from acute to chronic inflammation.  
 
Selectively targeting DAMP signalling in early disease provides scope for novel 
translational strategies in the management of tendon disorders.  
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Figure 3.9 S100A8 and S100A9 promote immune cell recruitment and development in 
tendinopathy
Proposed mechanism whereby damage induces release of CCL2 from tenocytes recruiting 
monocytes to the site of injury. Soluble factors stimulate release of S100A8 and S100A9 from 
monocytes recruited to the tendon matrix. S100A8 and S100A9 bind receptors on the tenocyte 
surface to induce release of cytokines and chemokines promoting further recruitment and 
development of immune cells. Formation of an inflammatory microenvironment facilitates 
immune cell-matrix cross talk and promotes a state of chronic inflammation.
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Chapter 4: Phenotyping of tendon stromal cells 
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4.1 Introduction 
 
Historically, the stroma was considered to be immunologically inert and exist 
purely as a tissue specific scaffold that participates in wound healing responses.24 
Until recently, tenocytes were perceived as a biochemically active cell population 
merely responding to biomechanical force. Excessive loading of tendons was 
considered the main pathological stimulus for degeneration, conferred by the 
mechanosensing properties of tenocytes. It was deemed that the initial response 
to an injurious stimulus was recruitment and proliferation of tenocytes in addition 
to synthesis and release of ECM components (including matrix degrading proteins 
such as MMPs). 428,429 
  
This theory has subsequently been supplanted by increasing evidence of damage 
induced inflammation being crucial to disease initiation and progression.111,29 More 
recently it has been postulated that recruitment, influx and retention of immune 
cells is controlled by cytokine and chemokine gradients created by resident 
stromal cells.419 Fibroblasts are highly specialised to the tissue in which they 
reside and vary phenotypically according to their anatomical location or so called 
‘stromal address code’.430 It is thought stromal cell properties are defined 
according to tissue structure at an individual site and the external stimuli they 
receive. For example, tenocytes are interspersed uniformly throughout the tendon 
matrix and are adapted to respond to mechanical force and DAMPs through pattern 
recognition receptors.162 Recent studies have suggested that repeated exposure 
to pathological stimuli induce epigenetic changes that drive a persistent state of 
activation.431,432 This is characterised by phenotypic alterations including 
constitutive expression of cell surface receptors termed ‘fibroblast activation 
markers’.418 
 
Traditionally, fibroblasts were perceived as a homogenous population with a 
relatively limited functional capacity. However, emerging evidence suggests that 
fibroblasts display a degree of plasticity and can exist as functionally distinct 
subsets analogous to subsets of leukocytes.433 Recent studies in cancer 
immunobiology and autoimmune disease have proposed that phenotypically 
distinct stromal cell populations drive pathology.434,315,435,319 Single cell sequencing 
of rheumatoid synovium has described distinct subsets of fibroblasts that are 
expanded in RA. It is proposed these fibroblasts (characterised by varying 
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proinflammatory cytokine expression phenotypes) may be pathogenic based on 
their roles in matrix invasion, immune cell recruitment and osteoclastogenesis.315 
 
In addition to extensive characterization of fibroblasts in RA synovium, recent 
studies in adhesive capsulitis have identified the expression of stromal cell surface 
markers in vitro and ex vivo.436 In order to explore the concept of tenocyte 
heterogeneity in tendinopathy the aims of this chapter are: 
 
1. To characterise the expression of disease relevant surface markers 
expressed in whole tendon tissue and tenocytes  
 
2. Profile fibroblast subsets in fresh human tendon tissue (healthy and 
diseased) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 123 
4.2 Results 
4.2.1 Differential gene expression in normal and diseased tendon 
The heatmaps in Figure 4.1 show preliminary datasets from our lab group 
generated from human BeadChip Array which allows high throughput differential 
gene expression analysis.  Figure 4.1A illustrates a heatmap generated from a 
normalized expression matrix that depicts differences between groups. 5 control 
(healthy subscapularis tendon) and 5 torn supraspinatus tendons (representative 
of late tendinopathy) were used. These are further subdivided into 4 clusters 
based on differences in gene expression between control and tendinopathic 
groups. Clusters 1 and 3 show upregulated genes and clusters 2 and 4 show genes 
that are downregulated in tendinopathy. Based on recently published datasets we 
observed several genes of interest that were upregulated between control and 
torn tendons. Cluster 1 (Fig 4.1B & Table 4.1) shows increased expression of CD90 
(Thy1), podoplanin (PDPN) and cadherin 11 (CAD11) which have recently been 
identified as key markers of fibroblast activation and heterogeneity in RA.437,315 
Table 4.1 summarises key matrix associated genes upregulated in supraspinatus 
samples.  
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Figure 4.1 Heatm
ap of differential gene expression in norm
al and tendinopathic tendon 
Euclidian clustering analysis of differential gene expression (p<0.05) perform
ed using Genom
eStudio. C1-C5 represent  control subscapularis tendon, 
n=5. ssp 1-5 represent torn supraspinatus tendon representative of late pathology, n=5.  
 A
 
B
 
C
 
 
E 
D
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Cluster Gene upregulated in tendinopathy 
Cluster 1  o Thy-1 (CD90) 
(fibroblast markers) o PDPN 
 
o CDH11 (cadherin 11) 
Cluster 3 • TNC (tenascin C) 
(matrix associated 
genes) 
• COL3A1 
 
• COL5A1 
 
• COL5A2 
 
• COL6A3 
 
• SPARC (osteonectin) 
 
• POSTN (periostin) 
 
• ADAMTS1 (metalloproteinase) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Summary of matrix associated genes upregulated in tendinopathy 
Matrix associated genes identified as differentially expressed by clustering analysis  
(Fig. 4.1, control vs late tendinopathy). 
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4.2.2 Stromal surface marker expression is increased in tendinopathy 
Having established a pattern of upregulation of various fibroblast surface markers 
in tendinopathy we sought to further characterize this expression using a panel of 
candidate markers based on results from gene expression studies and current 
literature. Immunohistochemical staining of tendinopathic sections showed strong 
positive staining of CD34 which appears to be localised to blood vessels indicating 
the presence of this marker in the intimal and subintimal layers (Fig. 4.2A). A 
similar staining pattern was observed for CD146 (Fig. 4.2D) which is in accordance 
with literature indicating CD34 and CD146 are lineage markers of endothelial cells. 
In addition to the presence of vascular staining, Figure 2B, 2C, and 2E show diffuse 
staining of podoplanin, CD248 and CD90, respectively with this staining pattern 
likely corresponding to expression in tendon stromal cells. CD10 expression (Fig. 
4.2F) was observed around vessels, in the stroma and also in infiltrating immune 
cells. As positive staining was observed in tendinopathic tissue sections we sought 
to confirm this at a molecular level using a more extensive panel. RT-PCR of whole 
tendon tissue showed a significant increase in podoplanin and VCAM1 expression 
between control and late tendinopathy (Fig. 4.3A & B, p<0.01). Significant 
upregulation of CD44 and FAP expression was observed between control and both 
early and late pathology groups (Fig. 4.3C & F). Less consistent increases in 
expression of CD90 (Fig. 4.3D), CD248 and CD146 were observed between control 
and late tendinopathy. Similarly, CD34 (Fig. 4.3E), CD29 (Fig. 4.3G) and CD47 
(Fig. 4.3J) showed a trend towards increased expression in both early and late 
tendinopathy; however, this was not significant in all analyses. Interestingly, a 
reduction of CD10 expression was observed between control and early/late 
tendinopathy groups.  
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Figure 4.2 Immunostaining of surface markers in tendinopathic tissue
Supraspinatus tendon sections with stained with antibodies directed against (A) CD34 (B) PDPN (C)
CD248 (D) CD146 (E) CD90 (F) CD10. All images shown at 10x and 40x magnification. Isotype controls
shown in bottom right corner.
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Figure 4.3 Stromal cell surface marker gene expression in tendinopathic tissue
(A-K) Relative mRNA expression (2^-!CT) of surface marker expression in control (hamstring tendon,
n=9), early tendinopathy (intact subscapularis biopsy, n=10) and late tendinopathy (torn supraspinatus
tendon, n=14). Data represent mean ± SEM relative to housekeeping gene GAPDH (mean of duplicate
analysis). * p<0.05, **p<0.01, (Kruskal-Wallis test) versus control.
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4.2.3 Inflammatory mediators increase surface marker expression in 
tenocytes 
Having observed upregulation of various markers in whole tendinopathic tissue we 
next sought to characterize their expression profile at a cellular level. As staining 
was observed in various areas of the tissue section we sought to confirm the 
expression of these markers in human tenocytes and examine their response to 
inflammatory stimuli in vitro to mimic the tendinopathic environment. Upon 
stimulation with LPS (1ng/ml) a significant induction of VCAM1 expression (Fig. 
4.4B, p<0.05) was observed and a 20-fold increase in expression was noted in 
response to IL1b stimulation (10ng/ml). Podoplanin (Fig. 4.4A) and CD34 (Fig. 
4.4E) expression was also increased in response to both IL1b and LPS; however, 
this was not statistically significant.  
 
4.2.4 Characterising surface marker expression in normal and diseased whole 
tendon tissue 
In order to fully characterize surface marker expression in human tendon we next 
performed screening of 11 markers known to be expressed in stromal cells using 
flow cytometric analysis of disaggregated tendon tissue. Due to the large number 
of markers and availability of fluorophores these were divided into two panels for 
phenotyping studies.  
 
4.2.4.1 Panel 1  
 
In both normal and tendinopathic tendons all markers were found to be positive 
(to a varying degrees) between patients and the normal and tendinopathic groups 
(Fig. 4.5B & C). A significant increase in surface expression of CD44 (Fig. 4.5D, 
p<0.01), podoplanin (Fig. 4.5E, p<0.05) and CD90 (Fig. 4.5F, p<0.05) was 
observed between normal and tendinopathic samples. There did not appear to be 
any discernible change in cadherin 11 (Fig. 4.5G) or CD146 (Fig. 4.5H) surface 
expression. Interestingly, CD34 (Fig.4.5I) showed a greater spread of percentage 
positive cells and the expression pattern appears to be divided into highly and 
lowly expressed groups. 
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Figure 4. 4 The effect of inflammatory stimuli on surface marker expression in tenocytes
(A-K) Fold change in mRNA (2-!!CT) of surface marker expression in tenocytes stimulated with
10ng/ml IL-1β (n=3) or 1ng/ml LPS (n=3) for 24 hours. Data represent mean ± SEM relative to
unstimulated control (mean of duplicate analysis). * p<0.05 (Friedman test) versus control.
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We next sought to identify any consistent co-expression profiles of cells within the 
tendon tissue samples based on comprehensive analysis of flow cytometry data. 
Subpopulations based on CD34 and CD146 expression were identified in both 
normal and tendinopathic samples (Fig. 4.6A-E). The highest percentage of 
singlets was observed for the CD146-CD34+ population; accounting for 
approximately half of all cells. A discreet population of double positive 
CD146+CD34+ cells was also observed and distribution of this population appears 
to be consistent between normal and tendinopathic donors.425 
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Figure 4.5 Panel 1 surface marker expression in normal and tendinopathic tendon
(A) Gating strategy for quantification of surface marker expression in disaggregated tendon tissue  (B) & (C) Percentatge of 
cells positive for CD44, PDPN, CD34, cadherin 11, CD146 and CD90. Data expressed as mean ±SEM. (D) Percentage of cells 
positive for CD44 (E) podoplanin (F) CD90 (G) cadherin 11 (H) CD146 in normal hamstring (n=9) or torn supraspinatus tendon 
(n=8). Data expressed a median, * p<0.05, **p<0.01, (paired t-test).
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Figure 4.6 Panel 1 surface marker expression in normal and tendinopathic tendon
Representative pseudocolour plot of populations gated on CD34 and CD146 expression in (A) normal 
hamstring and (B) torn supraspinatus tendon. Negatives gated on isotype controls (C & D). 
normal tendinopathic
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4.2.4.2 Panel 2  
 
As with Panel 1, all surface markers were found to exhibit varying degrees of 
expression in normal and tendinopathic tendons (Fig. 4.7B & C). Median CD47 
surface expression was the highest of all markers tested with the median value 
largely unchanged between normal and tendinopathic groups (Fig. 4.7D). 
Similarly, CD10 expression did not appear to vary between groups (Fig. 7E). 
Although not significant, a notable increase in CD29 expression (Fig. 4.7F) was 
observed between control and tendinopathic samples. CD81 (Fig. 4.7G) and CD91 
(Fig.4.7H) showed the least percentage of positive cells with no expression in 
some donors in the control group and low levels of expression in tendinopathic 
samples.  
 
Distinct cell populations were observed when gated on CD10 and CD29 (Fig. 4.8A-
E) with a prominent CD10-CD29+ population present in both healthy and diseased 
groups. Quantitative analysis showed this population was consistently elevated in 
the tendinopathic group (Fig. 4.8E). Another small double positive (CD29+CD10+) 
population was consistently present in both groups. The total number of CD29-
CD10+ cells was negligible and varied expression of CD29-CD10- cells was observed 
in both normal and tendinopathic samples.  
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Figure 4.7 Panel 2 surface marker expression in normal and tendinopathic tendon
(A) Gating strategy for quantification of surface marker expression in disaggregated tendon tissue  (B) & (C) Percentatge of 
cells positive for CD29, CD10, CD47, CD81 and CD91 in normal hamstring (n=12) or torn supraspinatus tendon (n=6). Data 
expressed as mean ±SEM. (D) Percentage of cells positive for CD29 (E) CD10 (F) CD47 (G) CD81 (H) CD91 in normal hamstring 
(n=12) or torn supraspinatus tendon (n=6). Data expressed a median, * p<0.05, **p<0.01, (paired t- test) 
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Figure 4.8 Panel 1 surface marker expression in normal and tendinopathic tendon
Representative pseudocolour plot of populations gated on CD29 and CD10 expression in (A) normal hamstring (n=12) and (B)
torn supraspinatus tendon (n=6).  Gating based on isotype controls (C & D). 
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4.2.3 Characterising surface marker expression in vitro   
As digested tendon tissue does not yield a homogenous population of cells we next 
sought to confirm the expression of these markers in human tenocytes in vitro. 
Positive expression of all 11 markers was observed (Fig 4.9A & B) with almost all 
tenocytes screened positive for CD44, CD90, CD29, CD10, CD47 and CD91 across 4 
donors. Podoplanin and CD81 were also found to be highly expressed 
(approximately 60% of singlets positive). Less than half of all cells were positive 
for CD34, CD146 and cadherin 11 with these figures consistent between biological 
replicates.  
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Figure 4.9 Surface marker expression in normal  tenocytes
Percentage of cells positive for (A) CD44, podoplanin, CD34, cadherin 11, CD146 and CD90 (B) CD29, 
CD10, CD47, CD81 and CD91 in normal tenocytes (n=4). Data expressed as mean ±SEM. 
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4.2.4 Spanning-tree Progression Analysis of Density Normalised Events 
(SPADE) of tenocyte subpopulations 
 
In order to gain a more comprehensive insight into the phenotype of tenocytes 
extracted from whole tendon tissue we next employed the use of bioinformatic 
tools that allow greater visualization of high dimensional data. SPADE is an 
algorithm that clusters phenotypically similar cells into hierarchy and allows 
multidimensional analysis of heterogenous samples. The algorithm was applied to 
flow cytometry data from four normal and four tendinopathic tissue digests.  
 
Panel 1 
Figure 4.10 and 4.11 show four individual SPADE trees representing data obtained 
from four normal and four tendinopathic tendons. Each node represents a cluster 
of cells (where size corresponds with the number of cells in each cluster). Gates 
or ‘bubbles’ were drawn around populations identified of interest. All markers 
from Panel 1 including CD44, CD146, CD34, podoplanin, CD90 and cadherin 11 
displayed positive populations using the SPADE algorithm. Cadherin 11 positive 
populations were not identified in three normal donors and CD146 populations 
were not identified in one tendinopathic donor (data summarised in Table 4.2). 
A CD146+CD90+ population was observed in 75% of all samples (three normal and 
three tendinopathic) whereas a CD34+CD90+ positive population was only 
identified in one normal and one tendinopathic sample. As observed previously, 
CD90 and podoplanin show different patterns of expression between normal and 
tendinopathic samples. CAD11+PDPN+ and CD90+PDPN+ double positive populations 
were identified in one normal and three out of four tendinopathic samples or no 
normal and three tendinopathic samples, respectively. Similarly, 
CAD11+PDPN+CD90+CD44+ positive populations were only identified in 
tendinopathic tissues.   
 
In order to validate populations generated by the SPADE algorithm we undertook 
back-analysis of flow cytometry data and identified these by manual gating based 
on isotype controls. Fig. 4.12 shows a representative example of a SPADE tree 
and corresponding pseudocolour plots of populations identified by the algorithm.  
 140 
7992
(A) N1
(B) N2
(D) N4
(C) N3
Panel 1- normal
Figure 4.10 SPADE trees of of flow cytometry data from normal 
tendon tissue (Panel 1)
Each tree represents individual analysis of one normal donor 
(N1-N4) gated manually and annotated according to clusters 
positive for stromal surface marker expression.  Target number 
of nodes= 200, percentage downsampling= 10%. Trees are 
coloured by cell density.  
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Panel 1- tendinopathic
(A) TP1
(B) TP2
(D) TP4
(C) TP3
Figure 4.10 SPADE trees of flow cytometry data 
from tendinopathic tendon tissue (Panel 1) Each 
tree represents individual analysis of one 
tendinopathic donor (TP1-N4) gated manually and 
annotated according to clusters positive for stromal 
surface marker expression.  Target number of 
nodes= 200, percentage downsampling= 10%. Trees 
are coloured by cell density.  
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CD44+ CD146+ CD34+ PDPN+ CD90+ CAD11+
N1 + + + + + -
N2 + + + + + -
N3 + + + + + +
N4 + + + + + -
TP1 + - + + + +
TP2 + + + + + -
TP3 + + + + + +
TP4 + + + + + +
CD34+CD90+ CD146+CD90+ CD34+CD146+ CAD11+PDPN+ CD90+PDPN+ CD34+PDPN+
CAD11+PDPN+
CD90+CD44+
N1 + + - - - - -
N2 + - + - - + -
N3 + + - + - - -
N4 - - + - - - -
TP1 - - + + + - +
TP2 + - - - + + -
TP3 + - - + - -
TP4 + + - + + + +
Table 4.2 Tabular comparison of populations identified by SPADE analysis (Panel 1)
n=4 normal hamstring tendon, n=4  tendinopathic (torn) supraspinatus tendon 
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Figure 4.12  Validation of SPADE analysis using manual gating (Panel 1)
Representative comparison of populations derived from SPADE analysis and manual gating using FlowJo. SPADE tree 
represents individual analysis of flow cytometry data from one donor gated and annotated according to clusters positive 
for stromal surface marker expression. Pseudocolour plots represent data from the same experiment file analysed on
FlowJo. Gating shown is of singlet cells, positive populations were gated relative to isotype controls.  
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Panel 2 
As reported previously, SPADE trees for Panel 2 expression were generated from 
four normal and four tendinopathic samples (Fig. 4.13 and 4.14). Positive 
populations were identified in all samples for CD29, CD10 and CD47 with only one 
normal donor lacking CD10 clusters (Table 4.3). CD91 populations were identified 
in two samples and CD81 was only present in one tendinopathic donor. With the 
exception of CD29+CD47+ double positive populations (present in three normal and 
three tendinopathic samples) clustering observed was generally less well defined 
for this panel of markers. CD29+CD10+CD47+ populations were identified in three 
samples and one CD47+CD10+CD29+CD91+ population was observed in a 
tendinopathic donor. As with the previous panel we were able to validate the 
SPADE clustering analysis using manual gating (Fig. 4.15).  
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Panel 2- normal(A) N1
(B) N2
(D) N4
(C) N3
Figure 4.13 SPADE trees of flow cytometry 
data from normal tendon tissue (Panel 2)
Each tree represents individual analysis of 
one normal donor (N1-N4) gated manually 
and annotated according to clusters positive 
for stromal surface marker expression.  
Target number of nodes= 200, percentage 
downsampling= 10%. Trees are coloured by 
cell density.  
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Panel 2- tendinopathic
(A) TP1
(B) TP2
(D) TP4
(C) TP3
Figure 4.14 SPADE trees of flow cytometry data 
from tendinopathic tendon tissue (Panel 2) 
Each tree represents individual analysis of one 
normal donor (N1-N4) gated manually and 
annotated according to clusters positive for stromal 
surface marker expression. Target number of 
nodes= 200, percentage downsampling = 10%. 
Trees are coloured by relative cell density.
 147 
 
CD47+
CD47
SS
C-
A
CD10
CD
91
CD29
SS
C-
A
CD10
CD
81
Figure 4.15  Validation of SPADE analysis using manual gating (Panel 2)
Representative comparison of populations derived from SPADE analysis and manual gating using 
FlowJo. SPADE tree represents individual analysis of flow cytometry data from one donor gated and 
annotated according to clusters positive for stromal surface marker expression. Pseudocolour plots 
represent data from the same experiment file analysed on FlowJo. Gating shown is of singlet cells, 
positive populations were gated relative to isotype controls.  
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CD29+ CD10+ CD47+ CD81+ CD91+
N1 + + + - -
N2 + + + - -
N3 + - + - +
N4 + + + - -
TP1 + + + - -
TP2 + + + - -
TP3 + + + - -
TP4 + + + + +
CD29+CD47+ CD10+CD47+ CD29+CD91+ CD29+CD47+CD10+ CD29+CD10+CD81+
CD47+CD29+
CD10+CD91+
N1 + - - + - -
N2 + - - - - -
N3 - - + - - -
N4 + - - + - -
TP1 + - - - - -
TP2 + + - - - -
TP3 - - - + - -
TP4 + - - - + +
Table 4.3 Tabular comparison of populations identified by SPADE analysis
n=4 normal hamstring tendon and n=4 tendinopathic (torn) supraspinatus tendon
Table 4.3 Tabular comparison of populations identified by SPADE analysis (Panel 2) 
n=4 normal hamstring tendon, n=4 tendinopathic (torn) supraspinatus tendon 
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4.2.5 viSNE analysis of normal and tendinopathic tissue samples 
viSNE is a tool that maps high dimensional cytometry data onto 2D while 
conserving its high dimensional structure. viSNE highlights structure in the 
heterogeneity of surface phenotype expression.438 It differs from other tools, such 
as  SPADE, as SPADE clusters cells and determines the average of each cluster 
while viSNE maintains single cell resolution. Our SPADE analysis identified several 
distinct clusters of cells in our first panel of markers (Panel 1) and a relative lack 
of clustering in Panel 2 thus we applied to viSNE algorithm to normal and 
tendinopathic samples stained for Panel 1. Figure 4.16/17 A & B show overlay 
plots of normal and tendinopathic tissue samples gated for positive staining with 
CD90, CD44, CD34, CD146, cadherin 11 and podoplanin. Overall, distinct clustering 
patterns are observed between normal and tendinopathic samples. Most notable 
differences appear with CD44 clustering (Fig. 4.16E & F) where two clusters are 
observed in normal but absent in tendinopathic samples. A similar pattern is seen 
with CD90 clustering in the same area although this is not as distinct as observed 
with CD44. As per our FlowJo and SPADE analysis, a relative lack of cadherin 11 
expression in normal donors is evident (Fig.4.17E). Visually, the most apparent 
difference between the normal and tendinopathic samples is the large cluster 
observed in the bottom right hand of the overlay plots (Fig. 4.16/17 A & B). In 
the tendinopathic donors this cluster is positive for CD90, CD44, CD34, CD146, 
cadherin 11 and podoplanin. This co-expression profile may indicate the presence 
of phenotypically similar activated populations in disease.  
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normal
Figure 4.16 viSNE visulisation of flow cytometry data from normal and tendinopathic tissue samples
viSNE algorithm run on concatenated flow cytometry data from 3 normal and 3 tendinopathic donors. (A & 
B) overlay plots of populations manually gated on positive expression of  CD90, CD44, CD34, CD146, CAD11 
& PDPN. (C -H) viSNE plots showing only ungated and CD90, CD44 & CD34 positive populations in normal and 
tendinopathic donors, n=3. Plots represent equal sampling of normal and tendinopathic donors (18033 
events per file, 36066 events total). 
BA
C D
H
F
G
E
tendinopathic
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Figure 4.17 viSNE visulisation of flow cytometry data from normal and tendinopathic tissue samples 
viSNE algorithm run on concatenated flow cytometry data from 3 normal and 3 tendinopathic donors. (A & 
B) overlay plots of populations manually gated on positive expression of  CD90, CD44, CD34, CD146, CAD11 
& PDPN.  (C -H) viSNE plots showing only ungated and CD146, CAD11 and PDPN positive populations in 
normal and tendinopathic donors, n=3.  Plots represent equal sampling of normal and tendinopathic 
donors (18033 events per file, 36066 events total). 
BA
C D
H
F
G
E
normal tendinopathic
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4.3 Discussion and conclusions 
 
In the context of the tendinopathy little is known about the properties of stromal 
cells and whether any phenotypic discrepancies may relate to pathology. Within 
the literature there are no globally accepted markers of tenocyte phenotype and 
their distinction from other fibroblast populations is not well understood.  
Previous studies have addressed the concept of stromal ‘activation markers’ in 
tendinopathy; however, the aim of this work was to explore the concept of 
multidimensional subpopulations in health and disease.  This chapter has 
identified the presence of stromal surface markers in human tendon and found 
their expression is upregulated in disease. Furthermore, we have identified the 
existence of distinct subpopulations present under both homeostatic and 
pathological conditions.  
 
Our initial screening confirmed the presence of several markers at both protein 
and transcript level. Several previously reported ‘activation’ markers including 
podoplanin, FAP, VCAM-1 and CD248 were found to be upregulated in 
tendinopathic tissue. In addition, podoplanin and VCAM1 expression in tenocytes 
was increased in response to IL1b and LPS simulation in vitro. ‘Activation’ was not 
as pronounced in vitro which suggests that upregulation of surface protein 
expression is dependent on a number of local factors present in the tendon 
microenvironment rather than a single inflammatory stimulus. Interestingly, we 
found most significant differences in surface protein and transcript expression 
between control and late disease indicating a sustained stimulus is required to 
induce phenotypic modifications.  
 
A recent study has highlighted the presence of a CD90+CAD11+PDPN+ synovial 
fibroblast subpopulation in RA.315 Although not identified by initial analysis, our 
hierarchical clustering data showed the presence of such populations in two 
tendinopathic biopsies. In addition, CD90+PDPN+ and CAD11+CD90+ populations 
were observed in three of four tendinopathic donors. Podoplanin expression has 
been associated with an inflammatory phenotype in RA and tumour invasion in 
metastatic disease.439,440 Furthermore, CD90+ fibroblasts are the major source of 
IL-6 that supports the expansion of cancer stem cells in inflammation.441 Coupled 
with the absence of these populations in normal tendon biopsy samples, this 
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suggests a potentially pathological tenocyte subpopulation may exist in disease. 
CD90 and podoplanin mediate adhesion of leukocytes and platelets to stromal 
cells442,443 and cadherin 11 has been shown to modulate adhesion between 
fibroblasts.444 This indicates these surface proteins may also act to direct cellular 
behaviour in the stromal microenvironment. Expression of CD90, cadherin 11 and 
podoplanin was low in normal donors compared with diseased samples; however, 
we still observed distinct clustering of these markers. It is plausible these small 
tenocyte subpopulations in healthy tendon may be expanded in under pathological 
conditions.  
 
Interestingly, we observed a small yet distinct population of exclusively CD44+ 
cells in almost all SPADE analyses. Although CD44 expression was upregulated in 
tendinopathic tissue this population appeared to be consistent between normal 
and diseased samples. viSNE analysis identified distinct CD44 clustering most 
prominent in normal samples which suggests these CD44+  populations may play a 
role in tendon homeostasis. Our hierarchical clustering and viSNE analysis showed 
the expanded CD44+ population in tendinopathic samples was present alongside 
podoplanin, cadherin 11 and CD90 which suggests that CD44 may be expressed in 
phenotypically distinct tenocyte subsets in health and disease. CD44 and 
podoplanin are co-ordinately upregulated in aggressive cancer cell lines; they 
directly bind to each other and such interaction is thought to promote directional 
cell migration.445 This provides further evidence to suggest the possibility of 
‘pathogenic’ tenocyte subpopulations in tendinopathy. 
 
We did not observe any significant alterations in surface protein expression in our 
second panel of markers. CD29 and CD47 showed a trend towards increased 
expression in tendinopathic samples; however, these populations appear to 
display a bimodal distribution that indicates inherent differences in gene 
expression between donors. These differences in gene expression were also 
apparent in our sub analysis based on CD29/CD10 gating.  The clustering generated 
by the SPADE algorithm showed the majority of cells displayed concomitant 
expression of CD29 and CD47. CD29 and CD47 are also known as integrin b1 and 
integrin associated protein, respectively. CD47 is able to modulate the behaviour 
of b1 integrin complexes thus it possible this  subpopulation is active in mediating 
cell adhesion.446   
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We additionally observed the expression profiles of tenocytes in vitro varies 
significantly to those freshly isolated from tendon tissue. Differential expression 
profiles are likely highly dependent on the tissue niche and local 
microenvironmental factors that are absent under culture conditions. Initial 
analysis of flow cytometry data showed an interesting CD34+CD146+ double 
positive population consistent between normal and tendinopathic samples. 
Although CD34 and CD146 are both expressed on fibroblasts, endothelial cells are 
known to express these proteins concomitantly.447 As disaggregated tendon is not 
a homogenous population of cells it is possible there is a small population of 
endothelial cells present that originate from the small vessels within the tendon. 
In future studies it would therefore be prudent to add an endothelial cell exclusion 
channel to omit these cells from analysis. Similarly, it is likely that a small 
population of immune cells is present in these digest samples (existing as a small 
resident compartment in normal tendon with additional inflammatory infiltrate in 
the tendinopathic samples). For this reason, a CD45 haematopoietic exclusion 
channel would also serve to preserve the purity of the tenocyte populations 
obtained from tissue digests.  
 
We acknowledge that immune cell subsets may express some of the surface 
markers tested; however, CD45+ cells typically account for 2% of total cells 
obtained from normal digests and 5% of cells in tendinopathic samples thus it is 
unlikely there is significant contamination. When considering the concept of tissue 
heterogeneity the effect of enzymatic digestion on cell subsets must also be taken 
into consideration due to its possible effect on the expression profile of different 
cells. However, all samples were subject to the same protocol and surface marker 
expression profiles appear to be consistent between transcript data and cells 
isolated from fresh tendon.  
 
It is evident that complex tenocyte phenotypic variations exist within the live 
tendon stroma. Discerning these differences ex vivo and translating them to in 
vitro functional studies presents a host of challenges that should be met with 
caution to preserve the organic nature of this differential gene expression. 
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 On the basis of these results we propose that tenocytes are a heterogenous 
population of cells that exist as phenotypically distinct subpopulations in health 
and disease. Further characterization of tenocyte subsets may aid the 
development of strategies to target pathogenic stroma in diseases associated with 
abberant matrix remodelling.  
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Chapter 5: Assessing the effect of surface protein 
knockdown on stromal-immune cell interactions in 
tendinopathy 
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5.1 Introduction 
 
As discussed in the previous chapter, several studies have emerged highlighting 
the phenomenon of ‘fibroblast activation’ in various soft tissue 
pathologies.418,436,448 Stromal biology is a relatively new area of pharmacologic 
interest that is commonly considered a branch of immunology. Fibroblasts, the 
main cellular component of the stroma, regulate the structure and function of 
healthy tissues and participate in tissue repair following periods of acute 
inflammation.419 Under certain conditions, such as chronic inflammation, they can 
acquire specific properties that include expression of surface proteins and 
aberrant stimulatory properties.435 
 
The previous chapter demonstrated upregulation of several surface proteins 
including podoplanin and VCAM1. Having identified myeloid cells as a source of 
DAMPs within the tendon we next sought to directly assess the interactions of 
immune and stromal cells. It is well cited within the literature that podoplanin 
and VCAM1 modulate cell interactions thus we hypothesised tenocytes may be 
express these proteins to facilitate immune cell contact.362,449  
 
Podoplanin is a small cell-surface mucin-like glycoprotein expressed on a number 
of cells including fibroblasts and macrophages. Its expression is upregulated under 
high levels of inflammation associated with chronic conditions such as RA, 
psoriasis and multiple sclerosis (MS).450  CLEC-2 (C-type lectin 2) is the only known 
ligand for podoplanin and is most abundantly expressed on platelets.363 Recently 
it has been identified on myeloid cells, specifically monocytes and dendritic 
cells.451 Binding of podoplanin with its ligand is thought to modulate signalling 
pathways that regulate cell proliferation, migration and ECM remodelling.450 Little 
is known about the physiological properties of podoplanin; however, recent 
studies have highlighted its role in regulating the inflammatory reaction and 
immune cell infiltration during sepsis.452  
 
VCAM1 (vascular cell adhesion molecule-1) expression is associated with the 
progression of several immunological disorders including RA, asthma and 
cancer.449 It is primarily expressed on the surface of endothelial cells; however, 
its expression is upregulated in other cell types including fibroblasts and 
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macrophages under inflammatory conditions.436,453 It primarily functions as an 
adhesion molecule and is involved in adhesion and transmigration of monocytes 
across blood vessel walls. Its binds to integrin a4b1 (VLA-4) and this interaction is 
thought to play an important role in leukocyte recruitment during 
inflammation.454  
 
To assess the physiological significance of stromal activation markers in 
tendinopathy the aims of this chapter are: 
 
1. To assess the effect of podoplanin and VCAM1 knockdown on tenocyte 
behaviour 
2. Characterize the effect of tenocyte-monocyte co-culture on monocyte 
phenotype and development 
3. Assess the effect of podoplanin and VCAM1 knockdown on monocyte 
phenotype in our monocyte-tenocyte co-culture system 
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5.2 Results 
5.2.2 Podoplanin knockdown does not directly alter tenocyte behaviour 
We first tested the effect of podoplanin knockdown in tenocytes using 
commercially available siRNA. Fig. 5.1A and 5.1C show podoplanin protein 
knockdown measured by flow cytometry. On average, we obtained an 80% 
knockdown in protein expression and a 92% knockdown in podoplanin transcript 
by RT-PCR (Fig. 5.1B).  
 
We next sought to assess the effect of podoplanin knockdown on the intrinsic 
behaviour of tenocytes by measuring cytokine release and production of matrix 
proteins. We found no significant effect of podoplanin knockdown on release of 
IL-6 (Fig 5.2 A &B), IL-8 (Fig. 5.2 C & D) or CCL2 (Fig. 5.2E & F) in normal or 
tendinopathic tenocytes compared with untransfected tenocytes and scramble 
transfection control. Additionally, the transfection procedure alone (represented 
by scramble negative control) did not appear to have any discernible effect on 
cytokine release.   
 
Under the same conditions, tenocytes were stimulated with 10ng/ml IL-1b to test 
the effect of transfection and podoplanin knockdown on responsiveness to an 
inflammatory stimulus. Tenocytes responded by producing significantly greater 
levels of cytokines including IL-6 in normal (Fig. 5.2A, all conditions p<0.05) and 
tendinopathic (Fig 5.2B siPDPN vs siPDPN + IL-1b p<0.05) cultures. Similarly, IL-8 
expression was significantly upregulated in normal (Fig. 5.2C siPDPN vs siPDPN + 
IL-1b p<0.01) and tendinopathic tenocytes (Fig. 5.2D scramble vs scramble + IL-
1b and siPDPN vs siPDPN + IL-1b p<0.05). CCL2 release was most significantly 
increased in response to IL-1b stimulation in normal tenocytes (Fig. 5.2E control 
vs control + IL-1b p<0.001, scramble vs scramble + IL-1b and siPDPN vs siPDPN + 
IL-1b) and also in tendinopathic tenocytes (Fig. 5.2F control vs control + IL-1b 
p<0.05, scramble vs scramble + IL-1b p<0.05). Podoplanin knockdown did not 
appear to affect the response of tenocytes to IL-1b under any of the conditions 
tested. It should be noted that IL-1b stimulation produced a great magnitude of 
response under every stimulatory condition despite some not displaying statistical 
significance.  
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Figure 5.1 Podoplanin knockdown in tenocytes
siRNA knockdown of podoplanin in scramble control and transfected tenocytes (siPDPN) (A)
expressed as % positive singlet cells based on isotype control gating, n=3 (B) percentage
knockdown of podoplanin measured by RT-PCR (relative to 18S endogenous control), n=4 (C)
representative histogram of podoplanin surface expression in transfected tenocytes relative to
scramble control. All data represent mean ± SEM.
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Figure 5.2 Cytokine release from tenocytes with podoplanin knockdown
IL-6, IL-8 and CCL2 release from (A, C, E) normal tenocytes (B, D, F) tendinopathic tenocytes left 
untransfected (control), transfected with scramble control and transfected with podoplanin siRNA 
in the presence or absence of 10ng/ml IL-β stimulation. p<0.05, **p<0.01 (One way ANOVA with 
Tukey’s multiple comparisons test) All data represent mean  ± SEM, n=4. 
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The effect of podoplanin knockdown and simultaneous stimulation with IL-1b on 
matrix production was measured by RT-qPCR using a panel of genes associated 
with matrix regulation by tenocytes. Neither podoplanin knockdown or IL-1b 
stimulation appeared to have any effect on production of collagen 1 (Col1a1) in 
normal and tendinopathic tenocytes (Fig. 5.3A & B). There was a trend towards 
increased expression of collagen 3 (Col3a1) (Fig. 5.3C & D), tenascin C (Fig. 5.3 
E & F) and decorin (Fig. 5.3 I & J) expression in response to IL-1b stimulation in 
normal and tendinopathic tenocytes; however, podoplanin knockdown did not 
appear to have any demonstrable effect. In normal tenocytes periostin expression 
did not change in response to podoplanin knockdown or IL-1b stimulation (Fig. 
5.3G). There appeared to be a small (0.75 fold) deviation in periostin expression 
in tendinopathic tenocytes in response to podoplanin knockdown and IL-1b 
stimulation; however, this was not significant (Fig. 5.3H).     
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Figure 5.3 Podoplanin knockdown does not directly alter matrix regulation by tenocytes   
 (A & B) Col1α1 (C & D) Col3α1 (E & F) tenascin C (G & H) periostin (I & J) decorin expression in  
normal or tendinopathic tenocytes transfected with scramble control or podoplanin siRNA in the presence 
or absence of 10ng/ml IL-1β stimulation. All data are normalized to 18S housekeeping gene and expressed 
as fold change relative to scramble control, data represent mean  ±  SEM, normal n=4, tendinopathic n=3.  
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5.2.2 VCAM1 knockdown does not directly alter tenocyte behaviour 
As reported previously, we tested the effect of VCAM1 knockdown in vitro using 
commercially available siRNA and achieved 90% knockdown by RT-qPCR and a 71% 
knockdown in protein expression (Fig.5.4A & B). 
 
Our cytokine release experiments yielded similar results to podoplanin knockdown 
with the only significant differences being observed with IL-1b stimulation. We 
found significant upregulation of IL-6 (Fig. 5.5A &B p<0.05, 0.01 or 0.001) and 
CCL2 (Fig. 5.5E & F p<0.05 or 0.01) expression in both normal and tendinopathic 
tenocytes under all stimulatory conditions and significant induction of IL-8 
expression in normal and tendinopathic tenocytes (Fig. 5.5 C control vs control + 
IL-1b p<0.05, , siVCAM1 vs siVCAM1 + IL-1b p<0.05, Fig 5.5D scramble vs scramble 
+ IL-1b p<0.01, siVCAM1 vs siVCAM1 + IL-1b p<0.05).  
 
VCAM1 knockdown did not appear to have any effect on expression on matrix 
proteins in normal or tendinopathic tenocytes (Fig. 5.6A-J). As observed 
previously there was a trend of increased expression of collagen 3 (Fig. 5.6C & D) 
and tenascin C (Fig. 5.6G & H) in normal and tendinopathic tenocytes in response 
to IL-1b stimulation. There appeared to be no change in expression of collagen 1 
(Fig. 5.6 A & B), periostin (Fig. 5.6E & F) or decorin (Fig. 5.6I & J).    
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Figure 5.4 VCAM1 knockdown in tenocytes
siRNA knockdown of VCAM1 in scramble control and transfected tenocytes (siPDPN) (A) expressed as %
positive singlet cells based on isotype control gating, n=3 (B) percentage knockdown of VCAM1
measured by RT-PCR (relative to 18S endogenous control), n=3 (C) representative histogram of VCAM1
surface expression in transfected tenocytes relative to scramble control.
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Figure 5.5 Cytokine release from tenocytes with VCAM1  knockdown
IL-6, IL-8 and CCL2 release from (A, C, E) normal tenocytes (B, D, F) tendinopathic tenocytes left 
untransfected (control), transfected with scramble control and transfected with VCAM1 siRNA in 
the presence or absence of 10ng/ml IL-β stimulation. * p<0.05, **p<0.01, ***p<0.001 (One way 
ANOVA with Tukey’s multiple comparisons test) All data represent mean ± SEM, n=4. 
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Fig. 5.6 VCAM1 knockdown does not directly alter matrix regulation by tenocytes   
 (A & B) Col1α1 (C & D) Col3α1 (E & F) tenascin C (G & H) periostin (I & J) decorin expression in normal or 
tendinopathic tenocytes transfected with scramble control or VCAM1 siRNA in the presence or absence of 
10ng/ml IL-1β stimulation. All data are normalised to 18S housekeeping gene and expressed as fold change 
relative to scramble control, data represent mean ± SEM, n=3.  
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5.2.3 Macrophages derived from tendinopathic tissue express markers 
associated with a pro-resolving phenotype  
To fulfil our aim to assess the effect of tenocyte-monocyte co-culture on 
monocyte phenotype and differentiation into mature macrophages we next 
undertook phenotyping studies of macrophages extracted from tendinopathic 
tendon tissue by enzymatic digestion. We chose a panel of markers associated 
with a pro-resolving or ‘M2’ like phenotype based on the current literature. Figure 
5.7A shows the percentage of CD45+ and CD64+ cells isolated from tendon tissue 
measured by flow cytometry. We found approximately 6% of singlets were CD45+ 
(haematopoietic marker representing immune cells) and of these, 4% were also 
CD64+ indicating the presence of mature macrophages. We stained cells for the 
presence of CD206, CD163, MERTK and HLA-DR (MHC-II). Figure 5.7B shows the 
expression of these markers expressed as percentage of macrophages (CD64+). We 
observed high levels of expression of CD206 in all donors ranging from 70% to 
around 100% (illustrated in Fig.5.7C). Similarly, MHC-II expression was maximal 
with all donors displaying almost 100% positive expression. Conversely, CD163 and 
MERTK show a different pattern of expression with expression not detected in 
three out of four donors in each case (illustrated in Fig 5.7 D & E). The remaining 
donor exhibited high levels of expression of CD163 and MERTK  (approximately 60% 
positive) indicating the expression profile may be donor specific. We postulate 
this may be attributed to the stage at which the samples were taken and may be 
relative to the progression of pathology. As such, we decided to proceed with all 
markers tested in our in vitro co-culture model. 
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Figure 5.7 Macrophage marker expression in tendinopathic tissue
(A) Percentage of CD45+ and CD64+ cells in torn supraspinatus (late tendinopathy) tendon tissue
expressed and percentage of singlet cells. Data represent mean ± SEM, n=4. (B) Expression of CD206,
CD163, MERTK and HLA-DR in tendinopathic tendon (expressed as percentage positive of CD64+
cells). Data expressed as median, n=4. (C-F) Representative histograms of CD206, CD163, MERTK and
HLA-DR expression in macrophages from tendinopathic tendon.
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5.2.4 Direct monocyte-tenocyte co-culture induces monocyte development 
and a pro-resolving phenotype 
To assess the effect of the tenocyte-monocyte interactions on monocyte 
phenotype we first performed direct co-cultures to allow for contact dependent 
signalling. We performed parallel cultures using soluble factors IL-6 and CCL2  
(identified in Chapter 3 as possible drivers of monocyte development) and 
tenocyte conditioned supernatant. M-CSF and GM-CSF were used as controls for in 
vitro monocyte differentiation.  
 
We found direct co-culture resulted in an approximate 40% increase in CD206 
expression. CD206 expression also increased in response to tenocyte conditioned 
supernatant and IL-6, CCL2, and IL-6 and CCL2 together; however, the response 
was slightly less marked than the co-culture (Fig. 5.8B & C). Basal CD163 
expression was the lowest of all surface markers at 10% and increased to 
approximately 60% in the direct co-culture. The effect of IL-6, CCL2 and tenocyte 
conditioned supernatant was not as marked although slight increases in expression 
were still observed (Fig. 5.8D & E). Similarly, MERTK expression was relatively low 
in the monocyte only control and induced in the co-cultures to around 80% positive 
expression. More discreet increases were observed in response to tenocyte 
conditioned supernatant, IL-6 and CCL2 (Fig. 5.8F & G). In contrast, HLA-DR 
expression was high under control conditions and increased very slightly to almost 
100% positive in all other conditions tested (Fig. 5.8H & I).  
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Figure 5.8 Tenocyte-monocyte co-culture influences monocyte phenotype
(A) Gating strategy for isolating monocytes from co-culture. (B) CD206 (D) CD164 (F)MERTK (H) HLA-DR expression in
control monocytes, monocytes from direct tenocyte-monocyte co-culture, monocytes stimulated with 50% tenocyte
conditioned supernatant, 100ng/ml IL-6, 100ng/ml CCL2, 100ng/ml IL6 + CCL2, 25ng/ml MCSF or 100 ng/ml GMCSF.
All data represent mean ± SEM, n=4. (C) Representative histogram of CD206 (E) CD163 (G)MERTK (I) HLA-DR surface
expression in control CD14+monocytes andmonocytes co-cultured with tenocytes relative to isotype control.
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5.2.5 Induction of MMP3 expression is contact dependent 
Having observed upregulation of expression of CD206, CD163 and MERTK on 
monocytes in response to direct tenocyte-monocyte co-culture we tested the 
hypothesis that this response is contact dependent. We performed parallel direct 
and transwell co-cultures to exclude contact and retain soluble factors in the 
culture system.  We previously observed that unstimulated tenocytes to do not 
express MMP3 protein (Chapter 3: Fig. 3.7) and studies have shown that 
monocytes/macrophages express MMP3 in response to stimulation455 thus we used 
this as a measure of tenocyte-monocyte interaction. As anticipated, we found 
expression was absent in both tenocyte and monocyte controls as well as the 
transwell co-culture. Conversely, we found induction of MMP3 expression in the 
direct tenocyte-monocyte co-culture. This suggests there is essential surface 
receptor-ligand engagement taking place in this co-culture model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.9 MMP3 expression is induced by monocyte-tenocyte contact 
MMP3 release from tenocytes and monocytes in direct or transwell co-culture system. Data 
represent mean ± SEM, n=3.   
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5.2.6 Podoplanin and VCAM1 knockdown in tenocyte-monocyte co-culture 
model does not affect monocyte phenotype 
Having established a contact dependent tenocyte-monocyte co-culture model that 
induces the expression of macrophage associated genes we next sought to 
determine the effect of podoplanin and VCAM1 knockdown on monocyte 
phenotype.  
 
Podoplanin was knocked down in normal and tendinopathic tenocytes and the 
expression of surface proteins on monocytes was measured by flow cytometry. We 
observed no alterations in CD206 (Fig. 5.10A & B), CD163 (Fig. 5.10C & D) or HLA- 
DR (Fig. 5.10G & H) expression in monocytes subject to direct co-culture with 
normal or tendinopathic tenocytes with podoplanin knockdown. We observed a 
slight decrease in MERTK expression in the tendinopathic co-culture compared 
with normal tenocytes. However, there were no differences between control and 
podoplanin knockdown cultures (Fig. 5.10E & F). 
 
Similarly, we found no apparent change in expression of CD206 (Fig. 5.11A & B), 
CD163 (Fig. 5.11C & D), MERTK (Fig. 5.11E & F) or HLA-DR (Fig. 5.11G & H) in 
tenocyte-monocyte co-cultures subject to VCAM1 knockdown in both normal and 
tendinopathic tenocytes.  
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Figure 5.10  Podoplanin knockdown in tenocyte-monocyte co-culture model does not affect monocyte phenotype
(A)  CD206 (C) CD163 (E) MERTK (G) HLA-DR expression in monocytes from direct monocyte-tenocyte co-culture expressed as 
median fluorescence intensity (MFI). All data represent mean ± SEM, n=4. Representative overlay dot plots of  (B) CD206 (D)
CD163 (F) MERTK (H) HLA-DR expression in monocytes from monocyte-tenocyte co-culture.
CD206
HLA-DR
MERTK
CD163
A B
C D
E F
G H
 175 
 
  
co
ntr
ol 
siV
CA
M1
co
ntr
ol 
siV
CA
M1
0
5000
10000
15000
CD206
M
FI
normal tendinopathic
co
ntr
ol 
siV
CA
M1
co
ntr
ol 
siV
CA
M1
0
500
1000
1500
2000
2500
M
FI
CD163
normal tendinopathic
co
ntr
ol 
siV
CA
M1
co
ntr
ol 
siV
CA
M1
0
2000
4000
6000
8000
HLA-DR 
M
FI
normal tendinopathic
co
ntr
ol 
siV
CA
M1
co
ntr
ol 
siV
CA
M1
0
5000
10000
15000
MERTK
M
FI
normal tendinopathic
siVCAM coculture
Control coculture
Monocyte alone
CD206
CD163
MERTK
HLA-DR
A B
C D
E F
G H
Figure 5.11 VCAM1 knockdown in tenocyte-monocyte co-culture model does not affect monocyte phenotype
(A)  CD206 (C) CD163 (E) MERTK (G) HLA-DR expression in monocytes from direct monocyte-tenocyte co-culture expressed as 
median fluorescence intensity (MFI). All data represent mean ± SEM, n=4. Representative overlay dot plots of  (B) CD206 (D)
CD163 (F) MERTK (H) HLA-DR expression in monocytes from monocyte-tenocyte co-culture.
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5.3 Discussion 
 
This chapter sought to assess the functional properties of stromal activation 
markers in a human model of tendinopathy and explore mechanisms through which 
stromal and immune cells interact. Our findings suggest that increased expression 
of stromal activation markers does not direct any discernible phenotypical 
changes in tenocytes or alter their intrinsic properties. We observed expression of 
several ‘pro-resolving’ macrophage markers in macrophages extracted from 
tendinopathic tissue and found naïve monocytes respond to stimuli generated by 
tenocytes in a contact dependent manner. We did not, however, observe any 
alterations in myeloid cell phenotype in response to knockdown of stromal surface 
markers podoplanin and VCAM1 suggesting alternate communication mechanisms 
may be implicated in these tenocyte-monocyte interactions.  
 
Phenotyping studies of macrophages isolated from fresh supraspinatus 
(tendinopathic) tendon revealed expression of several genes associated with a 
pro-resolving or ‘M2’ like phenotype. CD206 is the prototypic marker of this 
phenotype and is described in the literature alongside many combinations of 
markers that represent a spectrum of ‘activation’ or ‘differentiation’  states.404 
We found expression of CD206 and HLA-DR (MHC-II) was ubiquitous in all of our 
samples; however MERTK AND CD163 were concomitantly expressed in only one 
donor. CD163 expression is exclusive to monocyte/macrophage lineage and is 
commonly linked with systemic inflammatory disorders.456 MERTK is associated 
with increased phagocytic capacity of macrophages, reduced inflammation and 
transition towards a homeostatic environment in a number of pathologies.457 It 
has been postulated that macrophages expressing CD206, MERTK and CD163 
represent a distinct sub-population of ‘M2’ macrophages that exhibit enhanced 
phagocytic capacity and ‘anti-inflammatory’ properties.458 In the context of 
tendinopathy, co-expression of these surface markers may represent an advanced 
state of activation exclusive to late stage pathology.  
 
In addition to ‘alternatively activated’ macrophages, CD206 and HLA-DR are 
expressed on tissue macrophages. These may represent an expanded pool of 
macrophages of tissue origin that cannot be segregated from infiltrating cells 
based on our gating on macrophage marker CD64. To further explore macrophage 
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phenotype in tendinopathic tissue, future studies would benefit from increased 
sample size along with multiple patient cohorts based on stage of disease 
progression. 
 
We established an in vitro model of direct tenocyte-monocyte interaction and 
found induction of contact dependent expression of surface markers associated 
with a ‘pro-resolving’ macrophage phenotype (Fig. 5.12A). This indicates that, 
within the tendon microenvironment, it is likely tenocytes that are driving 
monocyte differentiation and maturation. In vitro we found expression of CD206, 
CD163, MERTK and HLA-DR in all samples indicating tenocytes retain the capacity 
to induce expression of these genes under certain conditions. As postulated in 
Chapter 3, we found that IL-6 and CCL2 are capable of driving monocyte 
differentiation into macrophages and also influence their phenotype. The 
response of monocytes to soluble factors-including tenocyte conditioned 
supernatant-was more modest and less consistent than direct co-culture 
indicating a contact dependent mechanism or a combination of stimuli is 
necessary to illicit a complete response. We performed parallel transwell co-
cultures to remove cell surface contact from the system and used MMP3 expression 
as a measure of cell activation as neither tenocytes or monocytes/macrophages 
express MMP3 under homeostatic conditions. MMP3 was only detected in the 
supernatant of the direct co-cultures indicating there is surface receptor 
engagement acting as an activating stimulus. However; as this is a heterogeneous 
culture it is not possible to discern which cell type is the source of this protein or 
if both populations are active in secretion.  
 
Our phenotyping studies in the previous chapter highlighted the expression of 
several ‘activation markers’ in tenocytes and tendinopathic tissue thus we sought 
to explore their function in relation to tendon pathology. Previous studies have 
defined the activation state of tenocytes based on surface protein expression 
including podoplanin and VCAM1 and have proposed they are primed to respond 
to inflammatory stimuli.418 However, based on previous published works by 
ourselves and others we believe that the activation state of tenocytes is more 
appropriately reflected by relative expression of inflammatory mediators and 
matrix proteins.162,219,459,197,220 siRNA mediated knockdown of podoplanin or VCAM1 
did not have any marked effect on release of cytokines or expression of matrix 
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proteins in normal or diseased tenocytes. Furthermore, tenocytes subject to 
knockdown did not display any altered response to IL-1b stimulation in vitro. This 
conflicts with the notion that tenocytes expressing specific surface markers are 
primed to respond to inflammation as tenocytes lacking expression of these 
surface markers would, in theory, be less responsive.  
 
We applied podoplanin and VCAM1 knockdown to our co-culture model to test the 
hypothesis that knockdown of surface proteins upregulated in tendinopathy would 
diminish cell surface interactions and inhibit monocyte differentiation. However, 
reduced expression of podoplanin and VCAM1 in tenocytes did not have a 
deleterious effect on expression of macrophage associated genes indicating 
alternative signalling mechanisms are responsible for inducing these phenotypic 
changes. Based on our observations, it is evident there are some theoretical and 
practical challenges to consider when drawing conclusions from our data. In 
addition to podoplanin and VCAM1, the previous chapter identified upregulation 
of CD44 and CD90 in tenocytes from tendinopathic tissue and found co-expression 
of these proteins in tenocyte subpopulations. It may be plausible that knockdown 
of one surface protein is insufficient to evoke a response; therefore, simultaneous 
expression of multiple proteins may be required to alter the properties or 
responsiveness of the cell (Fig. 5.12B). 
 
The theory surrounding stromal activation in musculoskeletal disease has been 
reviewed several times419,460,461 and differential expression of surface proteins has 
been described in RA, tendinopathy and adhesive capsulitis.364,448,212,418,436,462  
However, to date, there has been a lack of experimental evidence to convey its 
biological significance.  The phenomenon of ‘fibroblast activation’ was first 
described in cancer associated fibroblasts (CAFs) and culminated in the 
designation of a cell surface glycoprotein as Fibroblast Activation Protein 
(FAP).320,321 FAP and other ‘activation’ proteins are generally absent from the 
stroma of normal tissues which suggests they play a role in disease pathology.322  
For example, in solid cancers  CAFs expressing activation markers establish a 
strong relationship with cancer cells to support growth, motility and invasion.463 
However, the role of stromal cells in soft tissue disease is less well defined and 
there is still ambiguity regarding the role they play in immune cell recruitment, 
inflammation and matrix remodelling. Consequently, in the present context, the 
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term ‘stromal activation’ should be used with caution to avoid overrepresenting 
a lesser understood phenomenon.   
 
It has been postulated that populations of fibroblasts displaying increased 
expression of certain surface proteins may be a result of an expansion of an 
existing fibroblast subpopulation.464 Our data from Chapter 4 supports this theory 
as we reported increased frequency of some tenocyte subpopulations in diseased 
tissue. These populations were largely defined by their expression of podoplanin, 
cadherin 11 and CD90, all of which are considered markers of pathogenic stroma 
or fibroblast activation. Insight from transcriptomic studies in RA synovial 
fibroblasts has revealed some of the functional properties of these subsets. 
Mizgouchi et al found enrichment of genes associated with fibroblast migration, 
osteoclastogenesis and an enhanced secretory phenotype characterized by 
expression of IL-6, CXCL12 and CCL2.315 Subsequent studies utilizing single cell 
transcriptomics and mass cytometry identified four fibroblast subpopulations with 
differential expression in leukocyte rich RA, leukocyte poor RA and OA. In 
leukocyte rich RA (representative a highly inflammatory environment) sub-lining 
specific subsets showed enriched expression of genes associated with regulation 
of leukocyte migration, regulation of the inflammatory response, NFkB signalling 
and IL-6 production.318. IL-6 expression in tendinopathy is well characterised191,192 
and NFkB signalling has recently  been  identified as a potential therapeutic target 
in tendon disease indicating that gene expression profiles of tenocyte 
subpopulations may be key to understanding mechanisms that underlie 
pathology.392 
 
To date, studies involving fibroblast subpopulations have been largely descriptive 
and it has been acknowledged that further studies are required to explore 
molecular mechanisms that regulate expansion of fibroblast populations.318 In the 
context of the present study it is evident the use of transcriptomics would advance 
our understanding of pathways that may regulate surface marker expression and 
potential expansion of tenocyte subpopulations in disease. However, it is pivotal 
that these studies are succeeded by molecular characterization of signalling 
pathways involved to inform therapeutic translation.  
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Based on our observations we propose that stromal-immune cell interactions rely 
on a combination of juxtacrine and paracrine signalling mechanisms to regulate 
the inflammatory microenvironment in tendinopathy. Furthermore, we believe 
that increased expression of stromal cell surface markers in tendinopathy may 
reflect expansion of existing tenocyte subpopulations that retain potential to 
modulate the inflammatory response under pathological conditions.  
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Figure 5.12 Tenocyte monocyte interactions within the tendon matrix
(A) Surface interactions between monocytes and tenocytes and soluble factors including IL-6 
and CCL2 induce the expression of MERTK, CD206, CD163 and HLA-DR in monocyte-derived 
macrophages (B) Illustrates the hypothesis that knockdown of multiple surface proteins may 
abrogate contact dependent signaling required for monocyte maturation. 
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Chapter 6: Discussion and future directions 
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The immune landscape in tendinopathy is diverse and host to several functionally 
and phenotypically distinct populations of cells. Interactions between these cells 
are mediated by complex signalling pathways that are likely activated sequentially 
to co-ordinate the immune response. Resident cells within the stroma (tenocytes 
and tissue macrophages) perform homeostatic functions whilst also acting as 
immune sentinels capable of responding to infection or injury. As tendinopathy is 
a damage-associated pathology the latter represents the predominant 
precipitating factor in the development of tendinopathy. This thesis identified a 
novel mechanism through which tenocytes respond to injury by inducing release 
of myeloid-associated alarmins S100A8 and S100A9 from monocytes. In the 
extracellular space these alarmin molecules promote the release of cytokines and 
chemokines from tenocytes but do not appear to affect matrix production. Of 
particular interest in the context of tendinopathy is the repertoire of cytokines 
expressed by tenocytes. It is well documented that IL-8, IL-6 & CCL2 are factors 
responsible for mediating the influx of immune cells following activation of the 
innate immune system and sequential accumulation of immune cells has been 
described in tendinopathy.465,187,239 IL-8 induces the recruitment of neutrophils 
within minutes of injury while, over a period of hours and days IL-6 and CCL2 
expression promote recruitment of mononuclear cells. True chronic inflammation 
occurs when physiological inflammation fails to resolve. It is unclear the point at 
which this occurs; however, it may be postulated that sustained activation of 
tenocytes and excessive production of IL-6 and CCL2 perpetuates inflammation 
(outlined in Fig.6.1).  
 
Targeting cytokines¾such as IL-6¾that mediate the transition from acute to 
chronic inflammation represents a viable and logical therapeutic approach in 
tendinopathy. Cytokine blockade has been highly successful in RA and has recently 
been approved for treatment of spondyloarthropathy, psoriasis and inflammatory 
bowel disease.466,467,468 Tendinopathy presents as local inflammation confined to 
connective tissue which may limit the translation of agents designed to treat 
systemic inflammation. However, thus far pilot studies have utilised techniques 
of local administration which may be sufficient to avoid unwarranted side effects 
disproportionate to the burden of disease associated with tendinopathy.  
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Dampening the ‘activation’ of tenocytes in this context refers to the heightened 
expression of inflammatory mediators and matrix components; however, the term 
‘activation’ is also associated with phenotypic alterations observed in fibroblasts 
under chronic inflammatory conditions. I investigated this phenomenon and 
identified upregulation of several surface proteins in tendinopathic tissue, most 
notably CD90, CD44, VCAM1 and prototypic ‘activation markers’ podoplanin and 
FAP. The concept of fibroblast activation is not new, originating in the late 
1990s.302  However, recent interest in the role of stromal cells in chronic 
inflammatory pathologies have focused largely on this fibroblast ‘activation’ 
phenotype with few accompanying functional studies. To address this, I undertook 
siRNA mediated knockdown of podoplanin and VCAM1 and assessed the effect on 
production of inflammatory mediators and matrix components. These experiments 
did not identify any alterations in either which does not align with my previous 
findings of ‘activated’ tenocytes releasing increased levels of cytokines and 
chemokines.  
 
The first observation of activation of fibroblasts and their participation in the 
innate immune response was described in the rheumatoid synovium where 
engagement of TLR ligands on the cell surface resulted in the release of 
chemokines.302,301 This is in line with my observation of tenocytes taking on an 
‘activated’ phenotype upon stimulation with S100A8 & A9. It should be noted that 
this form of activation occurs under acute inflammatory conditions upon initiation 
of the innate immune response. This is in contrast with observations of activation 
in late-stage pathology in tendinopathy described in this thesis and by others.418 
It may be postulated one state represents ‘acute activation’ while the latter 
describes a more chronic form of activation. It has been suggested that epigenetic 
alterations are responsible for the persistence of stromal activation once the 
inflammatory stimulus has been removed which leads to the development of the 
concept of ‘stromal memory’.431,469,432 It is plausible that sustained ‘acute 
activation’ induces these epigenetic changes that are responsible for the 
imprinting of the phenotype associated with ‘chronic activation’.  
 
Phenotyping studies illustrated variations in surface marker expression in healthy 
and diseased tendon and we identified distinct ‘subpopulations’ of tenocytes 
expanded under pathological conditions. The concepts of fibroblast activation and 
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heterogeneity are inextricably linked, and it is possible they represent a ‘cause 
and effect’ phenomenon whereby fibroblasts activated by inflammatory/immune 
stimuli in the early stages of disease give rise to distinct sub-populations present 
in established pathology. To gain further insight into the properties of tenocyte 
subsets identified in normal and tendinopathic tissue, cell sorting based on their 
surface protein expression (e.g. CD90+PDPN+CAD11+) and subsequent in vitro 
functional studies would address questions relating to functional differences and 
pathogenic potential of fibroblast subsets. Functional studies would include 
cytokine/chemokine profiling, measuring matrix expression and leukocyte 
migration studies. However, it should be noted that removing cells from their 
tissue environment may result in acquisition or loss of crucial characteristics that 
could potentially skew results.  
 
Recent studies have employed the use of transcriptomics and mass cytometry to 
gain insight into the properties of fibroblasts displaying different phenotypes. One 
study identified a CD34+ fibroblast subset characterized by increased expression 
of IL-6, CXCL12 and CCL2 and enhanced leukocyte recruitment while another 
mapped IL-6 expression to a CD90+HLA-DRAhi population of sublining fibroblasts 
expanded in RA.315,318 Going forward, a bioinformatic approach utilising an overlay 
analysis of bulk RNA-seq on sorted populations and unbiased single cell RNA-seq 
on tenocytes would provide detailed information on differential gene expression 
in health and disease. Furthermore, gene clustering analysis would act to clarify 
tenocyte sub-populations identified in this thesis and functional studies to validate 
transcriptomic data would be required as a critical step in the correct utilisation 
of these technologies.  
 
The primary aim of this PhD project was to assess the effect of interactions 
between stromal cells, namely tenocytes, and immune cells. Chapter 3 addressed 
this by identifying interactions occurring as a result of soluble factors and receptor 
mediated signalling in the tendon microenvironment. Conversely, Chapter 5 
addressed contact dependent interactions between tenocytes and monocytes in 
the form of direct co-culture experiments. These interactions had a notable effect 
on monocyte phenotype by inducing expression of several macrophage associated 
markers. CD206, CD163, MerTK and HLA-DR are associated with a ‘pro-resolving’ 
phenotype which indicates these interactions may be beneficial to healing. 
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However, the presence of these macrophages has also been noted in chronic 
inflammatory pathologies and fibrotic disorders suggesting tenocyte-monocyte 
interactions may become dysregulated somewhere in the transition from acute to 
chronic inflammation. It would also be interesting to assess the reciprocal effect 
of this interaction on tenocyte phenotype by measuring expression of our panel of 
surface markers.  
 
To assess the effect of ‘activation markers’ podoplanin and VCAM1 on tenocyte-
monocyte interactions I performed co-culture experiments with siRNA mediated 
knockdown of these proteins. I did not observe any discernible changes in our 
panel of macrophage associated markers. The heterogenous nature of the culture 
system limits the number of experiments that can be performed (with focus on a 
single cell type) thus I intend to sort the CD14+ monocytes from the tenocytes and 
perform bulk RNA-seq on all experimental conditions. As the literature 
surrounding monocyte/macrophage phenotype and activation is extremely 
convoluted this will allow us to concentrate on interrogating relevant signalling 
pathways rather than focus on potentially arbitrary phenotypic characteristics.  
 
In summary, this thesis has identified novel stromal-immune cell interactions in 
tendinopathy and highlighted the importance of the interface between acute and 
chronic inflammation in disease progression. Defining mechanisms through which 
stromal cells with varying expression profiles contribute to inflammation may be 
key to identifying the molecular switch that drives disease chronicity. On the basis 
of these results it is evident that stromal cells and immune cells exist in a diverse 
spectrum of activation states determined by niche specific environmental cues. 
Further characterization of discreet subpopulations of cells that predominate 
under pathological conditions may aid in stratifying treatment in musculoskeletal 
disease and other pathologies associated with chronic inflammation.  
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Figure 6.1 Summary of immune-cell matrix cross talk in tendinopathy     
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